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Routine Outcome Monitoring (ROM) is the systematic measurement of treatment 
outcomes in routine clinical practice. ROM can be used as a tool for both the patient and 
the clinician in monitoring treatment progress. With ROM, depending on the choice of 
measurement instruments, detailed information about psychiatric diagnosis, several 
domains of symptoms and complaints, and psychosocial functioning can be ascertained, 
in every phase of treatment. Furthermore, on a group level, anonymised ROM data can be 
used for conducting epidemiological research, as well as for purposes of benchmarking. 
ROM is a potentially important source of information regarding the e"ectiveness of 
treatment in daily –or real-world– practice, in addition to the available information 
about e#cacy of speci!c interventions derived from Randomised Controlled Trials (RCTs; 
Ellwood, 1988; Holloway, 2002; Relman, 1988; Zimmerman et al., 2006). Despite these 
potential advantages, ROM has not yet been broadly implemented in psychiatry (Carlier 
et al., 2010; de Beurs et al., 2011; Gilbody et al., 2002; Slade, 2002a). 
 In the Leiden region in the Netherlands, an extensive ROM infrastructure has 
been developed and implemented since 2002 by a collaboration of the Regional Mental 
Health Provider (RMPH) Rivierduinen (RD) and the Department of Psychiatry of the Leiden 
University Medical Center (LUMC), respectively secondary and tertiary psychiatric specialty 
care settings (de Beurs, et al., 2011). This thesis focused on real-world patients with Mood, 
Anxiety and Somatoform (MAS) disorders and real-world outcomes in daily practice, by 
using ROM-data collected in RD and the LUMC. The remaining part of this introductory 
chapter provides background information and de!nitions, as well as the main aims and a 
thesis outline.
Psychiatric diagnosis
An important precondition for a doctor to adequately treat an ill patient, is a reliable and 
valid diagnosis. This core criterion is true for all areas in medicine (Goodwin et al., 1996). The 
study of symptoms and occurrence of diseases, and hence the classi!cation and de!nition 
of diagnoses, are within the scope of epidemiology. Ideally, knowledge of underlying 
pathophysiological disturbances is used for disease classi!cation. Usually, a clinician 
gathers a medical history, physical examination and often laboratory tests and/or imaging 
tests to obtain a diagnosis (Fauci et al., 2008). Whenever a reliable and valid diagnosis 




patient has to be obtained. After initiation, the e"ect of treatment has to be monitored. In 
theory, treatment e"ect can be measured in several domains: disease activity in terms of 
pathological processes or biological parameters, subjective symptoms as experienced by 
the patient, symptoms observed by the clinician, (psychosocial) functioning, and health-
related quality of life (Fauci, et al., 2008; Smith et al., 1997).
Despite major research e"orts in psychiatry during the past decades, knowledge 
about the pathophysiological mechanisms underlying most psychiatric disorders is still 
limited. This is in contrast with many somatic disorders, where large breakthroughs in 
understanding of pathophysiology have been accomplished. This lack of knowledge 
about pathophysiology of aetiology of psychiatric disorders has implications for both 
diagnosis and monitoring of treatment e"ect. Firstly, the value of laboratory tests and 
other biomarkers in psychiatric diagnostics in the individual patient is merely marginal 
(Quinones et al., 2009). The psychiatrist uses medical history taking, i.e. the patient’s 
report of internal phenomena and the systematic mental-state examination to ascertain 
the symptoms and complaints of the patient. Instead of laboratory or imaging tests, 
rating scales that measure psychopathology can be applied. Secondly, the monitoring 
of treatment e"ect is limited to standardised rating of symptoms and psychosocial 
functioning, because at present, no biological parameters (i.e. biomarkers) can be used 
as measures of disease activity. However, as mentioned above, monitoring outcomes 
on a routine and standardised basis with ROM has not yet become standard practice in 
psychiatry. The various reasons for this lack of implementation will be discussed later in 
this chapter.
 Until 1980, no well-de!ned, international accepted diagnostic criteria existed 
in psychiatry (Mayes et al., 2005). The need for reliable and valid diagnoses urged the 
American Psychiatric Association (APA) to introduce the third edition of the Diagnostic 
and Statistical Manual of Mental Disorders (DSM-III) in 1980 (American Psychiatric 
Association, 1980). This document was based on validity !eld trials in the United States 
(US) and consensus of an APA task force, and contrary to the !rst two editions (DSM-I and 
DSM-II) it comprised detailed descriptions of symptom clusters and diagnostic criteria of 
psychiatric disorders. Since the introduction of DSM-III, psychiatric disorders are being 
classi!ed based on the presence of symptoms, providing syndromal diagnoses. This is 
exactly what the in#uential German psychiatrist Emil Kraepelin proposed almost a century 
earlier (Mayes & Horwitz, 2005). The introduction of the DSM-III has caused a revolution 
in psychiatry as it dramatically increased the possibilities of conducting epidemiological 
research with results that were internationally applicable. The current version of the DSM, 





ongoing epidemiological research and consensus (American Psychiatric Association, 
1994; American Psychiatric Association, 2000). The publication of the DSM-V is due in 2013 
(www.DSM5.org).  As examples of common MAS disorders, table 1.1 shows adapted DSM-















































In order to measure or classify psychiatric disorders, psychiatric symptoms preferably 
have to be assessed in an objective and reproducible, standardised manner (Zitman, 
1990). Since most psychiatric symptoms have a large subjective component (e.g. delusive 
thoughts, hallucinations, disturbed mood, somatic sensations), objective measurement 
is a challenge. These symptoms are not easily observed or veri!ed by an examiner 
(Gilbody et al., 2003). The need for objective measurement of psychiatric symptoms has 




A psychometric test is an instrument designed to produce a quantitative assessment of 
some psychological attribute(s). According to the psychometric principles, a psychometric 
test should be valid, reliable and free of bias (Ishak et al., 2002). Validity indicates that the 
test assesses the true state of the phenomenon being measured, reliability refers to the 
extent of reproducibility of the test and bias is a systematic error in the design of the test 
or study, or in data analysis. For use in ROM, a test should also be sensitive to clinically 
important change over time (Smith et al., 1997). Measurement in psychiatry can take 
place on the level of syndromal diagnosis, on the level of symptom severity, on the level 
of psychosocial functioning and on the level of health related quality of life. Ideally, a ROM 
test battery consists of measurement instruments that cover all these levels (de Beurs et 
al., 2011). 
DSM Diagnostic measurement instruments
Syndromal classi!cations are potentially less fundamental than classi!cations that make 
use of clearly disturbed biological etiological processes, e.g. the detection of tumor cells in 
cancer or the occurrence of a pathogen in infectious diseases. Nevertheless, the introduction 
of the DSM-II and its successive worldwide use has greatly facilitated the development of 
structured diagnostic measurement instruments, necessary for psychiatric epidemiologic 
research. Until the 1980’s, psychiatric epidemiology was hampered by methodological 
shortcomings, most importantly because of fuzzy de!nitions of diagnoses and outcomes 
(Tohen et al., 2000). 
The 1980 DSM-III criteria were used for the development of the Diagnostic 
Interview Schedule (DIS), for use in the !rst large US community epidemiologic study 
on mental health: the Epidemiological Catchment Area (ECA) study, sponsored by 
the US National Institute of Mental Health (NIMH). This structured interview could be 
administered by lay interviewers because of its closed-ended questions that did not 
require clinical judgment (Robins et al., 1981; Tohen et al., 2000). Some years later, the 
Composite International Diagnostic Interview (CIDI) was developed in collaboration 
with the World Health Organisation (WHO; Robins et al., 1988). A modi!ed version of 
the CIDI was used in the next large US community epidemiological study: the National 
Comorbidity Survey (NCS; Kessler et al., 1994). After the development of these structured 
diagnostic interviews, reliable prevalence estimates of psychiatric disorders were possible. 
Because of the extensive format of the CIDI, which limited use in clinical practice, Lecrubier 
and colleagues developed in a European-US collaboration a short validated structured 
diagnostic instrument: the Mini International Neuropsychiatric Interview-Plus (MINI-Plus). 





Symptomatic and functional measurement instruments
While diagnostic measurement instruments measure DSM diagnosis in a standardised 
manner, symptomatic and functional measurement instruments measure symptom 
severity and health status on a functional level. The latter two categories of instruments 
can be regarded as monitoring instruments, which may be applied at several time-points 
during treatment to evaluate progress of treatment and disease. Symptom-based scales 
may be generic or disorder-speci!c, and self-report or observer-rated. 
The Hamilton Depression Rating Scale (HDRS) and Montgomery-Åsberg 
Depression Rating Scale (MADRS) are examples of well-known disorder-speci!c observer-
rated rating scales that measure symptom severity in Major Depression (Hamilton, 
1960; Montgomery, 1979). Of these two scales, the HDRS has been predominantly used 
in RCTs, but the MADRS seems superior for outpatient use (Uher et al., 2008). The Brief 
Symptom Inventory (BSI) is an example of a generic self-report rating scale that measures 
psychopathological symptom severity in several domains, e.g. anxiety, depression, 
hostility, and somatic complains (de Beurs et al., 2006; Derogatis et al., 1983).
 Domains of functional monitoring instruments include general health status, 
quality of life (QoL) and social and role functioning. These instruments are ordinarily 
regarded as QoL scales, although a distinction between Qol and (psychosocial) functioning 
can be made. An example of a widely used instrument that measures general health status 
is the self-report Short Form-36 (SF-36; Ware, 1992). 
Psychiatric epidemiology
The large-scale epidemiological community studies facilitated by the sophistication of 
psychiatric diagnosis and the subsequent development and validation of comprehensive 
diagnostic measurement instruments have provided valuable data on prevalence and 
incidence of psychiatric disorders in the general population. Furthermore, these studies 
have described in great detail clinical characteristics and correlates of most psychiatric 
disorders. A disadvantage of these epidemiological studies, however, is the fact that 
the responding subjects do not necessarily re#ect treatment seeking populations, 
even when they meet criteria for psychiatric disorders. This may limit generalisability or 
external validity of these !ndings to the daily clinical practice in psychiatric specialty 
care. Nevertheless, these studies have played a major role in the development of the 
!eld of psychiatric epidemiology and the development of current psychiatry. Psychiatric 




disorders in speci!ed populations and of the risk factors associated with their onset and 
course” (Tohen et al., 2000). In analogy with epidemiology in somatic medicine, psychiatric 
epidemiology can be subdivided in community psychiatric epidemiology and clinical 
psychiatric epidemiology. 
In contrast with community epidemiology, which aims to describe disease 
phenomena and to estimate prevalence rates of diseases in the general population, the 
main goals of clinical epidemiology are to investigate the e"ects of presumed causal risk 
factors on the onset and course of illness in clinical patients, to evaluate the validity of 
diagnostic tests and to study predictors of treatment response that might be targeted 
in subsequent interventions (Kessler, 2007; Tohen et al., 2000). In the last three decades, 
descriptive community psychiatric epidemiologic research, with the ECA and NCS as 
examples, has prospered. On the other hand, clinical psychiatric epidemiology has remained 
under-developed as compared to clinical epidemiology in other !elds of medicine (Kessler, 
2007). This is mostly because of the fundamental problem of establishing psychiatric 
diagnoses (assessment of caseness) as compared with somatic diagnoses, because of the 
limited validity of most psychiatric diagnoses. Another reason for this di"erence is the fact 
that the treatment of psychiatric disorders is diverse −despite the availability of evidence-
based guidelines− making it more di%cult to conduct clinical epidemiological research of 
naturalistic variation in treatment response (Kessler, 2007). Finally, because many patients 
with psychiatric disorders do not seek treatment, representative descriptive data of 
psychiatric disorders in the general population are not necessarily applicable to everyday 
patients in clinical practice (Burger et al., 2007; Kessler, 2007).
Descriptive community epidemiological studies like the ECA and NCS have 
yielded valuable insights in prevalence rates and phenomenology of psychiatric disorders 
in the general population. Since these US community studies in the 1980’s, replications 
have been conducted (National Comorbidity Survey-replication; NCS-R), as well as 
community studies in Europe. The !rst and second Netherlands Mental Health Survey and 
Incidence Study (NEMESIS 1 and 2) are examples of the latter (Bijl et al., 1998; de Graaf et 
al., 2011). The prevalence rates of most psychiatric disorders appear to be quite consistent 
over time and across continents (table 1.2).
 Contrary to community epidemiological studies, clinical psychiatric 
epidemiological studies have the important potential of evaluating interventions in 
daily clinical practice. Kessler (2007) stated that “In addition to studying the aggregate 
magnitude of treatment e"ects, clinical epidemiological studies are needed to study the 
predictors of individual di"erences in treatment response”. This type of work would ideally 





illness in broadly representative clinical samples”. Examples of large scale, truly naturalistic 
studies are scarce nowadays. In order to conduct these studies, a ROM infrastructure could 
be used, in which outcome data of large naturalistic samples are collected. 
Randomised Controlled Trials 
The development of psychopathology measurement instruments several decades ago 
has also dramatically increased the possibilities of evaluating treatment e%cacy by means 
of clinical trials. Randomised Controlled Trials (RCTs) have widely been accepted as the 
gold standard in evaluating treatment e%cacy in medicine (Atkins et al., 2004; Kaptchuk, 
2001). For a new drug to be approved by the regulatory authorities, superior e%cacy 
compared to placebo in RCTs is needed. Indeed, the design of a typical RCT, in which two 
or more speci!c interventions with or without a placebo condition are directly compared 
in a double-blind way in a sample of patients with a speci!c disease, aims to maximise 
internal validity of the trial at hand. In other words, whenever an e"ect is found, it is most 
likely being explained by the intervention under study because confounding is largely 
eliminated through the randomisation process. This high level of internal validity can only 
be realised if both the disease under study is strictly de!ned, if the intervention is strictly 
de!ned, and if the sample is homogeneous in terms of comorbidity and other clinical 
characteristics. This means that often a large and strict set of inclusion and exclusion 
criteria are being used in RCTs. If those strict conditions are met, and the sample is large 
enough to detect clinically meaningful di"erences, in theory an RCT with maximised 
internal validity will provide the strongest possible evidence for superiority of a certain 
intervention (Rorty, 1977). 
However, in the real world those perfect ‘laboratory circumstances’ do not exist. 
The RCT populations usually are highly selected, and su"er from limited external validity. 
Yet, most evidence-based treatments in medicine are largely based on !ndings from RCTs. 
Of course, the !ndings from RCTs are a major leap forward in terms of evidence based 
medicine as compared to the mere descriptive ‘clinical expertise’ and case studies from 
the pre-RCT era. 
  A major disadvantage of RCTs, however, is the possible lack of external validity or 
generalisability (Licht et al., 1997; Wells, 1999; Zimmerman et al., 2002). In a recent study of 
our group we found that only 20-25% of our depressive outpatients would meet general 
inclusion criteria for RCTs (van der Lem et al., 2010). In other words, real-world patients 




have also played a role in our knowledge about characteristics of psychiatric disorders (e.g. 
symptom pro!les, comorbidity patterns). Typically, symptomatology of speci!c disorders 
has been analysed using only the baseline measurements in large RCT populations, and 
reports about these clinical characteristics are being published secondary to the main 
paper describing the primary outcome of the intervention (see for example Marcus et al., 
2005 and Zisook et al., 2007).   
Routine Outcome Monitoring
Historical perspective of Routine Outcome Monitoring
The limited generalisability of !ndings from RCTs and population studies to daily clinical 
practice and the lack of insight in processes and patient’s experiences of treatment has 
inspired Ellwood for his 1988 Shattuck lecture in which he pleaded for “assessing routinely 
and frequently the health of patients using appropriate reliable and valid measurement 
instruments and to build large databases with these data” (Ellwood, 1988). He predicted 
“a new revolution in health care”, and stimulated to systematically assess clinical, !nancial 
and health outcomes. Although this idea was well received in editorials (Holloway, 2002; 
Slade, 2002b), recent reviews have shown only a limited number of published studies 
of routinely assessed outcomes or ROM in psychiatric specialty care (Carlier et al., 2010). 
Institutions that have adopted ROM usually used a slim test battery (Burgess et al., 2009; 
Lambert et al., 2001). Several reasons for this lack of routine implementation of ROM in 
clinical practice are proposed: ROM is costly and time consuming, and requires a relatively 
complicated technical infrastructure. More important, no consensus exists about the 
optimal choice of measurement instruments so that outcomes are not easily comparable 
across clinics and across studies. Probably, parameters like treatment setting, patient 
population, and the limited availability of measurement instruments free of copyright 
may contribute to this lack of consensus. Furthermore, the aim of ROM may vary, as 
several parties have di"erent interests, e.g. policy makers, insurance companies, patients, 
clinicians and researchers (Carlier et al., 2010; Norquist, 2002).
Aims and methodological issues of Routine Outcome Monitoring
In theory, ROM can provide both clinician and patient with valuable information about 
symptoms and treatment outcomes in daily clinical practice, and e"ectiveness of 
treatments in real-world treatment settings. Evidence-based treatments are based on 





of ROM is improvement of the quality of patient care by measuring progress and giving 
feedback to the patient. Secondary aims of ROM are understanding mechanisms of disease 
and treatment, establishing cost e"ectiveness and benchmarking. For understanding the 
relationship between patients’ health status (outcomes), disease status and treatment 
(process of care) it is necessary to have access to detailed information about the type of 
treatment (Smith et al., 1997).
If observer-rated measurement scales are being used, it is important that the 
interviewer is well trained because clinical interpretation of symptoms or complaints 
is essential for reliable and reproducible results. To increase objectivity, preferably, 
measurement instruments are applied by an interviewer who is not directly involved 
in the treatment of the patient. In addition, inter-rater variability between interviewers 
should be minimised by recurrent training sessions in which calibration takes place.
Ideally, ROM measurement instruments should be clinically relevant, sensitive to 
change, minimally burdensome to the patient, to the sta", and to the institution in terms of 
costs of collection and data analysis (Dickey, 2002). This implies that a balanced selection of 
well-validated measurement instruments free of copyright is to be preferred. It is evident 
that di"erent instruments may be applied in di"erent patient groups. In the international 
literature, no consensus exists about the choice of measurement instruments, about the 
interval of measurement, and about the groups of patients or treatment settings in which 
ROM may be applied. 
Since the data gathering in ROM is naturalistic and observational, no experimental 
designs can be used if outcome data are routinely assessed. Hence, instead of causal 
inferences, only correlations can be established on group level (Kessler, 2007). Another 
methodological issue when analysing ROM data is the problem of confounding and 
selection bias, since the treatment that a patient receives will often be determined by a 
number of factors that are related to outcome, such as disease severity (Gilbody et al., 2002).
 The use of patient-based measures of health may itself be useful in improving 
treatment outcomes, because of the possibility to provide feedback of ROM assessments 
to both patient and clinician. This may enable clinicians to detect problem areas in 
treatment that would have been missed without the use of data derived from ROM 
(Carlier et al., 2010; Greenhalgh et al., 1999), and may increase patient’s compliance to 
treatment protocols (Carlier et al., 2010; Hysong, 2009). A limited amount of studies have 
demonstrated a positive impact of ROM on monitoring treatment, and on the quality of 
communication between clinician and patient (Carlier et al., 2010; Knaup et al., 2009). In 
the meta-analysis by Carlier et al., a favourable outcome of feedback by ROM on mental 




ROM in Mood, Anxiety and Somatoform disorders
MAS disorders are highly prevalent disorders with a large disease burden (Wittchen et al., 
2011). The frequent chronicity of depression contributes substantially to the global burden 
of disease. By the year 2020, depression is projected to reach the second ranking place of 
disability-adjusted life years for all ages in both sexes (Murray et al., 1997). In the second 
NEMESIS study, a representative survey of 6,646 adults in the Netherlands was conducted 
between 2007 and 2009 (de Graaf et al., 2011). Lifetime as well as 12-month prevalence 
rates of mood and anxiety disorders were highly comparable with NEMESIS-1, which 
dated from 1996 (Bijl et al., 1998), and with NCS/NCS-R data (see table 1.2). Prevalence 
rates of somatoform disorders have not been ascertained in those studies. 
MAS disorders show a considerable amount of overlap in diagnostic criteria and 
probably also share genetic and environmental factors, so these disorders occur frequently 
as comorbid disorders. MAS disorders are often regarded as ‘common mental disorders’ as 
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Since ROM is time-consuming and intensive, especially when a large test battery is 
applied, implementation of ROM in a treatment setting of MAS disorders might be more 
feasible than in a treatment setting of psychotic disorders. After all, psychotic patients 
may not be able to complete an extensive set of instruments (Mulder et al., 2010). These 
considerations have resulted in the implementation of ROM in an outpatient treatment 
setting of MAS disorders in the Leiden Region (Box 1.1).
Aims and outline of this thesis
Aims of this thesis
This thesis focused on several aspects of ROM in outpatients with MAS disorders. The 
main aims were to investigate clinical aspects –symptom pro!les, comorbidity, general 
health status and psychosocial functioning– in a large cohort of treatment-seeking 
real-world patients with MAS disorders, and to compare these aspects with data from 
RCTs and general population studies. In addition, using prospective data, we aimed to 
assess whether baseline characteristics measured with ROM could predict real-world –or 
naturalistic- treatment outcomes. The secondary aim of this thesis was to establish the 
feasibility of using routinely obtained outcome data for clinical epidemiological research 
purposes. 
General description of the patient population
The implementation of ROM (Box 1.1) in the department of psychiatry of LUMC and in 
the outpatient departments of RD from 2002 has taken place in several phases. In 2004, 
most locations had incorporated ROM in routine clinical practice. As from 2004, reliable 
ROM data has been systematically collected for research purposes. From January 1, 2004 
until December 31, 2006, a total of 3,798 patients who had been referred for treatment 
of a MAS disorder to one of the outpatient clinics in LUMC and RD had a baseline ROM 
assessment, and were included in the !rst ROM Baseline cohort of the Leiden Routine 
Outcome Monitoring Study. 
 In the !rst three studies of this thesis, the ROM baseline cohort has been used. The 
average age of this group was 39.6 (standard deviation [SD] =13.3) years and 63% were 
women (de Beurs et al., 2011). Diagnostic status was established with the MINI-Plus. It is 
important to stress that clinical or primary diagnoses have not been taken into account in 
all ROM analyses. The major advantage of this modus operandi is that diagnostic status is 




  BOX 1.1. ROM in the Leiden University Medical Center & Rivierduinen
In spring 2002, the Regional Mental Health Provider (RMHP) ‘Rivierduinen’ (an institute serving a region with more than 
1 million inhabitants) and the Department of Psychiatry of the Leiden University Medical Center (LUMC) started collabo-
ration for routine assessment of the DSM-IV diagnosis as well as the symptom severity, well-being and health status at time 
of the !rst interview of outpatients referred to the RMPH Rivierduinen. 
At the start, ROM was restricted to patients referred for treatment of mood, anxiety, and somatoform (MAS) disorders. 
These patients form a relatively homogenous group with substantial mutual comorbidity (Kessler et al., 1996) and they 
mainly receive outpatient care. To be eligible, patients had to have su%cient mastery of the Dutch language and had 
to be able to complete self-report instruments. Patients who are considered (by their clinician) to be too ill to complete 
questionnaires or refuse to be assessed are excluded from ROM assessment. 
All patients are assessed by an independent psychiatric research nurse at the start, and during follow up at intervals of 
three to four months, at the beginning of a new treatment step and at the end of the treatment. 
 A disadvantage may be that in the case of multiple diagnoses, one diagnosis 
could be more prominent, and treatment may be based on this clinically more relevant 
diagnosis. For example, a patient with a Major Depressive Disorder (MDD) and a social 
phobia, may either be treated according to the social phobia treatment or the major 
depression guidelines. Until now, no detailed information about treatment is ascertained 
in the Leiden ROM. Hence, this particular patient may be analysed both as a MDD case and 
a social phobia case (or as patient with comorbidity), irrespective of the primary diagnosis 





   
   BOX 1.1. Continued
 
During the !rst session, a standardised diagnostic interview is administered and observer- and self-reported ratings 
are determined. At baseline the Axis-I diagnosis according to the Diagnostic and Statistical Manual of Mental Disorders 
(DSM-IV) is established using the Mini-International Neuropsychiatric Interview-plus (MINI-plus, Sheehan et al., 1998). 
The interviews are performed by psychiatric research nurses who have been extensively trained and supervised. The 
Dimensional Assessment of Personality Pathology (DAPP-SF) is administered to assess maladaptive personality traits 
(Livesley et al., 2006; van Kampen et al., 2008). Until now, in ROM no detailed treatment information is available. 
Subsequently, a number of symptom severity rating scales are administered at baseline, which are also completed at 
each re-assessment to allow for the evaluation of treatment outcome. Together, these instruments cover change in three 
areas of functioning: symptom reduction, increased wellbeing, and improvement in general life functioning (Sperry et al., 
1996). They are commonly used in treatment-outcome research and have good psychometric properties as evidenced by 
national and international publications (an overview of instruments used is available at http://www.lumc.nl/psychiatry/
ROM-instruments). Outcome is assessed by patients’ self-report and by an independent assessor (observer-rated), and 
includes both generic and disorder-speci!c measures. Clinicians receive a report on the results of the baseline assessments 
as well as follow-up reporting on treatment outcome in the above mentioned domains. Results of the assessments are 
provided in detail by the research nurses as well as in a summarised form. The summaries facilitate clinicians to discuss the 
results with their patients and use them as a tool to evaluate the treatment. Results are also used, in an anonymous form, 
for scienti!c purposes.
Since ROM-data are primarily being used by clinicians and patients to monitor treatment progress, no speci!c informed 
consent is needed. The use of anonymised data for research purposes has been approved by the Medical Ethical 
Committee of the LUMC. 
According to the MINI-Plus, of the 3,798 patients, 1,788 patients (47.0%) met 
criteria for one or more mood disorders, 1,653 patients (43.5%) had one or more anxiety 
disorders, 653 patients (17.2%) had one or more somatoform disorders, and 851 patients 
(22.4%) had no MAS disorder (!gure 1.1). These latter patients had other diagnoses, e.g. 
adjustment disorders, attention de!cit hyperactivity disorder, substance abuse disorders, 




















In Chapter 2, we focused on gender di" erences in point prevalence rate, symptom pro! le 
and comorbidity patterns in 1,131 outpatients with MDD. The aim of this exploratory 
study was to investigate whether gender di" erences in a real-world sample of treatment-
seeking MDD patients existed and whether these di" erences would deviate from 
di" erences found in clinical trial or population-based samples.
Chapter 3 describes a study on di" erences in clinical characteristics including 
demographic correlates, comorbidity, symptomatology and general health status in 
patients with MDD onset before adulthood versus patients with MDD onset during 
adulthood. Again, results were compared with ! ndings from non-naturalistic studies.
In Chapter 4, we shifted the focus to lifetime deliberate self-harm and suicidal 
ideation (DSHI) in the total group of MAS patients. It is well-known that self-harm is a 





correlates of DSHI in a real-world sample of outpatients with common mental disorders. 
The aim of this study was to investigate prevalence and correlates of DSHI in a large real-
world outpatient mental health population.
In Chapter 5, we used longitudinal ROM data to identify predictors of outcome 
in MDD. Speci!cally, we aimed to investigate whether individual depressive symptoms 
measured with the Beck Depression Inventory-Revised (BDI-II) predict response or 
remission after follow-up of up to 24 months.
Chapter 6 describes a study on predictors of outcome in MAS outpatients using 
longitudinal ROM data. Since MAS disorders often have overlapping symptoms and 
mutual comorbidity is substantial, we investigated cross-diagnostic predictors of outcome 
measured on common generic rating scales: the BSI and the Clinical Global Impression 
(CGI) scale.
Finally, in Chapter 7, we summarised the main results of the studies. Furthermore, 
we discussed these results and we provided recommendations for further improvement 
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Abstract
Background: No previous large scale studies have assessed gender di"erences in 
naturalistic samples of major depressive disorder (MDD) outpatients. We therefore 
determined gender di"erences in comorbidity, symptom patterns and subjective health 
status in these outpatients in a mental healthcare setting. 
Methods: Of 3,798 consecutive adult patients (age range: 18-65), 1,131 (65.1% women) 
ful!lled DSM-IV criteria of current MDD on the Mini International Neuropsychiatric 
Interview (MINI-Plus). Patients were routinely assessed with Routine Outcome Monitoring 
(ROM), including the Montgomery-Åsberg Depression Rating Scale (MADRS), Beck 
Depression Inventory (BDI-II), Brief Symptom Inventory (BSI) and Short Form-36 (SF-36). 
Results: No gender di"erences were found in disease severity using the clinician-rated 
MADRS. However, women showed a signi!cant higher depression severity measured with 
the self-report BDI-II. Also, psychopathological symptoms self-reported with the BSI were 
higher, and reported health status on the SF-36 was lower in women. In men with MDD, 
social phobia, attention de!cit hyperactivity disorder, and alcohol and drug misconduct 
were more common co-morbid disorders, while in women with MDD posttraumatic 
stress disorder and bulimia nervosa were more common, as well as atypical features of 
depression. Limitations: The use of retrospective reports of lifetime psychopathology 
might have led to recall bias. 20% of subjects were excluded from ROM due to language 
problems or logistical reasons.
Discussion: Although women self-reported higher depression severity, more severe 
general psychopathological symptoms and lower health status, no di"erences in disease 
severity were found on interviewer ratings. These !ndings could have implications for 





Although di"erences in course and symptom patterns between male and female 
depressive patients are not re#ected in classi!cation systems, there is evidence 
that important gender di"erences exist that point to underlying di"erences in the 
pathophysiology of depression (Smith et al., 2008). Gender di"erences in the prevalence 
of major depressive disorder (MDD) have extensively been reported based on both 
population-based (Angst et al., 2002; Kessler et al., 2005; Kuehner, 2003) and clinical trial 
samples (Fava et al., 1996; Kornstein et al., 2000; Marcus et al., 2005; Marcus et al., 2008). 
Consistently, lifetime prevalence ratios are 2:1 for women as compared to men, whereas a 
ratio of 1.7:1 for point prevalence rates is reported (Angst et al., 2002; Kessler et al., 2003; 
Kuehner, 2003; Nolen-Hoeksema, 1987). The cause of the female preponderance of MDD 
remains to be elucidated (Kendler, 2001; Kuehner, 2003; Middeldorp et al., 2006; Piccinelli 
& Wilkinson, 2000). In addition to gender di"erences in prevalence rates, di"erences in the 
course, comorbidity patterns, clinical characteristics, and general health status between 
men and women with MDD have been studied. Studies on these gender di"erences in 
clinical manifestations of MDD have been conducted in population-based samples and 
in groups of MDD-patients who were recruited for randomised controlled trials (RCTs), 
but scarcely in naturalistic samples in psychiatric specialty care. One study on gender 
di"erences in severity and symptomatology of depression in a representative sample of 
depressive patients in general practice showed no clinically relevant gender di"erences 
(Hildebrandt, 2003). A recent study in a genetic-epidemiological cohort of 598 MDD-
patients, however, showed di"erences in the course and symptom pro!le of male and 
female depression with more atypical depression, self-reproach and diminished libido in 
women (Smith et al., 2008). 
Large population samples of six European countries were analysed in the 
European DEPRES study (Angst et al., 2002). In this study of more than 78,000 randomly 
selected subjects (38,434 males and 40,024 females), the sex-speci!c prevalence rates of 
all nine DSM-IV symptoms of depression were scored in a diagnostic interview. 2,921 men 
(7.6%) and 5,968 women (14.9%) were diagnosed with MDD. All symptoms were more 
prevalent in women than in men. In addition, women were more likely to seek help for 
their complaints. Overall, men reported fewer symptoms than women during a clinical 
interview, which made the authors conclude that the preponderance of women with 
a major depressive episode could be a result of the diagnostic (DSM-IV) threshold of 5 
or more symptoms used in this study. Indeed, when the criteria for ‘minor depression’ 
were applied, namely two symptoms instead of four symptoms in addition to one core 
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symptom, the gender ratio was much lower (female to male ratio 1.2: 1). In the literature, 
this phenomenon is regarded as ‘threshold artefact’ (Piccinelli & Wilkinson, 2000). In this 
study, however, it was unclear whether men with MDD would also report less severe 
depressive symptoms than women with MDD.
Studies in clinical trial samples were relatively small (Fava et al., 1996; Frank 
et al., 1988; Grigoriadis et al., 2007), with the exception of the STAR*D study samples 
(Rush et al., 2004). In this US outpatient treatment study, gender di"erences in baseline 
sociodemographic and clinical characteristics were studied in two cohorts of 1,500 and 
2,541 MDD patients respectively, after informed consent was provided (Marcus et al., 
2005; Marcus et al., 2008). Contrary to other treatment studies, the inclusion criteria were 
not too strict and equipoise randomisation was used in order to re#ect a real-life patient 
population. Depressed women had a greater overall symptom severity measured on 
observational and self-report scales, and were more likely to have a comorbid anxiety 
disorder, bulimia nervosa or somatoform disorder, similar to previous !ndings (Kuehner, 
2003; Middeldorp et al., 2006).
To our knowledge, no data on gender di"erences in large naturalistic samples 
of depressed outpatients in routine psychiatric care have been published. Therefore we 
studied gender di"erences in point prevalence rate, symptom pro!le and comorbidity 
pattern of MDD in patients enrolled in the Leiden Routine Outcome Monitoring (ROM) 
Study database. The extensive phenotyping provided a unique opportunity to analyse 
these gender di"erences in a large naturalistic sample of patients with MDD in secondary 
and tertiary routine psychiatric care. 
Methods
Routine Outcome Monitoring
We used a sample of 3,798 adults (age range 18-65) who were referred for treatment of 
a mood, anxiety, or somatoform (MAS) disorder to the Dutch Regional Mental Health 
Provider (RMHP) Rivierduinen (RD) or the psychiatric outpatient department of the Leiden 
University Medical Center (LUMC) in the Western part of the Netherlands between January 
2004 and December 2006. At baseline, subjects were assessed as part of the usual Routine 
Outcome Monitoring (ROM) procedure. In ROM, all patients referred to RD or LUMC for 
treatment of a mood, anxiety or somatoform disorder are routinely assessed with an 
extensive psychometric battery at baseline and prospectively during treatment. Only 




complete computerised and written questionnaires are ineligible for ROM. On average, 80 
percent of the referred patients with a tentative MAS disorder were assessed with ROM in 
the study period. ROM data are primarily used for diagnosis and to inform clinicians and 
patients about treatment progress. Informed consent is not required.
For our study, we used only the baseline ROM assessments. These baseline 
ROM assessments comprised a standardised diagnostic interview (Dutch version of the 
Mini International Neuropsychiatric Interview-Plus, version 5.00-R; MINI-Plus) focussing 
on DSM-IV-TR diagnosis (Sheehan et al., 1998; van Vliet & de Beurs, 2007), collection 
of sociodemographic and socioeconomic data, observer-rated scales and self-report 
questionnaires, and general measures of health and quality of life in order to assess 
psychopathology dimensionally as well as categorically. Both generic and disorder-speci!c 
scales were used. The observational scales were completed in a face-to-face interview, 
whereas the self-report questionnaires were !lled out by the patient using a touch-screen 
computer. The assessments were performed by trained research nurses in the outpatient 
clinics. The use of anonymised data for research purposes has been approved by the 
Medical Ethical Committee of the Leiden University Medical Hospital. 
We included all patients with a current DSM-IV-TR MDD according to the MINI-
Plus in the present analyses. Patients with incomplete data, a bipolar disorder or lifetime 
psychotic illness were excluded, but a diagnosis of psychotic depression was allowed. The 
MINI-Plus was shown to have a sensitivity of 0.94 and a speci!city of 0.79 in identifying MDD. 
Furthermore, the MINI-Plus has been validated with Composite International Diagnostic 
Interview (CIDI) diagnoses (World Health Organisation, 1990), and a good reliability has 
been shown (Lecrubier, 1997). 1637 patients with a current MDD according to the MINI-Plus 
were identi!ed (43.1%). Complete data on all variables of interest were obtained from 1131 
of these patients (69.1%) aged 18-65 years, of whom 53 (4.7%) were tertiary care patients. 
Patients who were missing one or more variables did not di"er signi!cantly from the patients 
with complete data coverage of the outcome variables (data not shown).
Variables
Demographic variables were obtained using a self-report questionnaire that assessed 
ethnic background, education, marital status, housing situation and employment status. 
A Dutch ethnic background was assumed when the patient and both parents were born in 
the Netherlands. Subjective depression severity and individual symptoms were assessed 
with the Beck Depression Inventory-revised (BDI-II), a 21-item self-report instrument with 
good psychometric properties (Beck et al., 1988, Beck et al., 1996). Individual symptoms 
were de!ned as present if the patient scored 2 or 3 on a 4-point likert-scale ranging from 
6FULSWLHB%LQQHQZHUNB&6LQGG Z$0
2
Gender di!erences in MDD
37
0 to 3. The two items that assess eating and sleeping activity were recoded into four 
variables: insomnia, hypersomnia, anorexia and hyperphagia.
The abbreviated Comprehensive Psychopathological Rating Scale consists of 
the Montgomery-Åsberg Depression Rating Scale (MADRS; Montgomery, 1979), the Brief 
Anxiety Scale (BAS; Tyrer et al., 1984) and a scale that assesses psychomotor inhibition (REM; 
Goekoop, 1992). In our study, objective depression severity was assessed with the MADRS. 
The MADRS has a good internal consistency and reliability (Montgomery, 1979). In addition 
to the continuous measure, we distinguished a MADRS score of <20 for mild depression, 
20-35 for moderate depression, and ≥35 for severe depression (Muller, 2003; Snaith, 1986).
The Brief Symptom Inventory (BSI) is a short version of the Symptom Checklist 
(SCL-90), a self-report instrument that assesses pychopathological symptoms in several 
domains, e.g. somatic symptoms, depressive symptoms, anxiety symptoms and hostility 
(de Beurs & Zitman, 2006; Derogatis & Melisaratos, 1983). The BSI has shown good internal 
consistency, reliability and validity (Derogatis, 1977).
If a patient had a MDD according to the MINI-Plus, the patients age at the time of onset 
of the !rst MDD episode was assessed by asking: “how old were you when you !rst 
experienced these symptoms of depression?” Subsequently, the number of MDD episodes 
was asked for. Both prior suicide attempts and current suicidal thoughts (during the past 
month) were assessed with the MINI-Plus.
Melancholic features of depression were assessed with the MINI-Plus according to 
the DSM-IV criteria. Since the MINI-Plus does not systematically assess the DSM-IV atypical 
features of depression, we considered atypical depression present when patients had two 
or more symptoms of polyphagia, fatigue and hypersomnia according to the BDI-II items, 
as previously used by Angst et al. (2006) 
Generic health status was assessed with the Dutch version of the Short Form-36 
Health Survey (SF-36), a 36 item self-report questionnaire that measures health status in 
eight domains (Aaronson, 1998; Ware, 1992). 
Statistical analyses
Chi squared tests were used to compare categorical variables and t-tests for independent 
samples to compare continuous measures between men and women. Bonferroni-
correction was performed in post-hoc tests. In case of a skewed distribution of the 
data, square-root and natural logarithm transformations were applied to obtain a 
normal distribution before the use in statistical testing. Consecutively, data were back-
transformed, and geometric means with 5% and 95% percentiles are given in the tables. 




(for discrete variables). Alternatively, analysis of covariance (ANCOVA, for continuous 
variables) was used. Comorbidity and individual BDI-II symptoms were adjusted for the 
MADRS score which re#ect depressive symptom severity. Signi!cance level was set at 
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Sample and demographic data
Table 2.1 shows the sociodemographic characteristics of the subjects. The sample 
consisted of 395 men (34.9%) and 736 women (65.1%), a male to female ratio of 1 to 1.86. 
The mean age at assessment was 3.8 years higher in men than in women (p<0.001). Ethnic 
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background did not di"er signi!cantly between men and women. 21.5% of men and 
20.0% of women were of non-Dutch origin. More men reported to be living alone than 
women. Women worked part-time signi!cantly more frequently than men, and men were 
more likely to have full-time employment. 
Rating scale scores and clinical characteristics (Table 2.2)
Women reported more severe depressive symptom scores on the BDI-II than men (BDI-II 
total scores of 32.6 vs. 29.3., respectively, p<0.001 adjusted for age and ethnic background). 
Also, the number of BDI-II symptoms (presence de!ned as a score of 2 or 3 on the 0-3 point 
Likert-scale) was higher in women than in men (10.36 out of 21 items vs. 8.89 out of 21 items, 
respectively, p<0.001, data not shown). However, depressive symptom severity assessed by 
the research nurse on the observational MADRS did not di"er between men and women. 
Mild (MADRS <20), moderate (MADRS 20-35) and severe depressive symptoms (MADRS ≥35) 
were distributed equally over the sexes. No signi!cant di"erences were found in severity 
of anxiety symptoms measured with the observational BAS, but observed psychomotor 
inhibition was signi!cantly more pronounced in men than in women.
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Women displayed a higher score than men on the BSI self-report scale (p-value 0.03, 
adjusted for age and ethnic background). Women reported an earlier mean age of onset 
of about 2.5 years than men. When adjusted for age and ethnic background a statistical 
trend remained. No gender di"erences were found in reported number of MDD episodes. 
Women revealed more prior suicide attempts than men, whereas suicidal thoughts during 
the month before assessment were equally reported in both sexes.
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Depressive subtype and DSM-IV comorbidity (Table 2.3)
Men and women equally reported melancholic features, providing the diagnosis ‘MDD 
melancholic subtype’ in 45% of the subjects. Atypical features, however, were 63% more 
prevalent in women than in men (p=0.001 adjusted for age, ethnic background and 
MADRS score). Signi!cant di"erences between the sexes were also found in the DSM-IV 
comorbidity patterns: posttraumatic stress disorder and bulimia nervosa were more 
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common in women with MDD, whereas social phobia, abuse or dependence on alcohol 
or drugs, and attention de!cit hyperactivity disorder (ADHD) were more common in men. 
Women were more likely to have a singular depression, i.e. without any comorbid DSM-IV 
axis I diagnosis. 
Symptoms of depression
We found several di"erences in reported symptoms between men and women, as 
measured with the BDI-II self-report scale. After adjustment for age, ethnic background 
and MADRS score, women reported signi!cantly more loss of energy, hypersomnia, 
worthlessness, loss of appetite, tiredness, loss of interest in sexual activity, feelings of guilt 
and crying than men. In !gure 2.1, the proportional di"erences in occurrence of BDI-II 
symptoms between women and men are shown.
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Generic health status (Table 2.4)
After adjusting for age and ethnic background, self-reported generic health status was 
signi!cantly lower in women than in men on six of eight subscales of the SF-36: physical 
functioning, social functioning, physical problems, emotional problems, vitality and 
bodily pain. No gender-speci!c di"erences were found in the subscales mental health 
and general health.
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We found important di"erences in MDD severity and symptom pro!le between men and 
women in our large secondary and tertiary psychiatric care naturalistic sample of MDD-
outpatients. Women reported a signi!cantly more severe phenotype, with more severe 
symptoms of depression as compared to men on several self-report scales (i.e., BDI-II, BSI 
and SF-36) and more symptoms on the BDI-II, but no di"erences in symptom severity 
were observed on most observer-rated scales (i.e., MADRS and BAS). The second major 
!nding was that more women than men su"ered from atypical features of depression 
and comorbid PTSD, whereas men su"ered more from psychomotor inhibition, comorbid 
social phobia, ADHD and alcohol or drug abuse than women.
Since our patient sample re#ects a naturalistic treatment seeking population 
in psychiatric specialty care, our !ndings add importantly to the existing literature on 
gender di"erences in MDD, which consists mainly of information based on data from RCTs 
and community samples. It is known that RCTs are much more prone to selection-bias 
than naturalistic patient samples, partly due to the strict selection-criteria (e.g., patients 
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with suicidal tendencies or comorbidity are generally excluded) that are often used in 
RCTs. Such patient selection criteria limit the generalisability of !ndings to real-world 
clinical practice (Zetin, 2007; Zimmerman, 2002; Zimmerman, 2005). Speci!cally, patients 
who would be excluded from an antidepressant e%cacy trial may be more likely to have 
somatic and psychiatric comorbidity, more previous episodes of MDD, greater psychosocial 
impairment and more personality pathology (Zimmerman, 2005). In addition, community 
samples may also poorly re#ect a treatment seeking naturalistic sample. 
Although the STAR*D study more closely re#ected a real-life treatment-seeking 
patient population because less strict inclusion criteria were used compared to most RCTs, 
a selection has still been made from patients who chose and gave informed consent to 
participate in the trial. 
Our main !nding that women tend to report more and more severe symptoms 
than men is largely consistent with previous studies in non-naturalistic patient samples 
(Frank et al., 2005; Kornstein et al., 2000; Marcus et al., 2005; Marcus et al., 2008; Verhagen, 
2008). Similar scores for men and women on clinician rated scales of depression (Hamilton 
Depression Rating Scale (HAMD), MADRS) were found in most studies (Carter et al., 2000; 
Frank et al., 1988; Kornstein et al., 2000; Marcus et al., 2005), with the exception of the 
2008 STAR*D replication study, which found a slightly higher HAMD and clinician-rated 
Inventory of Depressive Symptomatology (IDS) score in women versus men (Marcus et 
al., 2008). Higher scores on the BDI and SF-36 self-report scales in women with MDD as 
compared to men were also reported by Kornstein et al (Kornstein et al., 2000). In general, 
self-report scales tend to show a more subjective score as compared to clinician-rated 
scales, although the latter scales may su"er from speci!c forms of rater-bias. These errors 
may be compensated for by combining the two types of rating-scales (Möller, 2009). 
Our !ndings also suggest that subjective distress, and not objective distress, measured 
in both the amount of symptoms, symptom severity and health status, is higher in 
depressed women than in depressed men. Alternatively, men could be less inclined to 
admit depressive symptoms and its impact on self-report scales. The fact that the research 
nurses were all female may also have played a role, although in the latter case one would 
expect to !nd di"erences in observational scales as well. Young et al. did not !nd any 
gender-related rater bias in a comparable setting (Young et al., 1990). 
Not only did we !nd more subjective distress in women than men, we also showed 
that their subjective symptom pro!le was di"erent (see !gure 2.1). These quantitative 
and qualitative di"erences may have several implications for diagnosis and treatment. 
Firstly, if in studies or treatment settings depressed patients are included based on a cut-




withhold treatment they need in case their subjective scores would be taken into account. 
How large this group is and to what extent these patients indeed would be able to pro!t 
from treatments should be a subject of further investigations. Secondly, the di"erences 
in subjective symptom pro!le suggest that psychotherapeutic interventions could be 
more e"ective if these gender di"erences were taken into account. The same is true for 
pharmacological treatment as pharmacological treatment choices are often based on 
clinical characteristics (Trivedi et al., 2008; Zimmerman et al., 2004). Thirdly, as subjective 
di"erences in symptoms are related to gender, these di"erences might also be related 
to the di"erences in hormonal status between women and men. This also needs further 
study. 
Other !ndings in both clinical trial and population-based samples that are in line 
with our !ndings include the age of onset of depression, suicidality and rates of atypical 
depression. We found that women reported an earlier onset of depression, in line with 
previous studies (Kessler, 2003; Marcus et al., 2005). However, this younger age of onset 
was confounded by the age at assessment – lower in women than in men – and ethnic 
background. The 30% higher proportion of female patients than male patients with prior 
suicide attempts in our study is consistent with most studies (Marcus et al., 2005; Marcus 
et al., 2008; Petronis, 1990; Rapaport, 1995). The high percentage can be explained by the 
fact that the sample consisted of secondary and tertiary care patients, which implicates 
rather severe psychopathology. In most RCTs, suicidality is an exclusion criterion. Hence, 
reported information about suicidality in RCTs is likely to be an underestimate of the true 
suicidality in MDD. We found a higher predominance of atypical features of depression in 
women than in men. A higher female preponderance of atypical depression is generally 
found in the literature, although di"erent de!nitions or constructs of atypical depression 
are used (Angst et al., 2006; Khan et al., 2002; Silverstein, 2002; Smith et al., 2008). This 
higher level of atypical depression in women could re#ect a di"erent underlying biological 
aetiology for depression or a di"erent expression of a similar underlying aetiology in men 
and women (Gold, 2002; Smith et al., 2008). Comorbidity patterns that di"ered between 
the sexes, eg. more ADHD and alcohol and drug abuse in men, and more bulimia and PTSD 
in women, were previously found in population-based and clinical trial studies (Breslau, 
Schultz, & Peterson, 1995; Kornstein & Sloan, 2005;  Marcus et al., 2008). But interestingly, 
overall we found no higher number of comorbid anxiety disorders in women, in contrast 
to most studies (Breslau, Schultz, & Peterson, 1995; Kornstein & Sloan, 2005; Marcus et al., 
2005; Marcus et al., 2008)
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Several theories have been proposed to explain gender di"erences in MDD, 
for example di"erences in treatment seeking behaviour between men and women, 
psychological factors, genetic factors, neuroendocrine factors like di"erences in sex 
hormones, and changes during the menstrual cycle in premenopausal women. Exact 
mechanisms, however, remain unclear (Kendler, 2001; Kuehner, 2003; Middeldorp et al., 
2006; Piccinelli & Wilkinson, 2000). 
Strengths and limitations
Strengths of this study are the large study population of over 1,100 MDD patients, the 
routinely, as part of the normal clinical process adapted computerised assessments by 
specially trained research nurses and the fact that this population re#ects a naturalistic 
treatment-seeking population in psychiatric specialty care. 
Our study also has several potential limitations. Firstly, no information about 
somatic comorbidity, familial status or use of medication was ascertained. A previous 
population-based study showed evidence for gender-related di"erences in comorbidity, 
dependent on familial status of MDD (Verhagen, 2008). The fact that women reported 
more bodily pain or more impaired functioning due to pain on the SF-36 (table 4) could 
correlate with the presence of more somatic comorbidity in women. Secondly, we were 
not able to assess all referred MDD patients, because about 20% of all patients in RD and 
LUMC did not have a baseline ROM assessment due to language problems or logistical 
reasons. So in spite of the fact that only a minimal selection was made in our patients due 
to the routinely applied ROM assessments, this sample may not be wholly representative 
for all MDD outpatients. Thirdly, since DSM-IV atypical features have not been assessed 
systematically, we de!ned atypical depression by the presence of two or more from the 
BDI-II items of hyperphagia, hypersomnia and fatigue (Angst et al, 2006) This construct 
is not per se comparable with DSM-IV atypical depression since information about 
interpersonal rejection sensitivity and mood reactivity was lacking.
We conclude that in our naturalistic MDD-sample, depression severity in women 
was higher compared to men when measured on self-report scales (BDI-II, BSI), whereas no 
di"erence was found on observational scales (MADRS, BAS). In addition, reported health 
status was worse in women than in men, measured on the SF-36. These !ndings may be 
an explanation for the higher predominance of women with MDD that attend psychiatric 
specialty care. The prognostic and therapeutic implications of these !ndings should be 
further studied. Furthermore, the need for studying psychological factors, genetic liability 
and biological mechanisms underlying the gender di"erences in depression and its 
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Abstract
Background: Pre-adult onset of Major Depressive Disorder (MDD) may predict a more 
severe phenotype of depression. As data from naturalistic psychiatric specialty care 
settings are scarce, we examined phenotypic di"erences between pre-adult and adult 
onset MDD in a large sample of consecutive outpatients.
Methods: Altogether, 1,552 outpatients, mean age 39.2 ± 11.6 years, were diagnosed 
with current MDD on the Mini International Neuropsychiatric Interview-Plus (MINI-Plus) 
as part of the usual diagnostic procedure. A total of 1,105 patients (71.2%) had complete 
data on all variables of interest. Pre-adult onset of MDD was de!ned as having experienced 
the signs and symptoms of a !rst Major Depressive Episode before the age of 18 years. 
Patients were strati!ed according to the age at interview (20-40 / 40-65 years). Correlates 
of pre-adult onset were analysed using logistic regression models adjusted for age, age 
squared and gender. 
Results: Univariable analyses showed that pre-adult onset of MDD had a distinct set of 
demographic (e.g. less frequently living alone) and clinical correlates (more comorbid 
DSM-IV-Text Revision diagnoses, more social phobia, more suicidality). In the multivariable 
model we found an independent association only for a history of suicide attempts (OR 
3.15; 95% CI: 1.97-5.05) and current suicidal thoughts (OR 1.81; 95% CI 1.26-2.60) in 
patients with pre-adult versus adult onset MDD. 
Discussion: Pre-adult onset of MDD is associated with more suicidality than adult onset 
MDD. Age of onset of depression is an easy to ascertain characteristic that may help 





Several studies suggest that pre-adult and adult onset major depressive disorder (MDD) are 
two distinct forms of MDD in terms of pathophysiology and phenomenology (see review 
by Kaufman et al., 2001). Diagnostic criteria according to the Diagnostic and Statistical 
Manual of Mental Disorders-Text Revision (DSM-IV-TR) for MDD are independent of the 
age of onset of the !rst major depressive episode (MDE; American Psychiatric Association, 
2000). This contrasts with dysthymic disorder, for which the DSM-IV-TR makes a distinction 
in age of onset before or after 21 years of age (early onset and late onset, respectively). 
In previous studies, demographic characteristics of pre-adult versus adult onset 
MDD were female gender, being unmarried (Benazzi, 2000; Zisook et al., 2004; Zisook 
et al., 2007a), impaired social and occupational functioning (Zisook et al., 2007a), and 
lower education (Parker et al., 2003). The course of the depressive disorder also di"ered 
signi!cantly in some studies, with pre-adult onset MDD being associated with more 
depressive episodes (Benazzi, 2000; Klein, 1999; Ramklint & Ekselius, 2003; Zisook et al., 
2004; Zisook et al., 2007a) and more chronicity (Benazzi, 2000; Coryell et al., 2009; Klein, 
1999; Parker et al., 2003; Zisook et al., 2004; Zisook et al., 2007a; Zisook et al., 2007b). In 
addition, pre-adult MDD patients showed more suicidality (Benazzi, 2000; Zisook et al., 
2004; Zisook et al., 2007a; Zisook et al., 2007b; Thompson, 2008), a higher amount of medical 
comorbidity (Zisook et al., 2007a), more familiality of depression (Klein, 1999; Parker et al., 
2003; Kendler et al., 2005; Zisook et al., 2007b), and more alcohol and drug abuse (Klein, 
1999; Parker et al., 2003; Zisook et al., 2007b). Early childhood risk factors like motor skill 
de!cits, perinatal insults and caretaker instability, criminality and psychopathology in the 
families of origin were associated with pre-adult onset MDD in a birth cohort that had 
been followed from childhood up to age 26 (Ja"ee et al., 2002). Taken together, these data 
suggest that pre-adult onset MDD points towards a more severe form of illness.
Previous investigations have been undertaken in various study populations, 
using varying study designs. Prospective !ndings from a New Zealand birth-cohort 
suggested that both heritable and childhood psychosocial factors contributed to a pre-
adult onset of depression (Ja"ee et al., 2002). These !ndings were consistent with results 
from family studies which suggested that pre-adult onset MDD might be more strongly 
associated with genetic factors and early childhood psychosocial risk factors (Kovacs et al., 
1997; Neuman et al., 1997; Klein et al., 2001). Several studies reported a di"erent course 
of illness of pre-adult onset and adult onset MDD. Adolescent MDD has been associated 
with elevated rates of subsequent MDEs in early adulthood in prospective case control 
studies (Harrington et al., 1990; Weissman et al., 1999). Yet, most studies used cross-
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sectional designs in selected populations. In three analyses in the Sequenced Treatment 
Alternatives to Relieve Depression (STAR*D) Study population (Zisook et al., 2004; Zisook 
et al., 2007a; Zisook et al., 2007b), using data from over 4,000 selected MDD patients 
the most prominent !ndings in pre-adult onset MDD patients were more psychiatric 
comorbidity and more suicidality. These !ndings were largely consistent with the !ndings 
in a large US community sample of 9,282 people (Thompson, 2008).
  It is well established that clinical treatment samples may be prone to selection 
bias, whereas population-based samples may not re#ect a treatment seeking population 
either (Zimmerman et al., 2002). Since data on naturalistic patients are generally considered 
to represent ‘real life patients’ more closely than selected populations, naturalistic data on 
di"erences between pre-adult onset versus adult onset MDD would be of great value. 
Therefore, the aim of the present study was to evaluate di"erences in demographic 
correlates, comorbidity, symptomatology and general health status between pre-adult 
and adult onset MDD in a large naturalistic outpatient sample from psychiatric specialty 
care. We used the Leiden Routine Outcome Monitoring study baseline sample (de Beurs et 
al., 2011; van Noorden et al., 2010). We hypothesised that pre-adult onset MDD would be 
characterised by markers of greater severity as compared with adult onset MDD. Pre-adult 
onset of MDD was de!ned as !rst MDE before the age of 18 years.  
Methods
Study design
The Leiden Routine Outcome Monitoring study baseline cohort sample comprised 3,798 
adult outpatients who were referred for treatment of a mood, anxiety, or somatoform 
(MAS) disorder to the Dutch Regional Mental Health Provider (RMHP) Rivierduinen (RD) 
or the psychiatric outpatient department of the Leiden University Medical Center (LUMC) 
in the Western part of the Netherlands, between January 2004 until December 2006 (van 
Noorden et al., 2010; de Beurs et al., 2011). At baseline, subjects were assessed as part 
of the Routine Outcome Monitoring (ROM) procedure. In ROM, all patients referred to 
RD or LUMC for treatment of a MAS disorder are routinely assessed, at baseline and at 
!xed intervals during treatment, with an extensive battery of psychometric instruments 
administered by specially trained research nurses. ROM is a method for the systematic 
collection of data on the diagnostic status and severity of complaints to assess the 
e"ectiveness of treatments in everyday clinical practice. The only exclusion criteria for ROM 




procedure due to severity of symptoms. In practice, more than 80% of the patients 
referred to the LUMC or RD for treatment of a MAS disorder are enrolled in ROM. During 
the !rst session, psychopathology was assessed with the Dutch translation of the Mini 
International Neuropsychiatric Interview-Plus 5.0.0.-R, structured diagnostic interview 
(MINI-Plus) developed to assess the presence of Axis-I disorders according to the DSM-IV-
TR diagnostic criteria (Sheehan et al., 1998; van Vliet & de Beurs, 2007). The MINI-Plus has 
been validated with the Composite International Diagnostic Interview (CIDI; World Health 
Organisation, 1990) diagnoses and has good psychometric properties (Lecrubier et al., 
1997). Patient data were stored anonymously in the Psychiatric Academic Registration 
Leiden (PAREL) database and were accessible for research purposes only. This procedure 
has been approved by the Medical Ethical Committee of the LUMC. For the present study, 
only the baseline ROM data were used. 
Study population
In the present analyses all patients with a current DSM-IV-TR MDD diagnosis according to 
the MINI-Plus (age range 20-65) were included. We used only baseline ROM assessments, 
administered at intake. No distinction was made between MDD as principal or comorbid 
diagnosis. Concomitant current DSM-IV-TR disorders were recorded as well. The presence 
of DSM-IV-TR melancholic features of depression was systematically assessed with the 
MINI-Plus, whenever the DSM-IV-TR criteria for MDD were ful!lled. Patients with a bipolar 
disorder or lifetime psychotic illness were excluded, but a diagnosis of psychotic depression 
was allowed. Only patients with complete data on all variables of interest were included in 
the initial analyses. 1,552 (40.9%) of 3,798 patients ful!lled the DSM-IV-TR criteria of MDD, 
current episode on the MINI-Plus, and were aged 20-65. Of these 1,552 MDD patients, 
1105 (71.2%) had complete data on all variables of interest and were included in the 
present analyses. The excluded 447 patients di"ered statistically signi!cant in age (mean 
age 40.6, vs. 39.3 for included patients, respectively; t =2.06, p=0.04), age of onset (mean 
age 31.4 vs. 28.3 for included patients, respectively, t =4.21, p<0.001), MADRS score (mean 
score 24.2 vs. 25.5 for included patients, respectively; t =-2.54, p=0.02), but not in gender, 
total BSI score, current suicidal thoughts or history of suicide attempts. 
Age of onset
Age of onset of MDD was de!ned as the age at which the !rst MDE initiated, regardless of 
whether treatment was sought. In the MINI-Plus, when a current MDD was diagnosed, the 
age of onset of the !rst episode was assessed by the question: ‘How old were you when 
you !rst experienced these symptoms of depression, for at least two weeks?’ In our study 
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we de!ned pre-adult onset of MDD as an onset of MDD before age 18, in accordance with 
the existing literature on this subject. Various cut-o" points to distinguish between pre-
adult and adult onset MDD have been used in previous studies. Cut-o" ages varied from 
17 (Ja"ee et al., 2002), 18 (Alpert et al., 1999; Benazzi, 2000; Fava et al., 1996; Zisook et al., 
2004; Zisook et al., 2007a; Zisook et al., 2007b), 21 (Klein, 1999), 25 (Parker et al., 2003) and 
26 (Ramklint and Ekselius, 2003) to 30 (Thompson, 2008), and despite the lack of widely 
accepted consensus most authors use a cut-o" age of 18 years. In sensitivity analyses we 
re-analysed our data with a cut-o" age of 25 years (see statistical analyses).
Other variables
Demographic variables were obtained using a self-report questionnaire that assessed 
ethnic background, marital status, housing situation, educational status, and employment 
status. A Dutch ethnic background was assumed when the patient and both parents were 
born in the Netherlands. 
Depression severity was assessed with the Montgomery-Åsberg Depression 
Rating Scale (MADRS; Montgomery, 1979), a 10-item observer-rated scale that measures 
symptoms of depression on a 7-point Likert-scale. The MADRS has a good internal 
consistency and reliability (Montgomery, 1979). In addition to the continuous measure, 
three categories were distinguished; a MADRS score of <20 for mild depression, 20-35 for 
moderate depression, and ≥35 for severe depression (Muller, 2003; Snaith, 1986). Post-hoc, 
we analysed MADRS item 10, that assesses suicidal thoughts. We dichotomised in symptom 
absent, if the score was 0 or 1, and symptom present if the score was 2 or higher. The Brief 
Anxiety Scale (BAS), an observer-rated scale that measures symptoms of anxiety, was used 
to assess severity of anxiety (Tyrer et al., 1984). General psychopathological symptoms were 
scored on the Brief Symptom Inventory (BSI). The BSI is a short version of the Symptom 
Checklist (SCL-90), a self-report instrument that measures psychopathological symptoms 
in several domains, e.g. somatic symptoms, depressive symptoms, anxiety symptoms 
and hostility on a 5-points Likert-scale (de Beurs & Zitman, 2006; Derogatis & Melisaratos, 
1983). The BSI has shown good internal consistency, reliability and validity (Derogatis, 
1977). In addition to the BSI-total score we studied presence of speci!c symptoms on the 
depressive and anxiety subscales of the BSI. A score of 0 or 1 on each individual item was 
de!ned as the absence of a symptom, whereas a score of 2, 3 or 4 was de!ned as the 
presence of a symptom. A history of suicide attempts and current suicidal thoughts were 
assessed with the MINI-Plus. In section C of the MINI-Plus, the following questions were 
asked respectively: “Did you ever in your life try to commit suicide?” and “During the past 




Comorbid DSM-IV-TR disorders, e.g. anxiety disorders, somatoform disorders 
and alcohol or drug related disorders were also assessed with the MINI-Plus. Generic 
health status was assessed with the Dutch version of the Short-Form-36 health survey 
(SF-36), a 36-item self-report questionnaire that measures health status in eight domains: 
physical functioning, role limitations due to physical health, bodily pain, general health 
perceptions, vitality, social functioning, role limitations due to emotional problems, and 
mental health (Aaronson et al., 1998; Ware, Jr. & Sherbourne, 1992). 
Statistical analyses
All group comparisons were made between pre-adult onset (age<18 years) and adult 
onset (age≥18 years) MDD-groups. T-tests for independent samples were used for 
continuous data, while categorical data were analysed with χ2 tests. In all previous cross-
sectional studies, the pre-adult onset MDD patients were younger than adult onset MDD 
patients at the time of assessment. Despite the fact that many studies adjusted for age, 
residual confounding by age at interview is possible as several demographic factors are 
highly associated with age (e.g., marital status, duration of disease, and comorbidity). 
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Therefore, we strati!ed the study population into two age strata (20-40 and 40-65 years 
of age at interview). If both age strata would yield similar associations and odds ratios, 
the confounding e"ects by age are likely to be small. Strati!cation based on the age of 40 
years was chosen because this age is generally considered to be the beginning of middle 
age, and it was close to the median age of the sample (i.e., 38 years). Also, it was assumed 
that the associations between the clinical characteristics and age of onset would vary by 
gender. Therefore we also made adjustments for gender and current age by including 
these characteristics in a logistic regression model with forced entry (adjusted analysis). 
To account for the potential curvilinear confounding e"ects of age, a quadratic term 
(age-squared) was added to the model. In the logistic regression model, we analysed 
the univariable !ndings with a p<0.1 in the two age strata and the combined group. 
Sensitivity analyses were performed in which patients with an age at interview of 20-25 
years were excluded from the analyses, to rule out the possibility that any di"erences in 
outcome could be explained by the very short disease duration. Sensitivity analyses were 
subsequently performed on the complete sample of 1,552 MDD patients while using 
multiple imputations of missing data. Finally, sensitivity analyses were performed in which 
a cut-o" age of 25 instead of 18 years was used to distinguish between pre-adult onset 
and adult onset MDD. The statistical signi!cance was set at p<0.05. When appropriate, 
Bonferroni correction for multiple testing was applied. Statistical analysis was carried out 




The sample consisted of 711 women and 394 men (35.7%). The mean age of the subjects 
was 39.2 (SD 11.6) years (range 20-65). Figure 3.1 illustrates the distributions of age of 
onset of MDD and age at interview of the 1,105 patients. In table 3.1 the sociodemographic 
characteristics of the study population are presented. In total, 246 patients (22.3%) had an 
early-onset form of MDD. These patients were younger than adult onset patients at the 
time of interview in both strata (in 20-40 group: median age 25 vs. 31 years, respectively 
[p<0.001], in 40-65 group: median age 46 vs. 49 years [p=0.03]). No di"erence in ethnic 
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Univariable analyses
Table 3.2 shows the relationship between age at onset and rating scale scores and 
subtype of depression. The main di"erence was that patients with pre-adult onset 
MDD had signi!cantly more often a history of suicide attempts (in 20-40 group 30.8% 
vs. 18.5% [p<0.001]; in 40-65 group 36.5% vs. 19.4% [p<0.001]). No di"erences between 
the groups were found in MADRS continuous scores, nor in MADRS categories. Only in 
the 20-40 group, pre-adult onset patients more often had a positive score on the MADRS 
suicidality item (47.1% vs. 37.8% [p=0.04]). No signi!cant di"erences were found between 
the early- and adult onset groups on the BSI or BAS scores, nor in the presence of subtypes 
of depression. 
Furthermore, we analysed the di"erences between pre-adult onset and adult 
onset groups on the symptom level, by focusing on the anxiety and depression subscales 
of the BSI. Signi!cant di"erences in univariable analyses were found for the following 
two items only: “thoughts of ending your life” and “feeling hopeless about the future”. 
Consistent with “suicidal thoughts” on the MINI-Plus, these a%rmative answers from the 
depression subscale were more prevalent in patients with pre-adult onset than adult 
onset MDD (data not shown).
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Table 3.3 summarises the presence of comorbid DSM-IV-TR disorders according 
to age of onset in each group, in univariable analyses. Pre-adult onset individuals had 
increased rates of comorbid social phobia, but no di"erences were found in the rates of 
other DSM-IV-TR anxiety disorders.
Patients with a pre-adult onset MDD were more likely to be dependent on drugs 
or to abuse drugs and had a higher number of comorbid MAS disorders.
No di"erences were found for any of the SF-36 subscale scores between pre-adult 
onset and adult onset MDD patients (data not shown).
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Multivariable and sensitivity analyses 
The results of the multivariable analyses are presented in table 3.4. After adjusting for age 
at interview and gender, in both strata pre-adult onset MDD patients signi!cantly more 
often had a history of suicide attempts compared to adult onset MDD patients (OR in 
20-40 group: 4.17; 95% con!dence interval [CI]: 2.25-7.72; OR in 40-65 group: 2.52; 95% 
CI: 1.12-5.67). Furthermore, pre-adult patients in the 20-40 group and in the combined 
groups more often had current suicidal thoughts. In the 40-65 group, a non-signi!cant 
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trend was found. In the combined groups, the OR for having a history of suicide attempts 
in pre-adult onset MDD patients was 3.15 (95% CI: 1.97-5.05), and the OR for having current 
suicidal thoughts was 1.81 (95% CI: 1.26-2.60). Results of sensitivity analyses as described 
in the methods section were as follows: In a !rst sensitivity analysis when excluding all 
patients between 20 and 25 years, the odds ratio’s for a history of suicide attempts and 
current suicidal thoughts remained largely unchanged (2.75 and 1.66, respectively, for 
the combined group). In our second sensitivity analysis we aimed to impute missing data 
and to analyse the complete sample of 1,552 MDD patients in the multivariable model. 
However, no variables used in the multivariable model were missing, so the analysis could 
be performed in 1,552 patients without imputation. Odds ratio’s for a history of suicide 
attempts and current suicidal thoughts were 2.71 and 1.52 respectively, for the combined 
group. In the third sensitivity analysis we used a cut-o" age of 25 instead of 18 years to 
distinguish between pre-adult and adult onset MDD. In this analysis, OR were again largely 
comparable to the original analysis (2.78 and 1.94, respectively for the combined group). 
Discussion
In our naturalistic patient sample we found that patients with pre-adult onset MDD, 
de!ned as an onset before age 18, more often had a history of suicide attempts and current 
suicidal thoughts compared to patients with adult onset MDD. We found no di"erences 
in severity of depression measured with the MADRS, nor di"erences in the presence of 
comorbid anxiety disorders or di"erences in self-reported generic health status.
 The main !nding of more previous suicide attempts and current suicidal thoughts 
after adjusting for age at interview and gender in multivariable models in patients with 
pre-adult onset MDD, is in accordance with the results of several studies in di"erent 
populations and settings. In three studies of Zisook et al. (Zisook et al., 2004; Zisook et 
al., 2007a; Zisook et al., 2007b), the STAR*D population was used to investigate factors 
that di"erentiate early and later onset MDD. The most prominent !nding of the !rst two 
studies in 1,500 and 2,541 patients, respectively, was a higher rate of suicidality and more 
previous suicide attempts in the pre-adult onset MDD group (Zisook et al., 2004; Zisook et 
al., 2007b). In the third study on the combined sample the study population was divided 
into !ve age-at-onset groups. Earlier onset was again associated with more suicidality in 
multivariable analyses adjusted for age at interview, duration of illness and gender (Zisook 
et al., 2007a). Most other !ndings of the !rst study, like more anxiety disorders in the pre-




second and third study. Our results are also in line with those of the National Comorbidity 
Survey, a large representative US population study in 9,289 respondents, where a higher 
degree of suicidal intent was associated with early onset MDD (Thompson, 2008).
 In our study, there were no signi!cant di"erences in a number of clinical 
characteristics, such as symptom severity or comorbid anxiety disorders, which were 
found previously in several clinical trial samples to di"er between pre-adult and adult 
onset MDD (Benazzi, 2000; Zisook et al., 2004; Zisook et al., 2007a; Zisook et al., 2007b). For 
example, after adjusting for age at interview and gender, pre-adult onset was found to be 
associated with more social and simple phobias and more alcohol abuse or dependence 
in a sample of 381 adult MDD patients who were recruited for outpatient clinical trials 
(Alpert et al., 1999). In a study of 269 MDD outpatients, partly consecutive referrals 
and partly recruited patients, patients with an MDD-onset before age 25 showed more 
irritability, anxiety, and more alcohol and drug use in multivariable models adjusting for 
age at interview (Parker et al., 2003). The fact that earlier cross-sectional studies identi!ed 
other clinical di"erences between pre-adult onset and adult onset MDD patients might 
be explained by the di"erences in study design and populations. These clinical studies 
often used selected groups of patients that had been recruited for clinical treatment 
trials. It is known that clinical treatment studies, particularly Randomised Controlled Trials 
(RCTs), use stringent criteria for patient selection which may reduce the generalisability to 
routine clinical practice. For example, patients with suicidality, comorbidity or unsuccessful 
previous treatments are often excluded from RCTs (Zetin & Hoepner, 2007; Zimmerman et 
al., 2002; Zimmerman et al., 2005). If suicidal patients are excluded, !nding an association 
between suicidality and age of onset would be impossible. (e.g. Alpert et al., 1999; Klein, 
1999) On the other hand, one would expect to validate previous !ndings from more 
selected populations in a replication study with a naturalistic design. Since the results of 
studies carried out in naturalistic patient samples are more applicable to ‘real-life’ patients, 
the probability of !nding ‘true e"ects’ is higher in these studies. Indeed, the !nding of 
more suicidality in pre-adult onset MDD was the main !nding of the three STAR*D trials, 
with a design that aimed to have maximum generalisability of patients in both specialty 
and primary care.
Another remarkable di"erence between previous cross-sectional studies and 
our study is the proportion of MDD patients that reported a pre-adult onset of MDD. The 
percentage (22%) of MDD patients that reported a pre-adult onset MDD in our study is 
lower than the 35-40% found in other studies (Alpert et al., 1999; Fava et al., 1996; Zisook 
et al., 2007a) also using a cut-o" age of 18. Since both our study and these earlier studies 
obtained the age of onset retrospectively, this cannot explain the observed di"erences. 
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Hence, the di"erences are probably the result of di"erences in study design and study 
samples. 
We found no di"erences between the groups in rates of patients with melancholic 
depression. The overall rate of 46.1% (509 from 1,105 patients, see table 3.2) is in line 
with previous prevalence estimates of melancholic depression in psychiatric specialty 
care outpatients, that vary from 16% to 67% (Mallinckrodt et al., 2005) depending on 
de!nitions being used.  
The !nding that patients with a pre-adult onset MDD are more likely to have 
attempted suicide and to have current suicidal thoughts could have several explanations. 
First, the increased occurrence of suicidality in pre-adult onset MDD could point towards 
a di"erent variant of MDD, with a di"erent genetic and familial load or other childhood 
experiences. Indeed, previous studies on suicidality in depression found that genetic 
factors and familial loading were risk factors for suicide attempts in depression as were 
early traumatic experiences (Malone et al., 1995). Unfortunately, no information about 
familial status or early trauma was ascertained in ROM in the study period. Second, 
MDD with an onset before age 18 could re#ect a more severe variant of MDD. Suicidality 
and suicide attempts generally occur in severely depressed patients and hence can be 
interpreted as a marker of severity of psychopathology (Forman et al., 2004). However, 
this explanation is not supported by the results of our study as we did not !nd di"erences 
between the pre-adult and late-adult onset MDD patient on global measures of severity, 
e.g. MADRS scores or BSI total scores. A third  explanation for the increased suicidality 
could be found in the time passed by since the onset of MDD as patients with pre-adult 
onset of MDD generally have been depressed longer or more often. Because we adjusted 
for current age and strati!ed in two age groups, we did not adjust for the highly correlated 
disease duration variable. Furthermore, in a sensitivity analysis in which we excluded all 
patients aged 20-25, the odds ratio’s remained largely unchanged. Hence, we believe that 
our data do not support the explanation of the increased suicidality being the result of the 
longer disease duration or in patients with pre-adult onset MDD. A !nal explanation could 
be that the increased suicidality is a chance !nding. However, the use of strati!cation with 
the consistent !ndings within each stratum, as well as the consistency with previous 
similar !ndings (Zisook et al., 2004; Zisook et al., 2007a; Zisook et al., 2007b; Thompson 





Our study has several strengths. First, to our knowledge, few previous studies investigated 
the di"erences between pre-adult MDD and adult MDD in a naturalistic sample of 
secondary and tertiary care MDD outpatients. More than 80% of the patients referred for 
treatment of a MAS disorder between 2004 and 2007 in RD or the LUMC were included 
in the ROM-database. The external validity of these !ndings from real-life patients is 
likely higher than !ndings in samples from RCTs. Second, the reliability of the results was 
enhanced by replication of the !ndings in the two age group samples, ruling out the 
confounding of age. Most previous studies adjusted for current age (Parker et al., 2003; 
Ramklint & Ekselius, 2003) or age and duration of illness (e.g. Zisook et al., 2004; Zisook et 
al., 2007b), which may still leave room for residual confounding. Third, in addition to using 
a cut-o" age of 18 years like in most previous studies, we performed a sensitivity analysis 
in which we used a cut-o" age of 25 years to distinguish between pre-adult and adult 
onset MDD. This analysis yielded largely comparable results. 
A limitation of our study is the fact that the initial onset of MDD was assessed 
retrospectively, by using self-report estimates, which limits the reliability. This was also 
the case in many previous studies. This method is more prone to measurement error and 
bias than assessment through medical records, e.g., a current depressive state can cause 
recall bias regarding the exact age of onset of the !rst depressive episode. In addition, the 
retrospective assessments did not allow for more subtle distinctions, such as the between 
the onset of !rst symptoms and the onset of the full syndrome. However, as other studies 
also assessed age of onset retrospectively, this limitation is not restricted to our study. 
Other possible limitations include the fact that not all patients were included in the ROM 
database (e.g. due to language problems) and the fact that excluded patients with missing 
variables had di"erent mean age, age of onset and MADRS score than included patients. 
Furthermore, no data regarding familial status, somatic comorbidity, Axis II disorders and 
information about (pharmacological) treatment was ascertained. Finally, by using the 
MINI-Plus diagnostic interview we were not able to make a distinction between principal 
and comorbid diagnoses.
Conclusion
Overall, our !ndings in a large naturalistic cohort of outpatients with MDD con!rm earlier 
studies that found pre-adult onset MDD associated with more suicidality. Our study 
stresses the importance of taking the age of onset of MDD in account in clinical decision 
making and suicide risk assessment. 
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Abstract
Background: Deliberate self-harm and suicidal ideation (DSHI) are common phenomena 
in general and mental health populations. Identifying factors associated with DSHI may 
contribute to the early identi!cation, prevention and treatment of DSHI. Aims of the study 
are to determine the prevalence and correlates of lifetime DSHI in a naturalistic sample of 
psychiatric outpatients with mood, anxiety or somatoform (MAS) disorders.
Methods: Of 3,798 consecutive patients from January 2004 to December 2006, 2,844 
(74.9%) patients were analysed (mean age=37.5, SD=12.0; age range: 18-65; 62.7% 
women). Lifetime DSHI was assessed with Routine Outcome Monitoring (ROM), including 
demographic parameters, DSM-IV diagnosis, depressive symptoms, symptoms of anxiety, 
general psychopathology and personality traits. 
Results: Of the 2,844 subjects, 55% reported lifetime DSHI. In multivariable logistic 
regression analysis, the most important factors associated with lifetime DSHI were being 
unmarried, low education, high number of psychiatric diagnoses, lower anxiety scores, 
higher depression scores and the personality trait of emotional dysregulation. 
Limitations: Deliberate self-harm may have been under-reported in self-report 
questionnaires; the assessment of personality traits may have been in#uenced by state 
psychopathology; traumatic events were not assessed.
Discussion: The !ndings suggest that DSHI is common among psychiatric outpatients 
with MAS disorders and that current symptoms and underlying personality vulnerabilities 
were independently involved in DSHI. Whether symptoms of somatic anxiety are 
protective should be con!rmed in subsequent studies. These !ndings may help clinicians 






Deliberate self-harm is a common problem in the general population, as well as in 
psychiatric populations (Briere & Gil, 1998; Klonsky et al., 2003). It has been de!ned as the 
intentional self-injury without (conscious) suicidal intent (Chapman et al., 2006; Klonsky 
et al., 2003), or as behaviour that was self-initiated with the intent to harm the body, 
regardless of intent to die (De Leo et al., 2004; Schmidtke et al., 2004) In the current study, 
both non-suicidal and suicidal self-harm, as well as thoughts about self-harm and suicide 
were analysed (deliberate self-harm or ideation; DSHI). 
With regard to deliberate self-harm behaviour, a lifetime prevalence of 4% 
was found in nonclinical populations in the US (Briere & Gil, 1998; Klonsky et al., 2003). 
Prevalence rates in selected populations were higher, especially for adolescents (7%-
9%; Hawton et al., 2002; Skegg, 2005) and psychiatric inpatients (21%-61%; Briere & Gil, 
1998; Suyemoto, 1998). In the UK, an estimated 170,000 deliberate self-harm patients per 
year are admitted at emergency departments of general hospitals with deliberate self-
poisoning (Kapur et al., 1998). The most frequent presentations of deliberate self-harm 
behaviour are skin-cutting and self-poisoning (Hawton et al., 2002; Schnyder et al., 1999). 
With regard to deliberate self-harm ideation in community samples, lifetime prevalence 
rates of 11%-14% were found for adults (Kessler et al., 1999; Ten Have et al., 2009) and 19% 
for adolescents (Evans et al., 2005a). Besides the fact that DSHI is a prevalent problem in 
various populations, persistence is also very common (Owens et al., 2002) and a history 
of DSHI increases the risk of a completed suicide (Cooper et al., 2005; Hawton et al., 2003; 
Hawton & Harriss, 2007; Kapur et al., 2006; Suominen et al., 2004, Sinclair et al., 2010). 
According to a large adult community survey the factors that were associated 
with deliberate self-harm and respectively with suicidal ideation were largely identical 
(Ten Have et al., 2009). Sociodemographic factors such as younger age and female sex 
were found to be related to DSHI. (Kessler et al., 1999 ; Kessler et al., 2005; Schmidtke et 
al., 1996; Evans et al., 2005b). Subjects with low socio-economic status (Schmidtke et al., 
1996) and divorced subjects (Kessler et al., 1999; Petronis et al., 1990) were more likely to 
engage in DSHI. 
Disease-related predictors of DSHI in community and clinical populations were 
the presence of psychiatric symptoms and disorders, such as major depression, substance 
abuse and anxiety disorders (Kessler et al., 1999; Haw et al., 2001; Plener et al., 2009). With 
regard to psychiatric symptoms, adolescents with DSHI showed higher levels of depressive 
(Hawton et al., 2002) and anxiety symptoms, and used more alcohol (Haavisto et al., 2005; 
Ross and Heath, 2002; Tuisku et al., 2009). 
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General vulnerability factors such as personality traits and emotion regulation 
di%culties were found to be related to DSHI in community and clinical samples. The 
presence of DSHI was increased in patients with personality disorders, especially in patients 
with borderline personality disorder (Shearer et al., 1988; Haw et al., 2001). Some of the 
Big-Five personality traits (neuroticism, agreeableness, extraversion, conscientiousness 
and openness to experience) were also described to be related to lifetime DSHI. In several 
community sample studies neuroticism was signi!cantly higher in patients with a history 
of DSHI compared to non-DSHI patients (Brown et al., 2007; Kessler et al., 1999; Klonsky 
et al., 2003; Williams & Hassanyeh, 1983). Brown found higher levels of neuroticism and 
openness to experience, and lower levels of agreeableness and conscientiousness in 
college students who had a history of (non-suicidal) self-harm compared to controls 
(Brown et al., 2009). Additionally, in a study by Klonsky et al., military recruits reporting a 
history of self-harm showed more personality pathology traits (borderline, schizotypical, 
dependent and avoidant) compared to the non-self-harm group (Klonsky et al., 2003). They 
also found a coherent ‘self-harm personality pro!le’, according to self- and peer reports: 
individuals with a history of self-harm tended to have strange and intense emotions and 
a heightened sensitivity to interpersonal rejection. ‘Emotion dysregulation’ di%culties in 
responding to one’s own emotions as a personality trait, may play a central role in DSHI 
(Chapman et al., 2006; Linehan, 1993; Gratz & Roemer, 2008). A study of DSHI risk factors 
in male students (Gratz & Chapman, 2007) found emotion dysregulation to distinguish 
between men with and without DSHI. 
Most studies of DSHI focus on the general community, students or inpatients. 
Knowledge about DSHI-related factors regarding outpatients with common mental 
disorders such as mood, anxiety and somatoform disorders in a naturalistic mental health 
care setting is scarce. Identifying associative factors of DSHI is of clinical importance 
and may assist clinicians, social workers, prevention workers and policy makers in the 
identi!cation, prevention and treatment of DSHI and eventually, in preventing suicide. In 
this explorative study, we aimed to investigate the prevalence rate of lifetime DSHI and 







The sample consisted of 3,798 outpatients from the Dutch Regional Mental Health 
Provider (RMHP) Rivierduinen and the psychiatric outpatient department of the Leiden 
University Medical Center (LUMC). Patients were referred to one of these locations for 
treatment of a mood, anxiety or somatoform (MAS) disorder between January 2004 and 
December 2006. All outpatients that enter the clinics were routinely assessed with Routine 
Outcome Monitoring (ROM), as part of the usual diagnostic procedure (De Beurs et al., 
2010). ROM consists of an extensive battery of psychometric instruments, both self-report 
and interviewer-based. All interviewer-based measurements were carried out by trained 
research nurses or psychologists. Self-report questionnaires were completed using a 
touch-screen computer. The assessment took about 120 minutes. Only patients with 
insu%cient mastery of the Dutch language and patients who were unable to complete 
computerised and written questionnaires were ineligible for ROM. Approximately, 80% 
of the referred MAS patients were assessed with ROM in the study period. For the current 
study, we used baseline ROM assessments only. 
Of the 3,798 outpatients, 2,844 patients between the age of 18 to 65 had 
complete data on variables of interest and were analysed (74.9%; Figure 4.1). In total, 116 
patients were excluded because of their age and 838 patients were excluded because they 
had missing data. The main reason for missing data (N=395) was that the Dimensional 
Assessment of Personality Pathology-Basic Questionnaire Short Form (DAPP-SF) had been 
introduced in ROM gradually. Mean age of the excluded patients was signi!cantly higher 
in comparison with the included group (M=39.6 vs. 37.5, p<0.001). The excluded patients 
had signi!cantly higher scores on general psychopathology (BSI; M=1.4 vs. 1.2, p<0.001), 
depression and anxiety (MADRS; M=19.9 vs. 17.7, p<0.001, BAS; M=15.8 vs. 14.2, p<0.001). 
The groups also di"ered on nationality and employment status (in the excluded patients 
less people were Dutch, p<0.001 or employed, p<0.001). Finally, excluded patients were 
more likely to be married or had a partner than the included patients (p<0.05). Concerning 
DSHI (N=448), education, number of diagnoses, gender, housing and suicide attempt 
history no di"erences were found between the included and excluded patients. Of the 
!nal 2,844 patients, 1,061 patients were male (37.3 %; mean age=38.8, SD=11.8) and 1,783 
were female (62.7 %; mean age=36.7, SD=12.0). 
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Measures
Demographics: For the current study, demographic variables were obtained 
using a self-report questionnaire that assessed age, gender, ethnic background, education, 
marital status, housing situation and employment status. A Dutch ethnic background 
was assumed when the patient and both parents were born in the Netherlands. ‘Other 
ethnicity’ was scored when these criteria were not ful!lled. 
DSHI and personality pathology: To assess lifetime DSHI and personality 
pathology, the DAPP-SF was used (Van Kampen et al., 2008). The DAPP-SF contains 
136 items and consists of 18 subscales covering clinically relevant dimensions of 
personality pathology, namely: Submissiveness, Cognitive Distortion, Identity Problems, 
A"ective Lability, Stimulus Seeking, Compulsivity, Restricted Expression, Callousness, 
Oppositionality, Intimacy Problems, Rejection, Anxiousness, Conduct Problems, 
Suspiciousness, Social Avoidance, Narcissism, Insecure Attachment and Self-Harm. The 
latter subscale was used to measure DSHI. 
There are four higher-order constructs containing several subscales, namely 
Emotional Dysregulation, Dissocial Behaviour, Inhibition and Compulsivity. The items of 
the DAPP-SF are rated on a 5-point Likert scale, with scores ranging from 1 (“very unlike 
me”) to 5 (“very like me”). A high total (and subscale) score indicates the presence of (a) 
deviant personality trait(s). The Self-Harm subscale consists of 6 items and measures 
lifetime self-harm ideation and behaviour, speci!cally a history of self-poisoning (1 item), 
repetitive self-injury (1 item) and suicidal ideation and intent (4 items) ranging from 1 to 
5 (mean score). The DAPP-SF has good psychometric properties. Cronbach’s alpha of the 
subscale Self-Harm in a previous sample with MAS disorders was 0.88. and respectively 
0.90 in a sample with personality disorders. Furthermore, the subscale correlated strong 
with general psychopathology (De Beurs et al., 2009). Cronbach’s alpha in the current 
sample was respectively 0.96 for the total DAPP-SF, 0.89 for the DSHI subscale, 0.97 for 
emotional dysregulation, 0.88 for dissocial behaviour, 0.80 for inhibition and 0.84 for 
compulsivity. Also the subscales had satisfactory internal consistencies, ranging from 0.77 
(conduct problems) to 0.91 (suspiciousness). We de!ned the presence of self-harm as a 
score of ≥2 on the self-injury and/or the self-poisoning item. The presence of self-harm 
ideation was de!ned if subject scored ≥2 on one or more suicidal ideation and intent 
items. 
Psychiatric diagnosis: Diagnostic status according to the Diagnostic and 
Statistical Manual of Mental Disorders IV-TR (American Psychiatric Association, 2000) was 
assessed with the Dutch version of the MINI International Neuropsychiatric Interview Plus, 




Vliet & De Beurs, 2007). The interview consists of 23 modules in which the presence or 
absence of DSM-IV criteria for the main psychiatric disorders was examined. The presence 
of a ‘prior suicide attempt’ and the amount of Axis I disorders was also assessed with the 
MINI-Plus. The MINI-plus was tested in di"erent samples and appeared to have good 
psychometric properties (Sheehan et al., 1998; Lecrubier et al., 1997).
Psychiatric symptoms: Depressive and anxiety symptoms were measured by 
the Montgomery-Åsberg Depression Rating Scale (MADRS; Montgomery & Åsberg, 1979) 
and the Brief Anxiety Scale (BAS; Tyrer et al., 1984). The MADRS and the BAS have good 
psychometric properties (Goekoop et al., 1994). Cronbach’s alpha for the MADRS in the 
current sample was 0.86 and for the BAS 0.68. General Psychopathology was measured 
by the Brief Symptom Inventory (BSI; Derogatis, 1975). This is a shortened version of the 
Symptom Checklist (SCL-90) and contains 53 self-report items. The BSI measures current 
symptoms of psychopathology in adults covering nine symptom dimensions and three 
global indices of distress (Derogatis, 1975; De Beurs & Zitman, 2006). The respondent 
indicates to what extent they have been bothered by a symptom in the past week, 
including today, with scores ranging from 0 (“not at all”) to 5 (“extremely”). The Dutch 
translation of the BSI has good psychometric properties (De Beurs & Zitman, 2006). In the 
current sample, the Cronbach’s alpha for the BSI was 0.97.
Statistical Analyses
Patients were categorised in three groups with no, intermediate and high DSHI (i.e., 
tertiles) in order to increase clarity and interpretability of the results. The chi-squared test 
for linear-by-linear association or Kruskal-Wallis nonparametric test were used to analyse 
associations with categorical and ordinal variables, respectively. A prediction model was 
built in which contributing factors to DSHI were added to a multinomial logistic regression 
analysis, and the potential predictive factors were chosen by univariable analysis (p<0.1), 
while age and gender were forced into the model. In Table 4.4, associations are presented 
as odds ratios (OR) with 95% con!dence intervals (95% CI) per one standard deviation 
increase in predictive factor (per 1-SD using z-scores; to facilitate the comparison between 
di"erent predictive factors), in which no DSHI was considered the reference category. The 
associations with predictor factors were examined using multivariable linear regression 
analysis, and these associations are presented as the p-value for linear trend over the 
tertiles of DSHI (i.e., 1, 2 or 3). In addition, forward stepwise linear regression analysis 
was used to !nd the minimum subset of independent predictive factors of DSHI from 
the longer list of possible factors. In this !nal model, the stringent signi!cance levels of 
0.01 for removal and of 0.005 for entry were chosen, and age and sex were forced into 
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the model. A two sided p-value of <0.05 was considered statistically signi!cant, and the 
statistical analyses were performed using SPSS version 17.0 statistical software. 
Results
Descriptives
In total, 1,549 patients (54.5%; 95% con!dence interval [CI]: 52.6%-56.3%) reported 
lifetime DSHI, based on the tertile distribution of the DAPP-SF. The sample consisted of 
1,295 (45.5%) patients with no DSHI, 597 patients (21.0%) with intermediate DSHI and 
952 patients (33.5%) with high DSHI. Because of the large number of subjects with no 
DSHI, the tertiles were not equally distributed. Of the total 2,844 patients, 689 (24.2%) 
reported a history of self-harm or suicide attempt whereas 1,433 (50.4%) reported a 
history of suicidal ideation. 573 subjects (20.1%) reported suicidal ideation and self-harm 
or a suicide attempt. According to the MINI International Neuropsychiatric Interview-Plus 
(MINI-Plus) 411 subjects (14.5%) reported a prior suicide attempt. Of the 2,844 patients 
1,300 (45.7%) had a current depression or dysthymia, 1,224 (43.0%) a current anxiety 
disorder, 368 (12.9%) a current somatoform disorder, and 672 (23.6%) had no MAS 
disorder. Comorbidity of MAS disorders occurred in 748 (26.3%) patients.
Demographic variables and DSHI
Table 4.1 presents demographic characteristics of the sample according to DSHI group. 
Linear-by-linear association revealed no signi!cant trend for gender and DSHI group. 
Linear-by-linear association tests revealed a signi!cant increasing association of other 
ethnicity from no DSHI (14.2%), to intermediate DSHI (19.4%) and high DSHI (19.7%), χ2 (1, 
2844)=12.60, p<0.001, and respectively for being unmarried with DSHI group, χ2 (1, 2844) 
=65.65, p<0.001, living alone or with family with DSHI group, χ2 (2, 2844) =55.77, p<0.001, 
lower education with DSHI group, χ2 (1, 2844) =6.67, p<0.05), being unemployed with 
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Disease-related variables: psychiatric disorders and DSHI
Table 4.2 shows psychiatric disorders and symptoms according to the level of DSHI. 
Signi!cant linear-by-linear associations were found for all MAS disorders with DSHI 
group except for dysthymia. Linear-by-linear associations revealed a signi!cant 
association between increasing prevalence rates of depression and anxiety disorders 
for each subsequent DSHI group, except for panic disorder, generalised anxiety disorder 
and somatoform disorder, where the test revealed a signi!cant inverse association. 
Additionally, a signi!cant increasing association was found for alcohol and drug abuse 
or dependence from no DSHI (2.6%; 2.2% for alcohol and drug abuse or dependence, 
respectively), intermediate DSHI (4.7%; 3.9%) to high DSHI (8.7%; 7.4%), χ2(1, 2844)=41.41,  
p<0.001; χ2(1, 2844) =35.63, p<0.001). Linear-by-linear associations also revealed a 
signi!cant increasing association of the number of diagnoses, F (1, 2841) =111.33, p<0.001, 
depressive symptoms (MADRS), F (1, 2841) =484.14, p<0.001, symptoms of anxiety (BAS), 
F (1, 2841) =76.37, p<0.001, and general psychopathology, F (1, 2841) =569.42, p<0.001 
from no DSHI, to intermediate and high DSHI. 
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Personality characteristics and DSHI
Table 4.3 shows personality characteristics according to the level of DSHI. Linear-by-linear 
associations revealed a signi!cant increasing association of total DAPP-SF score from no 
DSHI, to intermediate and high DSHI, F (1, 2841) =788.20, p<0.001. Signi!cant increasing 
associations were also found for the personality constructs emotion dysregulation, F (1, 
2841) =786.99, p<0.001, dissocial behaviour, F (1, 2841) =153.14, p<0.001, inhibitedness, F 
(1, 2841) =164.68, p<0.001 and compulsivity, F (1, 2841) =27.12, p<0.001. 
Multivariable analysis
Table 4.4 presents the results of a multinomial logistic regression analysis. The overall 
model signi!cantly predicted DSHI, R2 =0.35 (Nagelkerke), χ2 (28, 28) =1056, p<0.001. A 
forward stepwise linear regression analyses revealed signi!cant positive trends of DSHI for 
low education, β =0.08; unmarried or no partner, β =0.05; number of diagnoses, β =0.07; 
symptoms of anxiety, β =-0.27; depressive symptoms, β =0.39; and emotion dysregu-




According to the !ndings of the present study, deliberate self harm and suicidal ideation 
are prevalent problems in psychiatric outpatients with MAS disorders, with 55% of the 
patients reporting thoughts or behaviours concerning deliberately injuring one’s own 
body. This prevalence rate is comparable to previous studies among depressed adolescent 
outpatients where prevalence rates between 42% and 58% were found for any suicidality, 
including thoughts and behaviour (Tuisku et al., 2006; Pelkonen et al., 1997). This study 
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con!rmed the hypotheses that demographic factors, disease-related factors and general 
vulnerability factors are associated to DSHI in psychiatric outpatients with MAS disorders. 
We found that being unmarried, lower education, number of psychiatric diagnoses, 
lower anxiety scores, higher depression scores and emotional dysregulation were strong 
independent predictors of DSHI.
We found several factors associated to lifetime DSHI. First, sociodemographic 
factors such as being unmarried, unemployed and lower education were signi!cantly 
related to the presence of DSHI in univariable analyses. In multivariable analyses, being 
unmarried and lower education were independent predictors of DSHI. These !ndings are 
comparable to previous research where social disadvantages such as no work and lower 
education are seen as risk factors for mental disorders and suicide attempts (Kapur et al., 
2006; Taylor et al., 2004). A !nding that contrasts with some earlier research is the lack of 
signi!cant gender di"erences in the prevalence of DSHI (Herpertz, 1995). These results 
contribute to the discussion whether DSHI may be as common among men as it is among 
women (Muehlenkamp & Gutierrez, 2004).
Secondly, disease-related factors, speci!cally depressive and anxiety symptoms, 
general psychopathology, and number of diagnoses were positively associated with 
lifetime DSHI in univariable analyses. Consistent with previous research (Fliege et al., 
2006) DSHI patients reported a higher degree of symptoms of depression, anxiety and 
general psychopathology (measured with the MADRS, BAS and BSI, respectively). In 
multivariable analyses, higher depression scores and number of diagnoses predicted 
DSHI. Surprisingly, when controlled for the other variables in the multivariable analysis, 
anxiety symptoms measured with the BAS showed an inverse association with DSHI. In 
previous research anxiety scales in the social phobia domain were related to lower levels 
of suicidal behaviour after controlling for depression and suicidal ideation (Valentiner et 
al., 2002). In another study nonattempters had signi!cantly higher scores on anxiety than 
attempters of suicide (Placidi et al., 2000). In our sample, social phobia, posttraumatic 
stress disorder and obsessive compulsive disorder were more prevalent in the high DSHI 
group in univariable analyses, whereas panic disorder and generalised anxiety disorder 
were less prevalent in the high DSHI group. In this study, anxiety was measured with the 
BAS, a scale assessing mainly the somatic aspects of anxiety (Keedwell & Snaith, 1996). 
When corrected for depression in multivariable analyses, these somatic aspects of anxiety 
could be protective for DSHI. This is consistent with the !nding that in our univariable 
analyses, the presence of a somatoform disorder showed a decreasing trend over the DSHI 
groups. Future research might examine whether this results can be replicated in other 
samples, and with other measures of anxiety.
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Thirdly, with regard to general vulnerability factors, especially emotional 
dysregulation was strongly associated with lifetime DSHI, in both univariable and 
multivariable analyses.  Several researchers claim that DSHI may in fact be an emotion 
regulation strategy itself, suggesting that DSHI patients have di%culties in coping with 
distress (Nock & Prinstein, 2004; Slee et al., 2008b) and that DSHI can be a way to avoid 
emotional problems (Slee et al., 2008a, b) Thereby, Brown et al. (2007) found that college-
students with a past history of DSHI and with a recent history of DSHI both reported more 
negative emotions than the non-DSHI patients. This may indicate a general emotional 
vulnerability in patients with a history of DSHI. 
Strengths and limitations
Previous studies on prevalence and correlates of DSHI often focused on speci!c disorders 
(personality, anxiety or depressive disorders), or speci!c populations such as adolescents 
or inpatients. Strengths of this study are the large naturalistic psychiatric outpatient study 
population of 2,844 patients, the routinely adapted assessments by speci!cally trained 
research nurses and psychologists and the wide range of potential contributing factors 
assessed in the study, which focuses on current symptoms and disorders as well as on 
underlying vulnerabilities such as personality traits. 
The study also has several potential limitations. First, not all referred MAS 
patients were assessed, because about 20% of all patients did not have a baseline ROM 
assessment due to language problems or logistical reasons. A second limitation includes 
the assessments of DSHI and personality traits. The DAPP-SF self-harm subscale measures 
lifetime suicidal ideation (4 items) and speci!cally self-poisoning and repetitive self-injury. 
Only two items speci!cally assess lifetime self-harming behaviour. According to previous 
research, speci!c deliberate self-harm behaviours (such as cutting, scratching or head 
banging) may be underreported according to self-report questionnaires unless they are 
speci!cally asked for (Gratz, 2001). Additionally personality traits were assessed by a self-
report questionnaire. This may lead to bias such as social desirability and the predisposition 
to self-enhancement (Herpertz, 1995; Kocalevent et al., 2005; Paulhus & Vazire, 2007). 
Furthermore, the assessment of personality traits may be in#uenced by current symptoms 
of anxiety, depression and general psychopathology. Finally, in the current study, traumatic 
events were not assessed. Trauma was associated with deliberate self-harm behaviour and 
ideation in previous studies (Gratz et al., 2002; Romans et al., 1995). 
  In conclusion, with these results from psychiatric outpatients with MAS disorders 
about the factors associated with DSHI it may be easier to identify patients at risk for 




for DSHI should not primarily focus on associated mental disorders such as depression, 
but should also focus on DSHI itself and speci!cally target emotion regulation strategies. 
Whether symptoms of somatic anxiety are protective should be con!rmed in subsequent 
studies. Finally, the !ndings suggest that both present symptoms as well as underlying 
personality vulnerabilities seem to be involved in DSHI. Treatment should not merely 
focus on either personality pathology or for example depressive symptoms: an integrated 
approach seems more promising (Slee et al., 2008a, b; Slee et al., 2007; Weinberg et al., 
2010). Speci!c therapeutic implications of these !ndings should be further studied. 
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Abstract
Background: Being able to predict which patients are at risk for an unfavourable 
outcome is of high clinical importance. The aim of this study was to investigate the 
predictive value of items for individual depressive symptoms measured with the self-
rated Beck Depression Inventory-Revised (BDI-II) self-report scale on outcome in a large 
naturalistic cohort of depressive outpatients.
Methods: We used a cohort of 1,489 adult patients aged 18-65 years with major 
depressive disorder or dysthymic disorder established with the MINI-Plus diagnostic 
interview. All patients had a Routine Outcome Monitoring (ROM) baseline measurement 
in 2004-2009, with a maximum of 2 years follow-up. We used multivariable Cox regression 
models to predict remission (MADRS<10; where MADRS stands for Montgomery-Åsberg 
Depression Rating Scale) and response (≥50% improvement), and adjusted for clinical 
and demographic characteristics (i.e., marital status, level of education, working status, 
comorbid anxiety, avoidant and borderline personality traits, and suicidality) that were 
identi!ed as predictors in earlier studies. 
Results: Of the 21 BDI-II items, the items ‘pessimism’ and ‘loss of energy’ independently 
predicted for both remission and response. For pessimism, the HR for remission was 0.81 
(95% con!dence interval [CI]: 0.73-0.89, p<0.001) and for loss of energy, the HR was 0.81 
(0.72-0.92, p=0.001). 
Conclusions: These !ndings of robust prediction of poor outcome by baseline items of 
‘pessimism’ and ‘loss of energy’ in a naturalistic treatment setting may help clinicians to 






Despite extensive therapeutic options roughly one third of the patients with depressive 
disorders do not achieve remission after several adequate treatment trials (Rush et al., 
2006), which may result in chronic depression (Rush et al., 1995). Being able to predict 
which patients are at risk for an unfavourable outcome is of high clinical importance, 
because these patients who do not achieve remission despite treatment may su"er 
considerably, and result in a poor cost-e"ectiveness of psychiatric care (Thase, 2003; 
Wittchen et al., 2011). In prospective studies, several factors have been associated with 
a poor outcome in patients with major depression. Sociodemographic factors, including 
low education (Barkow et al., 2003; McKenzie et al., 2010), unemployment, (Barkow et al., 
2003; Sherbourne et al., 2004; Fournier et al., 2009; Frank et al., 2010) and being unmarried 
(Fournier et al., 2009; Frank et al., 2010; Meyers et al., 2002; Weinberger et al., 2008) were 
found to be independent predictors of a poor outcome. Also, clinical characteristics 
including greater severity of depressive symptoms (Barkow et al., 2003; Enns et al., 2005; 
Frank et al., 2010; Melartin et al., 2004; Meyers et al., 2002; Moos et al., 1999; Sargeant 
et al., 1990; Souery et al., 2007; Vuorilehto et al., 2009), loss of interest, reduced activity 
(Uher et al., 2011), suicidality (Barkow et al., 2003; Sherbourne et al., 2004; Souery et 
al., 2007), melancholic features (Souery et al., 2007), comorbid anxiety disorders (Enns 
& Cox, 2005; Melartin et al., 2004; Penninx et al., 2011; Souery et al., 2007; Weinberger 
et al., 2008) and personality traits or disorders such as avoidant, low extraversion and 
borderline (Enns & Cox, 2005; Skodol et al., 2011; Souery et al., 2007; Vuorilehto et al., 2009; 
Wiersma et al., 2011) were predictors of poor outcome. However, various de!nitions and 
operationalisations of poor outcome have been used in these studies, and duration of 
follow-up di"ered largely. Also, these studies have been conducted in di"erent settings, 
e.g. community (Sargeant et al., 1990; Skodol et al., 2011), primary care (Barkow et al., 
2003; Vuorilehto et al., 2009), psychiatric specialty care inpatient (McKenzie et al., 2010; 
Souery et al., 2007) and outpatient settings (Enns & Cox, 2005; Fournier et al., 2009; Frank 
et al., 2010; Meyers et al., 2002; Penninx et al., 2011; Souery et al., 2007; Uher et al., 2011; 
Weinberger et al., 2008). Moreover, most studies used data obtained from clinical trials, 
that limits generalisability to everyday clinical practice because of the usually much more 
extensive and stringent in- and exclusion criteria (van der Lem et al., 2011).
To our knowledge, no previous study investigated whether speci!c baseline 
symptoms, re#ected in individual items on depressive rating scales at baseline predict 
outcome in a naturalistic clinical outpatient setting. If the presence of speci!c depressive 
symptoms at baseline would be of value in predicting outcome of depression, assessment 
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of these symptoms using a self-report measure could help clinicians to identify patients 
at risk of a poor outcome in a relatively easy way. Since the standardised assessment of 
symptom presence is increasingly becoming part of the usual clinical process, identi!cation 
of symptoms that predict outcome could be helpful for clinician and patient. 
A recent study from Uher et al. including 811 major depressive disorder (MDD) 
patients tested whether baseline depression symptom dimensions predicted outcome upon 
a 12-week-treatment with escitalopram or nortriptyline. The authors found and replicated 
that higher scores on the interest-activity dimension (i.e. low interest, reduced activity, 
indecisiveness and lack of enjoyment) predicted poorer treatment outcome (Uher et al., 2011).
 The aim of the present study was to investigate whether individual baseline 
depressive symptoms measured with the widely used Beck Depression Inventory-Revised 
(BDI-II) self-report scale (Beck et al., 1988) would predict outcome in a large naturalistic 
cohort of depressive outpatients in a psychiatry specialty care setting. Outcome was de!ned 
as response and remission measured on the Montgomery-Åsberg Depression Rating Scale 
(MADRS) according to generally accepted criteria during up to 2 years of follow-up.
Methods
Participants
We used an initial cohort of 8,021 adult outpatients aged 18-65 years who were referred 
for treatment of a mood, anxiety, or somatoform (MAS) disorder to the Regional Mental 
Health Provider Rivierduinen (RD) and Leiden University Medical Center (LUMC). All 
patients had a Routine Outcome Monitoring (ROM) baseline assessment between 2004 
and 2009, during intake before the start of treatment (de Beurs et al., 2011). In ROM, data 
on diagnosis and complaint severity are collected systematically to assess treatment 
e"ectiveness in everyday clinical practice. In our setting, ROM is performed by well-trained 
and supervised psychiatric research nurses, who are not involved in treatment. A group-
wise quality control and calibration among research nurses ensures quality maintenance 
during data collection (de Beurs et al., 2011). All questionnaires are completed on touch-
screen computers, to prevent missing data within instruments. Patients with insu%cient 
mastery of Dutch and patients unable to complete assessments are ineligible for ROM. On 
average, 80% of the referred patients were assessed with ROM in the study period. ROM 
data are primarily used for diagnosis and to inform clinicians and patients about treatment 
progress. The use of the anonymised data for research purposes has been approved by 




Of these 8,021 patients, we selected all patients with a current MDD or dysthymic 
disorder according to the Mini International Neuropsychiatric Interview-Plus (MINI-Plus; 
n=3,632, 45.3%). The MINI-Plus is a standardised diagnostic interview that assesses current 
and lifetime Axis-I diagnoses according to the Diagnostic and Statistical Manual of Mental 
Disorders, fourth edition, text revision (DSM-IV-TR; American Psychiatric Association, 
2000). The inter-rater reliability ranges from 0.88 to 1.00, test-retest reliability from 0.76 
to 0.93 and validity is adequate compared to the Composite International Diagnostic 
Interview (CIDI; Lecrubier, 1997; Sheehan et al., 1998; van Vliet et al., 2007). Patients with 
a lifetime bipolar disorder or primary psychotic illness were excluded, but a diagnosis 
of psychotic major depression according to the MINI-Plus was allowed. Of these 3,632 
depressive patients, we selected all patients with a minimum of one follow-up ROM 
assessment (n=1,988, 54.7%). Patients who had only one ROM assessment were most 
likely not treated in the MAS outpatient clinics. Patients with a low baseline symptom 
severity (MADRS <10) were excluded (n=87, 2.4%) as well as patients with missing data 
on variables of interest (n=412, 11.3%). We thus included 1,489 patients in our analyses 
(41.0% of 3632 patients). There were no di"erences in age, gender, or level of education 
between included and excluded patients. Excluded patients had a lower MADRS baseline 
score than included patients (mean scores 21.9, standard deviation [SD] ± 9.7 vs. 24.1 ± 
7.0; t= -4.6, p<0.001).
Psychiatrists and clinical psychologists or psychotherapists in LUMC and RD 
provided outpatient treatment in accordance with the Dutch evidence based guidelines, 
consisting of pharmacotherapy, psychotherapy, or a combination of both. Treatment 
modalities were not taken into account in the analyses. 
Measures
ROM assessments: We used the baseline ROM assessments and all successive 
ROM assessments with a maximum follow-up of 2 years. During the !rst ROM session the 
MINI-Plus was administered, as well as observer-rated and self-report scales, both generic 
and disorder-speci!c. In addition, demographic variables were collected (an overview 
of instruments is available at http://www.lumc.nl/psychiatry/ROM-instruments), as 
previously described in detail elsewhere (de Beurs et al., 2011; van Noorden et al., 2010).
Remission and response: Remission and response of depression were assessed 
using the MADRS. The MADRS is an observer-rated scale that assesses depression severity, 
and that is sensitive to change. The MADRS has an internal consistency (Cronbach’s alpha) 
of 0.86, an inter-rater reliability coe%cient of 0.65-0.97 (Montgomery, 1979). Remission 
was de!ned as the !rst follow-up ROM assessment at which the MADRS score of <10 had 
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been reached (Hawley et al., 2002; Zimmerman et al., 2004a; Zimmerman et al., 2004b) 
and response was de!ned as the !rst ROM assessment at which a reduction of ≥50% of 
the baseline MADRS score had been achieved. The MADRS was administered at baseline 
and at every follow-up ROM assessment.
 Individual depressive symptoms as possible predictors: Baseline depressive 
symptoms were measured with the BDI-II (Beck et al., 1996; Beck et al., 1988). The BDI-II 
is a 21-item self-report questionnaire that assesses the presence and severity of a broad 
range of depressive symptoms on a 4-point Likert-scale (0-3), with good psychometric 
properties (Beck et al., 1988). Symptoms measured with the BDI-II that most closely would 
!t in the interest/activity dimension found by Uher et al. (2008) are loss of pleasure, loss 
of interest, indecisiveness, loss of energy, concentration di%culties, and loss of interest in 
sex. In the present study, the BDI-II was chosen because of the broad range of symptom 
coverage in 21 individual items, and because of the practicability of a self-report measure. 
Furthermore, with the MADRS as relatively objective and ‘gold standard’ outcome 
measure, the risk of circularity as the result of functional relatedness of dependent and 
independent variables was likely to be lower than when the MADRS would have been 
used both as predictor and outcome (Senn, 1994).
 Additional measures: Demographic variables were obtained at baseline with a 
self-report questionnaire. A Dutch ethnic background was assumed when the patient 
and both parents were born in the Netherlands. Marital status was assessed, as well as 
housing situation, educational status and working situation. The Dimensional Assessment 
of Personality Pathology-Short Form (DAPP-SF) was administered at baseline to assess 
maladaptive personality traits (van Kampen et al., 2008) Additional scales in ROM that we 
used for this study were the observer-rated Brief Anxiety Scale (BAS; Tyrer et al., 1984), the 
patient-rated Brief Symptom Inventory (BSI; de Beurs et al., 2006; Derogatis et al., 1983), 
the observer-rated Clinical Global Impression (CGI; Guy, 1976) and the Global Assessment 
of Functioning (GAF) scale (American Psychiatric Association, 2000; Endicott et al., 1976).
Statistical analyses
Using descriptive statistics, baseline characteristics are described as number (percentage) 
or mean (SD, with interquartile range [IQR]), when appropriate. Univariable Hazard Ratios 
(HRs) of remission and response were computed according to baseline individual BDI-
II items (predictor variables) using Cox regression on the time-to-remission and time-
to-response endpoints. Possible collinearity of the individual BDI-II items was checked 
using Variance In#ation Factor (VIF) analysis. If the endpoint of remission or response 




measurement, the case was censored at the last ROM assessment. All BDI-II items that 
predicted remission or response with HRs with p-values <0.10 in univariable analyses 
were subsequently selected for an initial forward stepwise multivariable Cox regression 
model, for both endpoints. We used criteria for selection and removal both of 0.10. In this 
multivariable model we adjusted for baseline MADRS score, age and gender. Furthermore, 
we repeated the multivariable model with adjustment for demographical factors (i.e., 
marital, educational and working status), comorbid anxiety (i.e., based on the MINI-Plus), 
avoidant and borderline personality traits (i.e., measured with the DAPP-SF), and current 
suicidal thoughts (i.e., based on the MINI-Plus) because these clinical characteristics had 
been associated with outcome in earlier studies (Barkow et al., 2003; Enns & Cox, 2005; 
Fournier et al., 2009; Frank et al., 2010; McKenzie et al., 2010; Melartin et al., 2004; Meyers 
et al., 2002; Moos & Cronkite, 1999; Penninx et al., 2011; Sargeant et al., 1990; Sherbourne 
et al., 2004; Skodol et al., 2011; Souery et al., 2007; Uher et al., 2011; Vuorilehto et al., 2009; 
Weinberger et al., 2008; Wiersma et al., 2011). 
Based on the combined presence and or absence of the BDI-II symptoms 
‘pessimism’ and ‘loss of energy’ four categories were constructed. In Kaplan-Meier 
analyses the cumulative incidence of remission is presented. Presence of a symptom was 
dichotomised as a score of 2 or 3 on the 4-point Likert scale.
We then performed sensitivity analyses in which we included only those patients 
with more severe complaints at baseline (MADRS ≥14), and additional analyses in which 
we excluded the patients with dysthymic disorder to include only patients with MDD.
We used SPSS version 17.0 for all statistical analyses (SPSS Inc., Chicago, Ill).
Results
Baseline Characteristics 
In the study sample of 1,489 depressed adults 62.3% were female. The mean age at 
ROM baseline assessment was 40.1 years (SD ± 12.1). Table 5.1 summarises the baseline 
characteristics of the sample. A Dutch ethnic background was found in 80.9%. The majority 
of the patients were living with a partner, 40.5% of the patients were currently working, 
93.3% were diagnosed with MDD, and 6.7% with a dysthymic disorder. The mean MADRS 
score at baseline was 24.1 (SD ±7.0), the mean BDI-II total score at baseline was 31.0 (SD 
±9.6), and the mean CGI score was 4.3 (SD ±0.8).
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Within the follow-up time of 2 years, 562 patients (37.7%) achieved remission on the MADRS, 
de!ned as the !rst ROM assessment with a MADRS score <10. In univariable Cox regression 
analyses 16 of 21 BDI items were associated with remission (Table 5.2). Among other 
symptoms, both ‘core symptoms of depression’, i.e. sadness and loss of interest, negatively 
predicted remission (HRs 0.76, 95% CI 0.68-0.86; p<0.001 and 0.81, 95% CI 0.74-0.89; p<0.001, 
respectively). In the !rst multivariable model, adjusted for age, gender and baseline MADRS 
score, only the BDI-II symptoms pessimism and loss of energy were independently associated 
with a lower chance of remission (HRs 0.81, 95% CI 0.73-0.89; p<0.001 and 0.81, 95% CI 0.72-
0.92; p=0.001, respectively), and the core symptoms sadness and loss of interest were not. 
The additional multivariable model, adjusted for previously established clinical variables, 
yielded the same predictors (data not shown). Figure 5.1 shows the cumulative incidence 
of remission in Kaplan-Meier curves according to the combined items of pessimism and 
loss of energy. Presence of both pessimism and loss of energy predicted a 72.2% chance of 
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remission in 2 years, and absence of both symptoms predicted a 49.1% chance of remission 
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Predictors of response 
According to the criterion of at least 50% improvement on the MADRS score compared 
to baseline MADRS score, 650 patients (43.7%) were responder within 2 years. 10 of 21 
BDI-II items were associated with treatment response in univariable analyses (Table 5.3). 
In the multivariable Cox regression model adjusted for age, gender and baseline MADRS 
score, again, only the BDI-II items pessimism and loss of energy independently predicted 
non-response with HRs of 0.86 (95% CI 0.78-0.94; p=0.001) and 0.84 (95% CI 0.75-0.95; 
p=0.003), respectively. Presence of both symptoms pessimism and loss of energy predicted 
a 61.1% chance of response in 2 years, and absence of both symptoms predicted a 49.4% 





In the sensitivity analyses we !rst excluded patients with dysthymic disorder (n=100), 
leaving 1389 MDD patients. In the multivariable Cox regression model adjusted for age, 
gender and baseline MADRS score, results remained unchanged. Also, when we elevated 
the threshold for inclusion in analysis to a baseline MADRS score ≥14 the multivariable 
model in the 1410 remaining patients yielded the same results (data not shown).
 Finally, the VIFs in a regression analysis were all <2, indicating that no 
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Discussion
In this large naturalistic cohort of 1,489 depressive outpatients, of all 21 BDI-II items 
measured at baseline, pessimism and loss of energy independently predicted poor 
remission and response. These poor remission and response rates were found 
independently from characteristics that had been identi!ed as outcome predictors in 
earlier studies (Barkow et al., 2003; Enns & Cox, 2005; Fournier et al., 2009; Frank et al., 
2010; McKenzie et al., 2010; Melartin et al., 2004; Meyers et al. 2002; Moos & Cronkite, 
1999; Penninx et al., 2011; Sargeant et al., 1990; Sherbourne et al., 2004; Skodol et al., 
2011; Souery et al., 2007; Uher et al., 2011; Vuorilehto et al., 2009; Weinberger et al., 2008; 
Wiersma et al., 2011). 
 To our knowledge, this is the !rst large scale prospective study that investigated 
whether baseline individual depressive symptoms could predict outcome in a naturalistic 
sample of MDD patients. Our !ndings may facilitate early identi!cation of patients at risk of 
poor outcome, in a relatively easy way by application of a self-report measure at baseline. 
This may have clinical consequences, since there is large consensus about remission of 
depression being the goal of treatment (Thase, 2003; Wade et al., 2009). 
Our !ndings are mostly in line with the recent !ndings of Uher et al. (2011), 
who tested baseline symptom dimensions rather than items as predictors of treatment 
outcome. Based on a previous study of the same group (Uher et al., 2008), in which a factor 
analysis of the MADRS, BDI and the 17-item Hamilton Depression Rating Scale (HDRS) 
revealed three higher order factors (i.e. observed mood, cognitive and neurovegetative) 
that further split in six dimensions (i.e. mood and anxiety, pessimism and interest-activity, 
and sleep and appetite, respectively), the predictive value of those 9 symptom dimensions 
was tested. The interest-activity dimension was found to be the strongest predictor of 
treatment outcome. The individual symptoms ‘pessimism’ and ‘lack of energy’ are both 
symptoms within the ‘cognitive’ higher order factor as described by Uher et al. (2008), but 
our results suggest that in addition to the loss of energy/low interest/low activity factor, 
pessimism may be an important factor in predicting  treatment outcome. 
In earlier studies, pessimism was found to be a predictor of depression in the 
general population (Giltay et al., 2006), patients with breast cancer (Schou et al., 2004), 
and patients with urogenital cancer (Zenger et al., 2010), but these studies mainly studied 
low optimism or pessimism as dispositional traits, and patients were not diagnosed with 
MDD at baseline. Although dispositional optimism is not simply the reverse of pessimism, 
optimism and depression were investigated as predictors of physical and mental health 




symptoms, and depressive symptomatology was associated with reduced levels of 
psychosocial functioning. In this study, participants were not diagnosed with MDD either 
(Achat et al., 2000). Also, low dispositional optimism was associated with depression and a 
higher likelihood of starting psychotherapy in a large Finnish community study (Karlsson 
et al., 2011). In yet another study, pessimism was one of the predictors of suicide acts in 
308 depressive patients that had been followed for2 years (Oquendo et al., 2004). The 
strongest predictors of future suicidal acts were prior suicide attempt, severity of episode 
and cigarette smoking. In this study, however, treatment outcome was not the focus. 
Loss of energy and fatigue, together with loss of interest or pleasure in usual 
activities were found to be predictors of chronicity in a study in 371 MDD patients that 
had been re-evaluated at 1, 4 and 10 years after initial screening and treatment (Moos and 
Cronkite, 1999). In this study by Moos et al. three symptom domains were constructed 
from a set of risk factors: severity of speci!c depressive symptoms, lack of self-con!dence 
plus social isolation, and avoidance coping. However, all analyses were univariable and 
the authors stated that no follow-up diagnostic interviews had been conducted. Still, 
loss of energy was identi!ed as a predictor of chronicity in this study as well. The authors 
hypothesise that loss of energy may be more persistent during treatment than depressed 
mood and therefore may have been a more robust predictor for outcome. 
Our !ndings !nd support in the cognitive theory of depression (see for example 
Newman & Beck, 2009), in which dysfunctional thoughts and viewpoints are thought to 
be maintained by cognitive distortive processes and biases. Depressed patients may for 
example think of themselves as failures, and selectively absorb information that points 
in that direction, neglecting the evidence for the contrary. This mechanism is believed to 
result in deepening of pessimism and worsening of mood, resulting in a vicious circle of 
withdrawal from social interactions (Newman & Beck, 2009). One could hypothesise that 
pessimism leads to social withdrawal, and that increasing isolation results in loneliness 
(Rius-Ottenheim et al., 2011) and lowering of physical activities leading to and loss of 
energy. Another mechanism could be that pessimism/low optimism and loss of energy 
both negatively in#uence the motivation for treatment resulting in lower adherence to 
treatment protocols (Leedham et al., 1995). Since the BDI-II measures state rather than 
trait symptoms, interpretations with respect to dispositional optimism/pessimism are not 
possible with the present results.
 Our study has several strengths. First, this study was conducted in a large 
naturalistic sample of depressive patients increasing the generalisability of !ndings. 
Second, the extensive standard battery of our ROM assessments included a structured 
clinical interview, the BDI-II and the observer-rated scale (MADRS). Third, outcome 
6FULSWLHB%LQQHQZHUNB&6LQGG Z$0
5
Predictors of outcome in MDD
107
predictors identi!ed in earlier studies were taken into account in our multivariable 
analyses. Fourth, assessments were done by well-trained research nurses who were not 
involved in treatment.
 Possible limitations of our study include the absence of information regarding 
treatment in ROM. We assume that patients were mostly treated according to evidence-
based guidelines; however, as our study represents a ‘real world’ setting, guideline 
concordance is often less strict than in a controlled setting (van der Lem et al., 2011). Second, 
no information on psychiatric history, family history and somatic comorbidity of the patients 
was available for our analyses. These parameters are assessed by clinicians and are not part 
of ROM. Third, the large proportion of patients lost to follow up at each ROM assessment is 
a limitation of our study. However, we believe that this large attrition rate is inherent to the 
design of the study that solely relies on ROM data collected as part of naturalistic treatment. 
A considerable loss to follow-up is common in cohort studies and trials with a ‘real world’ 
approach. In step II of the STAR*D multicenter trial for example, a study that aimed to be 
represent an everyday treatment setting, the loss to follow-up was 30% (Rush et al., 2006). 
Finally, the use of Cox regression analyses implies that subjects are censored upon reaching 
the de!ned endpoint of treatment response; therefore, the information about a possible 
relapse after an initial response could not be taken into account. 
  In conclusion, we found that the presence of baseline symptoms pessimism 
and lack of energy measured with the BDI-II strongly predicted naturalistic outcome in 
MDD outpatients. Systematic assessment of these depressive symptoms using validated 
rating scales is relatively easy to implement and often already form an invaluable part of 
clinical practice. Besides the goal to more objectively inform clinicians and patients about 
treatment progress, it may help the clinician in risk assessment of MDD patients already 
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Abstract 
Background: Mood, anxiety and somatoform (MAS) disorders are highly prevalent and 
comorbid disorders with substantial mutual comorbidity and a large disease burden. 
Cross-diagnostic predictors for poor outcome of MAS disorders in routine clinical practice 
are lacking. The aim of this study was to predict outcomes in outpatients with MAS 
disorders using Routine Outcome Monitoring (ROM) data.
Methods: We conducted a cohort study in 892 adult MAS patients in a naturalistic 
outpatient psychiatric specialty care setting and validated our results in a replication 
cohort of 1,392 patients. Poor outcome was de!ned as a <50% reduction (compared to 
baseline) on the self-report Brief Symptom Inventory (BSI) or a score of ≥3 on the observer-
rated Clinical Global Impression-Severity Scale (CGI-S), during follow-up during up to 2 
years.
Results: In multivariable Cox regression models, independent and replicated predictors 
for poor outcome were higher age (overall p<0.001 for combined cohorts in multivariable 
Cox regression model), having comorbid MAS disorders or a somatoform disorder 
(p<0.001), dysfunctional personality traits (i.e., tendency to self-harm [p<0.001], intimacy 
problems [p<0.001], a"ective lability [p<0.001]), and a low reported general health status 
(p<0.001).
Conclusions: MAS patients meeting the pro!le of being elderly, su"ering from comorbid 
MAS disorders or a somatoform disorder, with cluster B personality traits, and a poor 






Mood, anxiety and somatoform (MAS) disorders consistently rank as a highly prevalent 
group of disorders, responsible for a considerable burden of disease as measured by several 
indicators (Wittchen et al., 2005). Patients su"ering from single MAS disorders often display 
poor outcomes (with high disability, long duration of the illness, and high risk of recurrence) 
with more than half of all patients not achieving remission after !rst-line treatment, while 
the presence of one or more comorbid MAS disorders contributes to this even further (de 
Waal et al., 2004; Gaynes, 2009; Kessler et al., 2005; Maier et al., 1999). Longitudinal studies on 
patients su"ering from single MAS disorders have identi!ed several predictors for adverse 
outcomes. In general, poorer remission rates from depressive disorders were independently 
predicted by being unmarried (Fournier et al., 2009; Frank et al., 2011; Meyers et al., 2002; 
Weinberger et al., 2008), being unemployed (Fournier et al, 2009; Frank et al., 2011), a 
lower level of education (McKenzie et al., 2010), a greater severity of depressive symptoms 
(Frank et al., 2011; Melartin et al., 2004; Meyers et al., 2002; Souery et al., 2007), concomitant 
symptoms of pain, comorbid anxiety disorders (Melartin et al., 2004; Penninx et al., 2011; 
Souery et al., 2007; Weinberger et al., 2008) and borderline personality disorder (Skodol et 
al., 2011; Souery et al., 2007). Poorer remission rates from anxiety disorders were predicted 
by a higher severity of the anxiety symptoms, concomitant symptoms of pain, comorbid 
depression (Penninx et al., 2011) and prevalent personality disorders (Massion et al., 2002; 
Yonkers et al., 2000). Predictors of low remission rates for somatoform disorders were a lower 
level of education (McKenzie et al., 2010), concomitant symptoms of depression (Leiknes et 
al., 2007), a greater severity of the somatoform symptoms, and su"ering from a comorbid 
personality disorder (Phillips et al., 2005).
 However, the available studies did not include patients with di"erent MAS 
diagnoses concomitantly and showed important methodological di"erences. Sample size 
ranging from 165 (Meyers et al., 2002) to 1,996 (Skodol et al, 2011), a duration of follow-
up ranging from 3 months (Frank et al., 2011) to 5 years (Massion et al., 2002), the use of 
samples from highly selected populations (Fournier et al., 2009; Frank et al., 2011), a great 
variety in the number of determinants included in multivariable models, and not taking 
comorbidity into account. 
  Given the high frequency of mutual comorbidity in MAS disorders in routine clinical 
practice, cross-diagnostic predictors of poor outcomes would have clinical relevance. The 
present study aims to identify possible cross-diagnostic predictors of poor outcomes in a 
naturalistic cohort of 892 outpatients with MAS disorders during up to 2 years of follow-up, 
and to replicate the results in a second, independent cohort of 1392 MAS outpatients. 
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Methods
Routine Outcome Monitoring (ROM) 
In our Routine Outcome Monitoring infrastructure, all outpatients referred to Rivierduinen 
(RD) or Leiden University Medical Center (LUMC) for treatment of a MAS disorder are 
routinely assessed with an extensive psychometric battery at baseline during intake 
and, if treatment is initialised, repeatedly every 3-4 months during treatment (de Beurs 
et al., 2011; van Noorden et al., 2010). Patients with non-MAS disorders (e.g. psychotic 
disorders, main diagnosis of personality disorder) are referred to other specialised care 
settings within our institutions. In ROM, data on diagnosis and complaint severity are 
collected systematically to assess treatment e"ectiveness in everyday clinical practice. In 
our setting, ROM is performed by trained psychiatric research nurses who are not involved 
in treatment. A group-wise quality control and calibration among research nurses ensures 
quality maintenance during data collection (de Beurs et al., 2011). All questionnaires are 
completed on touch-screen computers, to prevent missing data within questionnaires. 
Patients with insu%cient mastery of the Dutch language are ineligible. During the study 
period, on average 80% of the referred patients were assessed with ROM. ROM data 
are primarily used for diagnosis and to inform clinicians and patients about treatment 
progress. Patient-identi!able data are removed from the database in order to secure 
patients’ con!dentiality. The use of these anonymised data for research purposes has 
been approved by the Ethical Review Board of the LUMC.
During the !rst ROM session, a standardised diagnostic interview is administered 
as well as observer-rated and self-report scales, both generic and disorder-speci!c. In 
addition, demographic variables are collected (an overview of instruments is available 
at http://www.lumc.nl/psychiatry/ROM-instruments). At intake, current and lifetime 
Axis-I diagnoses according to the Diagnostic and Statistical Manual of Mental Disorders, 
fourth edition, text revision (DSM-IV-TR) were established using the Mini-International 
Neuropsychiatric Interview-Plus (MINI-Plus; Sheehan et al., 1998). The MINI-Plus has good 
psychometric properties, with inter-rater reliability ranging from 0.88-1.00, test-retest 
reliability ranging from 0.76-0.93 and adequate validity compared to the Composite 
International Diagnostic Interview (Lecrubier, 1997). 
Assessment of outcomes
For the purpose of the present study, we used data collected with two generic, disorder-
independent instruments: the patient-rated Brief Symptom Inventory (BSI) and the 




the Symptom Checklist (SCL-90; Derogatis et al., 1983) that assesses psychopathological 
symptoms in eight symptom domains on a 5-point Likert scale (from 0 ‘not at all’ through 
4 ‘extremely’). The BSI subscales are: somatisation, obsessive compulsive, interpersonal 
sensitivity, depression, anxiety, hostility, phobic fear, paranoia and psychoticism. The total 
score is computed by taking the mean score of all individual items (range 0-4). The BSI 
has shown good internal consistency, with Cronbach’s alpha ranging from 0.71-0.85 (de 
Beurs et al., 2011; Derogatis & Melisaratos, 1983) and test-retest reliability coe%cients 
ranging from 0.68-0.91. The convergent validity has proven to be very good (Derogatis 
& Melisaratos, 1983). The CGI is a simple standardised observer-rated assessment tool for 
making global assessments of the severity of illness (Guy, 1976). The main item ‘severity of 
illness’, measured on a 7-point Likert scale (from 1 ‘normal, not at all ill’ through 7 ‘among 
the most extremely ill patients’; CGI-S), was used in the present analyses. The CGI is widely 
used in medical care and clinical research as an outcome measure because of its face 
validity and practicability (Kadouri et al., 2007). 
Within the cross-diagnostic design of our study, poor outcome was de!ned 
according to the rather stringent criteria of a <50% reduction of the baseline BSI score 
(Roy-Byrne et al., 2010) or a CGI-S score of ≥3 during a maximum of 2 years of follow-
up. Only when a patient reached a BSI reduction >50% and CGI-S score 1 or 2 during 
follow up, this patient was considered a responder at that time point. When there was a 
discontinuation of follow-up measurements, the survival time was censored at the last 
time point at which a ROM assessment was completed when response was not achieved. 
Patients
We used two cohorts of adult outpatients who were referred to RD and LUMC for 
treatment of a MAS disorder between 2004 and 2009. The !rst (initial) cohort consisted 
of 2,876 patients with a ROM-baseline assessment (aged 18-65 years) with one or more 
current DSM-IV-TR MAS disorders according to the MINI-Plus, included between 1 January 
2004 and 31 December 2006. The second (replication) cohort consisted of 2,966 patients 
(aged 18-65 years) with DSM-IV-TR MAS disorders according to the MINI-Plus with a ROM-
baseline assessment included between 1 January 2007 and 31 December 2009. Patients 
with a lifetime bipolar disorder or primary psychotic illness were excluded, but a diagnosis 
of major depression with psychotic features according to the MINI-Plus was allowed. 
We then !rst excluded all patients with low baseline severity, de!ned as a BSI total 
score of <0.5 or a score of <3 on the CGI-S, because these patients with minimal severity at 
baseline were unlikely to receive treatment and follow-up assessments (Roy-Byrne et al., 
2010). Then we excluded all patients who did not have follow-up ROM assessments after 
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the ROM baseline assessment. Finally, patients with incomplete data (missings on one or 
more outcome variables or predictor variables) were excluded. 
In the initial cohort, 892 of 2,876 patients (31.0%) were included, and in the 
replication cohort 1,392 of 2,966 patients (46.9%; Figure 6.1). There were no di"erences 
in gender between the included/excluded patients in either of the cohorts. In the initial 
cohort, no di"erence in age existed between the included/excluded patients. Included 
patients more often had a higher education than excluded patients (59.0% vs. 42.7%, χ2 
(2)= 252,43, p<0.001. In the replication cohort, excluded patients were slightly younger 
(mean age at baseline assessment 37.53 years vs. 38.53 years, t(2964)= 2.16, p= 0.03) than 
participating patients. As expected based on the exclusion criteria, excluded patients 
had lower mean BSI and CGI-S scores than included patients in both the initial cohort 
(mean BSI score 1.29 vs. 1.40, t(2786)= 3.84, p<0.001 and mean CGI-S score 4.04 vs. 4.14, 
t(2441)= 2.67, p= 0.008, respectively), and the replication cohort (1.23 vs. 1.42, t(2963)= 
7.39, p<0.001 and 4.02 vs. 4.17, t(2964)= 4.86, p<0.001, respectively)
Psychiatrists and clinical psychologists or psychotherapists in the LUMC and 
RD provided treatment according to the principle of stepped-care and based on the 
Dutch evidence-based treatment guidelines, consisting mainly of pharmacotherapy, 
psychotherapy, or a combination of both (Van Fenema et al., 2010). Treatment and 
therapist characteristics were not taken into account in the present analyses, because 
baseline treatment-independent patient characteristics were the focus of the present 
analysis.
Potential predictor variables
Categorical predictor variables: An extensive set of clinical and demographic 
variables was available. Demographic variables were obtained at baseline with a self-
report questionnaire. A Dutch ethnic background was assumed when the patient and 
both parents were born in the Netherlands. Marital status was categorised in ‘married’ 
(which also included living together in a relationship), ‘divorced or widowed’, and ‘never 
married’. Housing situation was categorised in ‘living alone’, ‘living with partner’, and ‘living 
with family’. Lower education was de!ned as having completed elementary school or 
lower general secondary education. Employment situation was categorised in ‘working 
full-time’, ‘working part-time’, ‘retired/unemployed’, and ‘on sick leave’.
 DSM-IV-TR diagnostic categories (as established with the MINI-Plus) were 
categorised as: mood disorders (major depressive disorder or dysthymic disorder), anxiety 
disorders (panic disorder, social phobia, generalised anxiety disorder or posttraumatic 
stress disorder) and somatoform disorders (hypochondriasis, pain disorder, body 
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dysmorphic disorder, somatisation disorder or undi"erentiated somatoform disorder), 
alcohol abuse or dependence, or drug abuse or dependence. If more than one MAS 
diagnosis was established with the MINI-Plus, the patients was assumed to have MAS 
comorbidity.
Continuous predictor variables: Disorder-independent clinical variables were 
assessed with the following self-report and observer-rated scales:
The observer-rated abbreviated Comprehensive Psychopathological Rating 
Scale (CPRS) consists of the Montgomery-Åsberg Depression Rating Scale (MADRS), the 
Brief Anxiety Scale (BAS) and a scale that assesses psychomotor inhibition (INH; Goekoop 
et al., 1992). The MADRS has an internal consistency (Cronbach’s alpha) of 0.86, and an 
inter-rater reliability coe%cient of 0.65-0.97 (Montgomery et al., 1979).
The Global Assessment of Functioning (GAF) scale is a rating scale for evaluating 
‘psychological, social and occupational functioning on a hypothetical continuum of 
mental illness’ (Axis V of the DSM-IV-TR). The GAF score is measured on a scale of 0-100, and 
the most severe condition on any of the three dimensions provides the overall score. The 
GAF score has a modest reliability, which strongly depends on the training and calibration 
of the raters (Vatnaland et al., 2007).
All participants also completed the Mood and Anxiety Symptom Questionnaire 
(MASQ), a questionnaire that measures the dimensions of the tripartite model of anxiety 
and depression (Watson et al., 1995). The MASQ is a 90-item self-report questionnaire 
that consists of !ve symptom dimensions and has good psychometric properties with 
Cronbach’s alphas ranging from 0.91-0.96 across subscales (Watson et al., 1995). 
The Dimensional Assessment of Personality Pathology-Short Form (DAPP-SF) was 
administered to assess maladaptive personality traits (van Kampen et al., 2008). The DAPP-
SF is the Short version of the DAPP-BQ, a self-report scale that consists of 18 subscales 
with a total of 136 items. Scores are on a 5-point Likert scale (1-5), and scores of subscales 
are computed by taking the sum scores of the subscale items. The DAPP-SF has good 
psychometric properties with Cronbach’s alphas ranging from 0.78-0.89 across subscales 
(van Kampen et al., 2008).
Generic health status was assessed with the Short Form-36 (SF-36), a 36-item self-
report questionnaire that measures health status in eight domains: physical functioning, 
social functioning, physical problems, emotional problems, mental health, vitality, bodily 
pain and general health (Ware & Sherbourne, 1992). The SF-36 has good psychometric 






Using descriptive statistics, baseline characteristics are described as number (percentage) 
or mean (standard deviation [SD]), when appropriate. Univariable hazard ratios (HR) of 
poor outcome were computed according to baseline categorical and continuous predictor 
variables in the initial cohort. HRs were calculated for poor outcome based on the BSI and 
the CGI-S separately, as well as on the more conservative combined CGI-S or BSI criterion 
for poor outcome. 
To allow comparison of the obtained e"ect sizes on di"erent predictor variables, 
standardised z-scores were calculated (as the di"erence between measured values and 
mean, divided by the SD). Since higher scores on the GAF scale and SF-36 subscales 
correspond with better functioning and health, we subtracted original scores from 100, 
and used these inverted scores in the analyses to facilitate the comparability among HRs. 
All predictor variables from the initial cohort that had yielded HRs with a p-value <0.10 
in univariable analyses were subsequently selected for an initial forward stepwise 
multivariable Cox regression model. The criteria used for both selection and removal 
were 0.10. Independent predictors of poor outcome as previously de!ned in the initial 
cohort were used for replication in the independent replication cohort. These predictors 
were selected in the replication cohort and forced in a multivariable Cox regression 
model. Because exact dates of reaching the de!ned endpoint of treatment response were 
unknown, a sensitivity analysis was performed in which we re-analysed the date of the ROM 
measurement during which response was achieved, taking the mid time point between 
the last two measurements. This mid-time point is probably more close to the ‘true’ time 
point at which response was reached. Additional sensitivity analyses were performed 
with less conservative response criteria had to be met (i.e. CGI-S and BSI criterion for 
poor outcome), and with less stringent exclusion criteria (low baseline severity de!ned 
as baseline BSI score <0.5 or CGI-S score of 1 or 2). Moreover, we performed a sensitivity 
analysis in which all patients with a single somatoform disorder were excluded from the 
analyses. All further tests were two-tailed with a p<0.05 denoting statistical signi!cance. 
The software used was SPSS version 17.0 (SPSS Inc., Chicago, Ill, USA).
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Results
Sample and demographic characteristics
Table 6.1 shows the predictor variables and DSM-IV-TR diagnoses at baseline of 892 and 
1,392 subjects of the initial and replication cohorts, respectively. A total of 62.4% of the 
initial cohort and 64.6% of the replication cohort were female. The mean age in the initial 
cohort was 38.3 (SD 11.6) years and was 38.5 (SD 12.5) years in the replication cohort. A 
Dutch ethnic background was found in 81.2% in the initial cohort and in 84.3% in the 
replication cohort. In both cohorts, the majority of patients was living with a partner, and 
more than half of the patients were not (currently) working. A single mood disorder was 
the most prevalent disorder in both cohorts (33.4% and 29.3%, respectively), followed 
by a single anxiety disorder (22.9% and 26.9%, respectively) and a single somatoform 
disorder (5.9% and 4.7%, respectively). MAS comorbidity was present in 37.8% and 39.0% 
of the patients in the initial and replication cohorts, respectively. 
Univariable predictors of poor outcome
Table 6.2 shows the univariable categorical correlates of poor outcome in the initial cohort. 
Lower education was associated with a higher HR of poor outcome, which was consistent 
among the two outcome variables. Using the ‘combined BSI or CGI-S poor outcome’ variable, 
lower education resulted in a 41% higher chance of poor outcome. Employment status 
was also consistently associated with poor outcome, with retired subjects, unemployed 
subjects and subjects being on sick leave having a higher chance of poor outcome on any 
of the three outcome variables. Su"ering from MAS comorbidity predicted a 51% higher 
HR of poor outcome using the ‘combined BSI or CGI-S poor outcome’ variable, as compared 
with having a single mood disorder. Patients su"ering from a single somatoform disorder 
three times more chance of poor outcome using the ‘combined BSI or CGI-S poor outcome’ 
variable, as compared with having a single mood disorder.
Table 6.3 presents the univariable continuous correlates of poor outcome in 
the initial cohort. Again, overall the !ndings were largely consistent when using either 
the BSI or CGI-S or the combined poor outcome criterion. An increase of 1 SD in age 
corresponded with a 22% higher chance of poor outcome using the ‘combined BSI or 
CGI-S poor outcome’ endpoint. The largest and most consistent e"ect sizes on the two 
and the combined outcome measures were found for the DAPP-SF subscales cognitive 
distortion, identity problems, a"ective lability, intimacy problems and self-harm, and for 
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Independent predictors of poor outcome
Table 6.4 shows the multivariable HRs of poor outcome on the ‘combined BSI or CGI-S 
poor outcome’ variable in both the initial and replication cohorts. 
When using the group with a single mood disorder as the reference group, we 
found that having a single anxiety disorder was not signi!cantly associated with a higher 
chance of poor outcome. However, the relatively small groups (of 53 and 66 subjects) with 
a single somatoform disorder had consistently more than three times higher chance of 
poor outcome. The group with MAS DSM-IV-TR comorbidity also had a 52% higher chance 
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Next, a 1-SD increase in the DAPP-SF A"ective Lability subscale was associated 
with an 22% and 36% higher chance of poor outcome in the initial and replication 
cohorts, respectively. A 1-SD increase in the DAPP-SF Intimacy Problems subscale 
resulted in a 28% higher chance of poor outcome in the initial cohort, and 16% in the 
replication cohort. Another independent predictor of poor outcome was the Self-Harm 
subscale of the DAPP-SF, with 1 SD increase of scores resulting in 16% and 11% higher 
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chance of poor outcome, respectively. Finally, one subscale from the SF-36 was strongly 
and independently associated with treatment response in both cohorts, i.e. unfavourable 
scores on the General Health subscale that predicted 22% and 26% higher chances of 
poor outcome, respectively.
Figure 6.2 shows the six independent predictors of poor outcome in subjects from 
the combined initial and replication cohorts in Kaplan-Meier curves, representing the 
cumulative incidence of naturalistic treatment response with a maximum follow-up time 
of 2 years. In all sensitivity analyses (as described in the statistical analyses section), the 
same independent predictors were found (data not shown). 
Discussion
In this naturalistic cohort study in 892 outpatients with MAS disorders and an independent 
replication cohort of 1,392 outpatients, we found that having an older age, MAS 
comorbidity, a somatoform disorder, high scores on the personality dimensions a"ective 
lability, intimacy problems and self-harm, and a poor general health were independently 
associated with poor outcome after up to 24 months of follow-up. Our samples were 
broadly representative of outpatients with major depressive, anxiety and somatoform 
disorders (or a combination of these disorders) treated in a naturalistic psychiatric 
secondary care setting. Detailed assessment of patient characteristics before the start of 
treatment proved to be useful in predicting poor outcomes. 
 Our data con!rms and adds to the growing body of evidence about risk factors 
for poor outcome in MAS disorders. First, in previous studies older age predicted slower 
recovery among outpatients with depression (Fournier et al., 2009) and outpatients 
with depression and/or anxiety (Penninx et al., 2011). Physical illness, disability, social 
isolation and loneliness may become more common with advancing age, which may 
adversely a"ect treatment outcome of comorbid psychiatric disorders (Luanaigh et al., 
2008). Second, comorbidity has repeatedly been related to poor outcomes (de Waal et 
al., 2004; Frank et al., 2011; Leiknes et al., 2007; Maier & Falkai, 1999; Melartin et al., 2004; 
Penninx et al., 2011; Souery et al., 2007), which may be due to the higher burden of disease 
and severity (de Waal et al., 2004; Maier & Falkai, 1999). Third, somatic symptoms and 
somatic comorbidity have been linked to poor outcomes (McKenzie et al., 2010; Speckens 
et al., 1996), but longitudinal studies in patients with somatoform disorders are scarce. 
Fourth, adverse personality traits were found to interfere with and compromise therapy 




Figure 6.2. Kaplan-Meier curves for 
poor outcome according to baseline 
characteristics; Kaplan-Meier curves are 
shown for the incidence of naturalistic 
treatment response based on a >50% 
improvement on the BSI and a score of 1 
or 2 on the CGI-S among 2,284 patients 
with a MAS disorder from the initial and 
replication cohorts combined. Patients 
were compared for age per decade (Box 
A), DSM-IV-TR diagnostic category (Box 
B), A"ective Lability (Box C), Intimacy 
Problems (Box D), Self-Harm (Box E), 
and General Health (Box F). To facilitate 
graphical presentation of data, catego-
risation of A"ective Lability, Intimacy 
Problems, Self-Harm and General Health 
into tertiles was applied.
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2005; Skodol et al., 2011; Souery et al., 2007; Yonkers et al., 2000).  Personality disorders at 
baseline in a sample of 303 patients with a depressive disorder were associated with long-
term adverse outcomes (Grilo et al., 2010). In a study among 514 patients with generalised 
anxiety disorder, social phobia and panic disorder, the presence of a personality disorder 
adversely in#uenced the time to remission during 5 years of follow-up (Massion et al., 
2002). Finally, somatic conditions and poor general health have often been associated 
with depressive and anxiety disorders (Katon et al., 2010; McKenzie et al., 2010; Mezuk et 
al., 2008; Weinberger et al., 2008). Besides a direct association, co-medication (e.g., opiate 
analgesics, antihypertensives, corticosteroids and interferons), may further adversely 
have induced or detrimented MAS disorders. 
 Taking our results together, a MAS patient who meets the pro!le of being 
elderly, su"ering from comorbid MAS disorders or a somatoform disorder, with cluster 
B personality traits and a reported poor general health, is at risk of poor outcome or 
chronicity in clinical outpatient practice. Our !ndings stress the importance of assessing 
the strengths and vulnerabilities of the patient’s personality, as high levels of a"ective 
lability, tendency to self-harm and intimacy problems, indicative of poor coping styles 
and dysfunctional interpersonal behaviour, predicted poor outcome and should be a 
focus of attention during treatment (van Kampen et al., 2008).  MAS patients with more 
pronounced personality traits may bene!t from speci!c therapeutic approaches, such 
as targeting cluster B personality characteristics, or cognitive behavioural therapy or 
dialectical behaviour therapy that combines cognitive-behavioural techniques with 
concepts of distress tolerance, acceptance, and mindful awareness (Robins et al., 2004). 
Self-perceived poor general health and somatoform disorders also deserve more research 
on focused treatment. Although patients su"ering from MAS disorders are likely to 
make illness attributions with somatic symptoms and experience illness behaviour, any 
underlying medical conditions should be clari!ed and treated if necessary, especially in 
the elderly. Also, these patients might bene!t from speci!c interventions to improve their 
physical condition, e.g. consulting a physiotherapist or dietician, and collaborative care 
management (Katon et al., 2010). Screening and assessment instruments can be routinely 
applied at baseline to systematically detect psychiatric comorbidity, adverse personality 
characteristics and self-perceived poor general health.
 Our study has several strengths. First, this was a cross-diagnostic study in 
naturalistic samples with high comorbidity rates, and with broad inclusion and few exclusion 
criteria representative of a ‘real world’ setting. Second, we con!rmed our !ndings in a large 
independent replication cohort. Third, a structured clinical interview was used to diagnose 
psychiatric disorders, and detailed self-report and observer-rated information was available 
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on individual characteristics including personality traits. Fourth, although no rating scale 
has generally been accepted as the gold standard to assess social and functional aspects 
of recovery in MAS patients, measures such as the BSI and the CGI-S are clinically useful 
instruments to evaluate treatment outcomes across the diverse MAS disorders and to assess 
the patient population in its entirety (Klinkman, 2009; Trivedi, 2001). Finally, all assessments 
were made by trained research nurses who were not involved in treatment. 
 Our study also has several potential limitations. First, there is a lack of information 
on the speci!c treatments given, thus treatment could not be taken into account in our 
analyses. We assume that patients were treated according to evidence-based guidelines; 
however, as our study represents a ‘real world’ setting, guideline concordance is often less 
strict than in a controlled setting. Nevertheless, a previous analysis in our ROM cohort 
showed that treatment broadly followed guidelines, and consisted of psychotherapy, 
pharmacotherapy, and combined therapy (van der Lem et al., 2011; Van Fenema et 
al., 2010). Second, no information on psychiatric history, family history and somatic 
comorbidity of the patients was available for our cohorts. Third, there was substantial 
attrition, as many patients completed only one ROM assessment. A considerable loss 
to follow-up is common in studies with a ‘real world’ approach such as the STAR*D trial, 
that reached a loss to follow-up of 30% after step II of the study (Rush et al., 2006). Third, 
we used the DAPP-SF for assessment of personality traits and identifying patients more 
likely to su"er from DSM-IV-TR personality disorders; however, the Axis I MAS disorder 
may have confounded and precluded a valid assessment of personality disorders. Fourth, 
the BSI may not be speci!c enough to fully capture clinical changes in all MAS disorders, 
especially in somatoform disorders (Arnold et al., 2010). Finally, the use of Cox regression 
analyses implies that subjects are censored upon reaching the de!ned endpoint of 
treatment response; therefore, the information about a possible relapse after an initial 
response could not be taken into account. 
 In summary, we discovered and replicated cross-diagnostic predictors that identify 
outpatients with MAS disorders who are at risk for poor outcome in a naturalistic outpatient 
treatment setting. These predictors are: an older age, diagnosis of a somatoform disorder 
or MAS comorbidity, a"ective lability, intimacy problems, self-harm, and a poorer general 
health. Since our patient cohorts were representative a large naturalistic treatment-seeking 
population in outpatient psychiatric specialty care, our !ndings contribute to the existing 
literature on predictors for outcome in MAS disorders. As MAS disorders are highly prevalent 
and often invalidating conditions, future studies should focus on the identi!cation of the 
most e"ective treatment modalities for the most vulnerable outpatient subgroups among 
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This thesis focused on real-world patients and real-world outcomes by using Routine 
Outcome Monitoring (ROM) in patients with Mood, Anxiety, and Somatoform (MAS) 
disorders. The primary aims of the series of studies were to investigate correlates of 
disease characteristics in a large cohort of treatment-seeking patients with MAS disorders, 
and to discuss these !ndings in relation to existing data derived from RCTs and general 
population studies. In addition, using prospective data, we investigated whether baseline 
characteristics measured with ROM could predict outcomes in real-world or naturalistic 
treatment settings. The secondary aim was to assess the feasibility of conducting large-
scale clinical epidemiological research with ROM data that had been collected in everyday 
clinical practice, thereby representing the phenotype of ‘real’ patients. In the remainder 
of this chapter we will summarise the major !ndings of the presented studies, discuss 
these !ndings and ROM in a broader perspective, and conclude with thoughts and 
recommendations about future studies.
Summary of major !ndings
The !rst study of this thesis (Chapter 2) concentrated on gender di"erences in patients 
with Major Depressive Disorder (MDD). Although gender di"erences in course and 
symptomatology of depression have frequently been studied, a closer look at the literature 
reveals that almost all studies have been conducted in population samples or clinical trial 
samples. In a recent study of our group we have shown that only 20-25% of our MDD 
patients would qualify for inclusion in a regular clinical trial (van der Lem et al., 2010), so 
we argued that patients from clinical trials do not adequately represent treatment-seeking 
everyday or real-world patients. In other words, external validity is limited. The aim of 
this study therefore was to investigate gender di"erences in clinical characteristics of a 
naturalistic sample of MDD patients from our ROM database. We used ROM baseline data of 
1,131 MDD patients, and analysed symptom severity, symptom pro!les, comorbidity and 
general health status. The most remarkable !ndings were that women reported a more 
severe ‘subjective’ phenotype on self-rated scales, with more symptoms and more severe 
symptoms of depression and a lower general health status than men. On more objective 
observer-rated scales, however, no signi!cant di"erences in symptom severity were found 
between women and men. These !ndings suggest that the burden of MDD is higher in 




was also di"erent in women compared to men, with women reporting more loss of 
energy, hypersomnia, feelings of worthlessness, loss of appetite, fatigue, loss of interest 
in sex, feelings of guilt and crying. The majority of these !ndings were largely consistent 
with previous studies in non-naturalistic patient samples. In Chapter 3, we extended the 
cross-sectional analyses on ROM baseline assessments in patients with MDD. In this study 
we compared clinical characteristics of patients with a pre-adult onset versus adult-onset 
MDD. Evidence from earlier studies pointed towards a more severe phenotype in pre-adult 
onset MDD. However, these !ndings again were mostly derived from studies in either 
population-based studies or clinical trials. In multivariable analyses in 1,105 MDD patients, 
we found that patients with pre-adult onset MDD more often had a history of suicide 
attempts and current suicidal thoughts compared with adult-onset MDD patients. This 
important study !nding replicated earlier !ndings in clinical samples and supports the 
hypothesis that pre-adult MDD is characterised by a distinct phenotype compared with 
adult-onset MDD. Other previous !ndings, e.g. having more severe symptoms (Zisook et 
al., 2004; Zisook et al., 2007) or anxiety (Parker et al., 2003) in pre-adult onset MDD, could 
not be replicated. This is important to ascertain, since our samples more truly represent 
‘real’ patients than previous studies did. Although possibly confounded by recall bias and 
measurement error, the age of onset of MDD can be obtained relatively easy and may help 
the clinician in risk-assessment of suicidality. 
 After these !rst two studies in MDD patients we expanded our cross-sectional 
analyses to all patients with MAS disorders. In Chapter 4 we studied prevalence and 
correlates of deliberate self-harm and suicidal ideation (DSHI) in a large group of patients 
referred for treatment of either a mood, anxiety or somatoform disorder, or a combination 
of these diagnoses. We analysed 2,844 patients with a ROM baseline assessment and used 
the self-harm subscale of the Dimensional Assessment of Personality Pathology-Short 
Form (DAPP-SF) to assess DSHI. Lifetime DSHI was reported by 55% of the total sample. 
Being married, having a higher educational status and having high anxiety symptoms 
were independently associated with lower risks of DSHI. Having a higher number of 
MAS diagnoses, having more depressive symptoms and higher scores on the emotional 
dysregulation subscale of the DAPP-SF were associated with higher risks of DSHI. The 
negative association with anxiety measured with the Brief Anxiety Scale (BAS) in adjusted 
analyses was unexpected. The most plausible explanation of this !nding would be that 
patients with high anxiety levels but similar levels of depressive symptoms were too afraid 
to hurt themselves. These results in a unique broad sample of outpatients with common 
mental disorders demonstrate that DSHI is a common phenomenon in MAS outpatients, 





increased risk for DSHI and completed suicide. 
 In the next part of this thesis we shifted the focus to clinical predictors of real-world 
outcomes, using prospective ROM measurements in addition to the baseline assessments. 
In Chapter 5 we used ROM baseline and follow-up assessments of up to 24 months to 
investigate whether individual baseline depressive symptoms would predict outcome in 
1,489 MDD patients. In earlier studies, many clinical correlates of MDD-treatment outcome 
have been identi!ed. Earlier age of onset, more severe complaints and cluster B and C 
personality traits were among the predictors of less favourable outcome (see for example 
Frank et al., 2010; Penninx et al., 2011; Souery et al., 2007; Vuorilehto et al., 2009). Most 
studies had a limited follow-up time of three months to one year. Moreover, the predictive 
value of speci!c depressive symptoms at baseline had not been systematically assessed 
before. In daily clinical practice, being able to predict which patients are at risk to become 
non-responders or develop a chronic course of the depression is highly important. We 
analysed the predictive value of all 21 individual depressive symptoms measured with the 
widely used Beck depression Inventory-Revised (BDI-II; Beck et al., 1988) on naturalistic 
treatment outcome, de!ned as remission (score <10) or response (≥50% reduction) on 
the Montgomery-Åsberg Depression Rating Scale (MADRS; Montgomery, 1979). Using 
multivariable Cox regression analyses, we found that after adjusting for known clinical 
variables correlating with treatment outcome, baseline presence of the two major 
symptoms ‘pessimism’ and ‘loss of energy’ strongly and independently predicted a higher 
chance of a chronic course. In daily clinical practice, the presence or absence of these 
symptoms are relatively easy to assess, and the presence of pessimism and/or loss of 
energy should alert the clinician to the higher risk of a chronic MDD course.
 In the !nal study (Chapter 6), we extended the prediction of real-world outcomes 
to the total group of patients with MAS disorders. In the DSM-IV-TR, MAS disorders show 
a considerable overlap in diagnostic criteria and in daily practice mutual comorbidity of 
these disorders is substantial. Although in most clinical trials only patients with certain 
primary axis-I diagnoses are included, the concept of primary diagnosis is rather vague 
(van der Lem et al., 2010). The frequent occurrence of MAS-comorbidity complicates the 
establishment of the primary or main diagnosis. Hence, in daily clinical practice, a patient 
with for example a MDD and a social phobia is treated according to the MDD guideline, 
the social phobia guideline, or a combination of both. In this particular study we aimed to 
assess predictors of ‘cross-diagnostic’ outcome in clinical practice. We de!ned outcome as 
a certain reduction on a combination of two disorder independent measurement scales: 
the observer-rated Clinical Global Improvement Scale (CGI; Kadouri et al., 2007) and the 




We used baseline ROM data as well as prospective data with up to 24 months of follow-
up. We used a sample of 892 MAS patients, and validated our results in an independent 
sample of 1,392 MAS patients. In multivariable Cox regression analyses, we found that after 
adjusting for age and gender, the following characteristics were independent predictors 
of unfavourable outcome: advancing age, having MAS comorbidity or a somatoform 
disorder, the personality traits intimacy problems, a"ect lability and self-harm, and a low 
self-reported general health status. These !ndings were con!rmed in a second sample of 
MAS patients, and could help the clinician to identify patients who are at risk for a chronic 
course of the MAS disorder. Whether these patients, based on the above pro!le, could 
bene!t from extra interventions should be the focus of future studies. 
General discussion
Routine Outcome Monitoring is the systematic assessment of treatment outcomes 
in everyday clinical practice. In psychiatric specialty care, ROM assessments include 
standardised and validated measurement instruments. The ROM-infrastructure in Leiden 
uses a broad test battery that comprises a range of both self-report and observer-rated 
scales. The test battery includes a diagnostic instrument, instruments that measure generic 
and disorder-speci!c symptom severity, and scales that measure psychosocial functioning. 
In general, ROM is primarily used as a tool for patient and clinician to monitor treatment 
progress. Although more speci!c research is necessary, studies indicate a positive impact 
of ROM and feedback on mental health status (Carlier et al., 2010). In anonymised form, 
the systematically obtained data can also be used for clinical epidemiological research 
purposes (de Beurs et al., 2011), as exempli!ed by this thesis. Whenever a broad range of 
instruments is applied, detailed phenotypic information of patients can be derived from 
ROM. In the Leiden region in the Netherlands, ROM assessments are part of the routine 
diagnostic and therapeutic procedure in patients with MAS disorders in the outpatient 
clinics at the Leiden University Medical Center (LUMC) and Rivierduinen (RD; see Box 1.1, 
Chapter 1). In Leiden, assessments ideally take place directly after referral (ROM baseline 
assessment) and at any step or change in the treatment protocol. In practice, this is on 
average every 3-4 months repeatedly during treatment. In Leiden, only patients who 
are unable to undergo ROM assessments due to language problems, disease severity or 
refusal are excluded from ROM. With approximately 80% of all patients taking part in the 





The Leiden ROM infrastructure is an example of an extensive ROM infrastructure. 
This extensive ROM has several advantages, e.g. detailed phenotyping, staging of 
psychiatric disease, identi!cation of residual symptoms (‘rollback phenomena’, see Fava et 
al. 2011). Furthermore, it provides opportunities for clinical epidemiological research and 
benchmarking. However, important di"erences exist among implemented ROM systems 
worldwide. For example, some institutions apply routine monitoring with the use of only 
one self-report instrument, that is administered at every visit (e.g. Zimmerman et al., 2005). 
The studies presented in this thesis focused on clinical characteristics and 
predictors of outcome in everyday patients with mood, anxiety and somatoform 
disorders. Although this seems a trivial fact, studies in naturalistic samples of MAS patients 
in psychiatric specialty care were scarce. The large-scale ROM infrastructure in the Leiden 
region provided a unique opportunity to investigate important clinical aspects in a 
relatively unselected treatment-seeking outpatient population, yielding !ndings that are 
easy to generalise to routine clinical outpatient practice. This contrasts with !ndings from 
clinical trials that included highly selected patient samples resulting in a more limited 
generalisability. Findings from population studies do neither re#ect a treatment-seeking 
population. In fact, 75-80% of our ROM MDD-patients would not have met the in- and 
exclusion criteria for most clinical trials (van der Lem et al., 2010).
 The !ndings of the explorative studies in this thesis have provided unique insights in 
the phenomenology of ‘real’ MAS patients in daily clinical practice. Predictors of natural-
istic outcome have been established. In addition, the strengths and weaknesses of a 
large-scale and extended ROM initiative have become tangible. In the next paragraphs, 
we will discuss our !ndings in a broader perspective.  
Phenotype of real-world MAS patients
In the process of designing the studies presented in this thesis, we decided to start our 
explorative analyses with a well-studied topic in psychiatric literature. As mentioned 
before, gender di"erences in depression have been studied extensively. The naturalistic 
character of our study sample was a new point of view. The results of this !rst study partly 
con!rmed and extended previous research. The most important implication of the !rst 
study was that for a balanced ROM assessment both observer-rated and self-report scales 
are necessary, which supported earlier work of Möller (2009). If the ROM assessments 
would have comprised only self-rating instruments, important nuances would have been 




between men and women on observer-rated scales, while substantial di"erences existed 
on self-rated scales. This stresses the need for maintaining the observer-rated scales in 
ROM, even in an era of inevitable cost reductions in healthcare. Another important 
conclusion of the !rst study in this thesis was that the quality of the anonymised patient 
data provided by our ROM database was successfully applied for the intended analyses. 
 The main !nding of the second study was that MDD patients with disease onset 
before the age of 18 years were more suicidal compared to those with onset at adult 
age. This was in part a replication of earlier studies in di"erent samples. The fact that in 
multivariable analyses all di"erences in clinical pro!le, except suicidality, became non-
signi!cant could at least in part explain the high variability of the !ndings in earlier studies, 
which not always had included a comprehensive set of potential confounders. The higher 
rates of current and past suicidality in pre-adult onset MDD may have important clinical 
implications, as completed suicide needs to be prevented in patients with psychiatric 
disorders, and it is one of the leading causes of death worldwide. The estimated global 
burden of suicide is a million deaths per year (WHO, 2002), or 14.5 deaths per 100.000 
people worldwide. These are probably underestimations. Large di"erences exist between 
countries, and men are much more at risk for completed suicide with a male-female ratio 
of 2-4 to 1 in developed countries (WHO, 2002). Previous self-harm or suicide attempts are 
major risk factors for completed suicide (Cavanagh et al., 2003; Coryell and Young, 2005). 
Based on psychological autopsies in completed suicide patients, it is estimated that 90% 
(Cavanagh et al., 2003) or even more (Ernst et al., 2004) had a DSM-IV Axis I psychiatric 
disorder at the time of suicide. More than half of the patients who die of suicide meet 
criteria for current MDD (Cavanagh et al., 2003; Hawton and van Heeringen, 2009), and 
about 4% of MDD patients die by suicide. Despite dramatic increases in awareness, 
prevention and treatment e"orts, no signi!cant decrease in suicide rates has occurred in 
the US from 1990 to 2003 (Kessler et al., 2005). These !gures stress the need for early and 
better identi!cation of suicidality, especially in MDD patients, and the need for speci!c 
interventions. Based on the results of Chapter 2, clinicians should be especially aware of 
suicidality in male MDD patients with pre-adult onset MDD and previous suicide attempts.
 The !nding of more suicidality in pre-adult onset MDD patients increased our 
interest in the phenomenon of suicidality and the broader concept of deliberate self-
harm. Since suicidal patients and patients who engage in self-destructive behaviour are 
excluded from most clinical trials in psychiatry, we investigated these phenomena in depth 
in our total group of MAS patients. This third study also in part replicated earlier studies 
in more strictly selected populations, but also yielded new insights. The most important 





suicidal ideation. Of course, this !nding needs replication in future studies. Furthermore, 
the broad sample of 2,844 treatment-seeking MAS patients with substantial comorbidity 
allowed us to identify correlates of self-harm irrespective of DSM-IV diagnosis, which 
increased applicability in clinical practice. 
Predictors of real-world outcomes
One of the most important topics for both patients and clinicians regards the chances 
of getting better. This is of course not speci!c for psychiatric patients. Large-scale 
epidemiological studies have identi!ed risk factors for adverse outcomes in a wide range 
of somatic diseases or disease variants. These studies have resulted in risk-assessment 
schedules that have been widely adapted in worldwide guidelines. A famous example 
is the Framingham heart study, a cohort study of over 5,000 inhabitants of Framingham, 
Massachusetts. This study, initiated in 1948, has calculated detailed chances of 
cardiovascular events if a patient corresponds to a certain pro!le, based on gender, age, 
systolic blood pressure, and serum lipids (Anderson et al., 1991; Dawber et al., 1951). Based 
on this study, with numerous publications and an o"spring study (Kannel et al., 1979), 
patients with certain risk pro!les are considered as subgroups for which risk scores can be 
calculated and di"erent treatments can be advised. International guidelines have adapted 
these risk calculators. In Europe, the Systematic Coronary Risk evaluation (SCORE) project 
has used data of over 200.000 European patients to calculate estimations of ten-year risk 
of fatal cardiovascular disease (Conroy et al., 2003). As discussed in the introduction of this 
thesis, for psychiatric disorders, those detailed studies have never been performed. Based 
on the available epidemiological literature, only rough estimations about the course of 
the disease can be provided for the total group of patients with a certain disorder (see 
for example Judd, 1997). Until now, guidelines and treatment algorithms only roughly 
di"erentiate between subgroups of patients. For example: The Dutch Multidisciplinary 
Guideline for the treatment of MDD (www.ggzrichtlijnen.nl) discriminates between 
!rst episode or recurrent episode, and between mild or moderate/severe depression. 
Furthermore, patients with moderately to severe depression have the options of a modern 
antidepressant or psychotherapy, whereas the treatment algorithm for patients with Major 
Depression with psychotic features suggests treatment with a tricyclic antidepressant, 
with possible addition of an antipsychotic agent. Depression with atypical features may 
better respond to monoamine-oxidase inhibitors than other classes of antidepressants. 




sophisticated subgroups of patients is of utmost importance, yet still very imprecise. 
Based on the !ndings of the studies in this thesis, in the next part of this discussion we 
present a theoretical future algorithm of risk assessment in MDD (!gure 7.1). 
 The fourth study of this thesis can be interpreted as an attempt to predict 
outcomes of MDD in a real-world treatment setting based on baseline symptoms that 
can easily be obtained. We have demonstrated that ROM assessments can be helpful in 
risk assessment and that the baseline presence of both lack of energy and pessimism 
symptoms measured with the widely used BDI-II, were highly predictive of non-remission 
of MDD after a follow-up of up to2 years. In the !fth and !nal study of this thesis we 
aimed to establish predictors of poor outcome in the whole group of patients with MAS 
disorders. The broad phenotypic assessment with ROM allowed us to closely investigate 
demographical and clinical risk factors of poor outcome in a naturalistic treatment setting. 
Furthermore, we used a cross-diagnostic design in which we included all MAS patients 
thereby abandoning the rather vague concept of primary diagnosis often used in studies. 
This made the results of this study easy and widely applicable to clinical practice. Although 
much more research is needed, our longitudinal ROM studies can be seen as one further 
step towards a more detailed risk assessment, based on extensive phenotypic data. In 
the future, hopefully, adding genotypes and endophenotypes (biological substrates) 
to phenotypic data may further enhance the precision of risk-assessment. In addition, 
important environmental information that might be important in epigenetic e"ects 
(e.g. childhood trauma, daily stress) may also be ascertained with ROM. E"orts in !nding 
biological substrates of symptom dimensions of depression and anxiety have already 
been published (Veen et al., 2011; Wardenaar et al., 2011). 
ROM and Comparative E"ectiveness Research
In the literature, research based on ROM data is often regarded as ‘patient-centered 
research’. If treatment details are taken into account, ROM-data driven research could 
be used for Comparative E"ectiveness Research (CER). CER is designed to improve the 
clinical decision-making process by providing research evidence on the e"ectiveness and 
risk-bene!t pro!le on di"erent therapeutic options for speci!c patient subpopulations 
(Mane et al., 2011; Sox and Green!eld, 2009). In the US, the Patient-Centered Outcomes 
Research Institute (PCORI) has been established to facilitate CER. The mission of this 
institute is to help people make informed healthcare decisions, and to improve healthcare 





a funding of more than 3 billion US Dollar for the next decade, allowing the support of 
numerous studies of CER, in di"erent areas of healthcare. In Europe, to our knowledge, 
no comparable large-scale initiatives are being developed. In theory, ROM databases of 
di"erent institutions could be merged in large collaboration e"orts and used for CER. 
For such overarching initiatives to be successful, many consensus steps have still to be 
taken. On a national level, for The Leiden Institute for the Advancement and Integration 
of ROM (LIAIROM), achieving consensus about implementation of ROM and e.g. choice 
of measurement instruments in order to integrate ROM databases is a priority area. For 
example: based on our studies, speci!c interventions for MDD patients meeting the pro!le 
of advanced age, comorbidity, cluster B traits and poor reported general health could be 
investigated. Or if treatment details become available in ROM, it would be possible to 
investigate which antidepressant is associated with the highest chance of remission in 
patients with baseline pessimism and lack of energy.
A theoretical future algorithm of risk assessment and treatment recommendations 
in MDD patients which resembles the cardiovascular disease risk calculation is presented 
in !gure 7.1. 
 In cardiovascular risk management di"erentiated treatment recommendations 
(e.g. lifestyle adaptations with or without treatment with statins) are based on several 
phenotypic and endophenotypic aspects (e.g. smoking and systolic blood pressure). One 
could imagine that in future psychiatric practice, comparable treatment recommendations 
would be possible (e.g. lifestyle adaptations, !rst-step interventions, versus psychotherapy 
or pharmacotherapy or extra interventions), based on ROM assessments comprising 
detailed phenotypic information and information about environmental factors, combined 
with genotypes and endophenotypes (e.g. cortisol levels).
ROM critically appraised
One of the aims of this thesis was to assess the feasibility of conducting large-scale 
clinical epidemiological research with data provided by ROM. The studies presented 
here demonstrate that the ROM infrastructure in RD/LUMC provide vast possibilities 
in conducting both cross-sectional and prospective analyses, with the opportunity of 
studying speci!c phenotypes of MAS patients and risk factors of outcomes and disease 
course. Several aspects deserve further noti!cation. We will now focus on the strengths 













































































The Leiden ROM infrastructure has been developed and implemented with the 
combined goals of treatment monitoring for patient and clinician, and to serve as a large 
database for research and for benchmarking. The use of computerised assessments and 
dedicated software prevents missing data within speci!c instruments, and provides high 
data quality. Another strength is the fact that assessments are performed by specially 
trained research nurses who are not involved in treatment, ensuring neutral assessments 
without the risk of measurement bias that could occur when clinicians would rate their 
own patients. Moreover, the extensive baseline assessments, including a comprehensive 
and well validated diagnostic measurement instrument (MINI-Plus), an instrument that 
assesses dysfunctional personality traits (DAPP-SF) and repeatedly administered scales 
that cover the symptom level and psychosocial functioning, provide detailed phenotypic 
information at every phase of treatment. Both phenotypic research on a group level and 
outcomes research can be performed. The choice of measurement instruments at the 
time of implementation (from 2002) was based on psychometric quality and applicability 
of the instrument, and on the availability in the public domain. For longitudinal research, 
obviously, the test battery should remain extensive and ideally unchanged. Unfortunately, 
in the past years copyright issues forced us to abandon certain scales (e.g. DAPP-SF, BSI). 
The high rate of ROM baseline assessments of approximately 80% is another strength. 
Because ROM is integrated in everyday clinical practice, only patients who are not #uent 
in Dutch or those patients who are too ill to undergo assessments are excluded from ROM.
 By utilising ROM data for the studies in this thesis we encountered several limitations 
of the Leiden ROM infrastructure. The most important limitation of the present Leiden ROM 
system is the current lack of integration with the (anonymous) electronic patient record 
forms (PRFs), preventing the researcher from retrieving information about exact treatment 
modality, detailed psychiatric history, family history of psychiatric diseases, and somatic 
status. In order to obtain detailed information about e.g. treatment, the researcher has to 
hand-search the patient record !les. This hand-searching could compromise anonymity. 
Integration of ROM with PRFs would have given us the opportunity to adjust for treatment 
modality or guideline adherence in the two longitudinal studies (Chapters 5 and 6). In 
these studies we have not been able to adjust for possible confounding by the treatment 
type, patient characteristics, and disease characteristics. On the patient level, integration 
of ROM and PRF could improve decision making by identifying subpopulations of patients 
with similar characteristics and to determine which treatments have been successful with 
minimal side-e"ects (Iglehart, 2009; Mane et al., 2011). This type of research is commonly 
regarded as Comparative E"ectiveness Research (CER). Another limitation of our present 




ideally follow-up assessments should be scheduled before every next treatment step. 
From a research perspective, ROM measurements at !xed time intervals, independent 
from disease severity are to be preferred for most longitudinal data analytic techniques. 
Cox regression analysis, the method we used in Chapter 5 and 6 for predicting outcome, 
is an example of a technique that is able to use variable numbers of measurements 
and variable time-intervals. In the current clinical practice in Leiden, measurements are 
initiated by the research nurse, the clinician or patient, but not always before a change of 
treatment or a next treatment step according to the guidelines. This unpredictable interval 
of ROM assessments without automatically scheduled re-assessments may contribute to 
bias due to attrition and complicates data analysis and interpretation. At present, e"orts 
are made to incorporate a more systematic measurement interval in the Leiden ROM.
 A potential limitation or pitfall of ROM in general is important to consider. 
In this modern era of excessive growth of healthcare and inevitable health-costs, the 
power of health insurance companies is growing and the professional autonomy of 
medical specialists is increasingly under pressure. Understandably, policy makers like 
health insurance companies and governments demand more and more insight in costs 
of treatments and treatment processes to be able to control these costs. Since ROM is 
a potentially valuable source of information regarding these processes, many health 
providers have implemented ROM initiatives over the past years, with benchmarking as 
one of the major goals. The studies in this thesis may illustrate that benchmarking based 
on ROM assessments is possible but could also be a hazardous operation. First of all, some 
institutions have adapted a ROM system in which only a succinct set of outcome scales 
or only one scale is used. Even with our extended ROM measurement scales, it would be 
hard to derive reliable benchmarking data because of important inter-patient di"erences 
that require complex statistics to take into account. For example, if in a certain clinic more 
MDD patients with comorbid personality disorders are being treated, outcomes may 
be worse compared to another clinic that uses the same guidelines but where patients 
with less complicated complaints seek treatment. Our major concern would be that in 
the case of a limited ROM assessment battery, policy makers will draw conclusions based 
on insu%cient or inadequately analysed data. For example, in tertiary care clinics or 
specialised secondary care clinics, typically patients with treatment-resistant complaints, 
somatic comorbidity, co-existent personality pathology, or a combination of these are 
being treated. Those patients are likely to have worse treatment-outcomes, irrespective of 






In this thesis we have shown that for a balanced ROM assessment it is necessary 
to apply both self-report and observer-rated scales. Ironically, due to the aforementioned 
e"orts to control healthcare costs, the current tendency is to limit or even omit the 
observer-rated scales and standardised diagnostic interviews from ROM. To base clinical 
and benchmark decisions solely on self-report scales would perhaps save salary costs of 
research nurses. However, eventually these self-report measurements could only re#ect 
part of the process of diagnostics and treatment outcome because more objective 
information derived from observer-rated scales would be lacking. In this thesis, we have 
shown that ROM, including observer-rated measurements, provides valuable and more 
objective information. Finally, the large variety of ROM assessment scales that are being 
used by di"erent health organisations limits comparability and is another caveat with 
respect to benchmarking. Calculating standardized scores or z-scores could help with 
respect to this problem.
 A last limitation of ROM in general to discuss here relates to the population under 
study. The studies described here focused on patients with MAS disorders, also regarded 
as common mental disorders. Our local decision to implement ROM !rstly in MAS disorder 
patients was based on the research pro!le of our department. However, substantial 
overlap of symptoms and mutual comorbidity of MAS disorders, the wide availability of 
validated rating scales in the MAS domain, and the fact that MAS patients were expected 
to be more compliant than e.g. psychotic patients or patients with personality disorders 
as main diagnosis, also played a role in this decision. Indeed, in several ROM initiatives in 
other patient populations, e.g. psychotic patients or Severe Mental Illness (SMI)-patients, 
these considerations have been underlined (Mulder et al., 2010).
Future Perspectives
The studies presented in this thesis can be regarded as a !rst set of explorative studies to 
demonstrate the possibilities of conducting clinical epidemiological research with ROM 
data. Several adjustments, e.g. adding treatment details in ROM, may further improve the 
potential of future studies in our setting (see table 7.1).
Besides for clinical epidemiological research, the Leiden ROM data can serve as basis 
for research in other domains. Examples of these are biological and psychometric research. In 
Leiden, many researchers already use the ROM-database for studies in these domains. Results 
have been published and will be in the near future. To further illustrate the potential of ROM, 




First, the lack of well-known biological markers in psychiatric disorders 
complicates the borders of disease. When can someone with certain complaints be 
classi!ed as a patient? The diagnostic classi!cation system DSM-IV only partially answers 
that question by operationalising disorders by consensus de!nitions. Due to the absence 
of clear markers and borders, the line between ‘healthy’ and ‘sick’ will be hard to de!ne. 
Validated measurement scales are helpful in de!ning and establishing that line. However, 
for many validated measurement scales used in ROM no reference values in the general 
population have been calculated. NormQuest is a study initiated in Leiden that aims to 
assess those reference values for the commonly used measurement scales in MAS patients 
(Schulte et al., in press).
Second, the ROM infrastructure with naturalistically obtained data also allows 
for add-on research. The Mood, Anxiety, Somatoform disorders and Hypothalamus 
pituitary adrenal (HPA) axis Biobank (MASHBANK) is an example of this type of research. 
The MASHBANK has been founded to investigate the link between genetic variants, 
functioning of the HPA axis and the phenotype in patients with MAS disorders, and 
comparing those with patients form the general population. Patients routinely enrolled 
in ROM have been asked informed consent to donate DNA for the MASHBANK, after MEC 
approval of the protocol. So far, almost 2000 samples of MAS patients and control subjects 
have been collected. 
 Third, as discussed earlier, ROM measurement scales should ideally be free of 
copyright in order to allow broad implementation. For longitudinal research, a stable test 
battery is paramount. Unfortunately, the past years publishers have claimed copyrights 
for measurement scales used in our ROM test battery forcing us to abandon those scales. 
The ROM Research Center (COROM) in Leiden facilitates ROM-related research of which 
the development of new measurement scales for the free domain is one of the topics. The 
development and validation of freely available scales comparable to copyright-protected 
scales are needed. An example of the latter is the construction of a new measure for 
the assessment of psychological distress. We developed and validated the Symptom 
Questionnaire-48 (SQ-48), a measurement scale that assesses 48 symptoms in nine 
symptom domains (Carlier et al., in preparation). Furthermore, translation and subsequent 
validation of measurement scales in di"erent languages is necessary to allow non-Dutch 
patients to be enrolled in ROM.
 As mentioned before, the studies in this thesis are examples of the potential 
of ROM. Many more studies and collaborations are necessary to develop useful risk 
calculators, to integrate biological markers in ROM, and to develop speci!c interventions 





from the cardiovascular !eld (Framingham, SCORE) but also oncology demonstrate that 
large-scale collaboration may dramatically improve outcomes step by step in large groups 
of patients. For example, acute leukemia is the most common form of childhood cancer, 
comprising approximately 30% of all malignancies in children. Survival rates for Acute 
Lymphatic Leukemia have increased dramatically since the 1980s, with current !ve-year 
overall survival rates of over 85% (Gatta et al., 2005; Pui et al., 2004; Pui and Evans, 2006). 
These improved survival rates are due to large-scale collaborations and treatment of large 
groups of patients according to standardised research protocols, based on staging of 
disease and constant monitoring of outcomes. These protocols have evolved over and 
over according to outcomes of trials and !ndings of more biological studies (Lee et al., 
2000; Pui and Evans, 2006). In psychiatry, establishment of the international schizophrenia 
consortium (ISC) has resulted in large-scale genetic studies in schizophrenia and bipolar 
disorder (e.g. Purcell et al., 2009). In Europe, the GENDEP consortium aims to use genetic 
pro!les to predict outcome of antidepressant treatment (e.g. Uher, et al., 2010). These 
initiatives demonstrate that large-scale collaborations are possible. Indeed, initiatives for 
staging and pro!ling in psychiatry are emerging. In a recent review of Fava et al. (2011), the 
authors stress the importance of staging in psychiatry. “Staging di"ers from conventional 
diagnostic practice in that it not only de!nes the extent of progression of a disorder in a 
particular point in time but also reveals a person’s current location on the continuum of 
the course of illness”. Detailed information about symptoms, comorbidity, psychosocial 
functioning, quality of life and response to treatment derived by ROM assessments could 
serve as basis for staging.
Concluding remarks
The studies in this thesis demonstrate that a proper ROM infrastructure is a valuable 
source for clinical epidemiological research in naturalistic or ‘real’ patients. We have 
studied in detail aspects of the phenotype of MAS patients, and established risk factors 
of poor outcome in both MDD and a treatment-seeking MAS population. Major !ndings 
were the phenotype of more suicidality in pre-adult onset MDD patients, and correlates of 
deliberate self-harm in a large group of MAS patients. Pessimism and lack of energy were 
found to be predictors of poor outcome in MDD patients, and advancing age, dysfunc-
tional cluster-B personality traits, MAS comorbidity and poor reported general health 
status were risk factors for poor outcome in MAS disorders. These risk factors need future 




calculators comparable to those used in cardiovascular medicine. Integration of treatment 
details in ROM would allow for comparative e"ectiveness studies in speci!c subgroups 
of patients. Integration of biological markers in ROM and (inter)national collaboration 
could bring ROM to a higher level. On a national level, regional mental health providers 
should give priority to reaching consensus about uniform implementation of ROM. We 
believe that consensus is important to be able to respond to demands of policy makers. A 
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Dit proefschrift gaat over het routinematig meten van klachten bij patiënten met 
Stemmings- Angst- en Somatoforme (SAS) stoornissen met behulp van gestandaardiseerde 
meetinstrumenten. Allereerst worden de klachten, symptomen en diagnoses systematisch 
vastgesteld, nog voordat een behandeling is gestart, om de beginsituatie vast te leggen. 
Vervolgens worden door vervolgmetingen behandeluitkomsten in kaart gebracht. De 
Engelse term van het routinematig meten van klachten is ‘Routine Outcome Montoring’, 
afgekort ‘ROM’. Het routinematig karakter van ROM maakt dat de metingen in grote mate 
representatief zijn voor de dagelijkse behandelpraktijk (‘real-world’). SAS stoornissen zijn 
potentieel invaliderende ziekten die frequent voorkomen. Zo krijgt ongeveer één op de vijf 
Nederlanders in zijn of haar leven een depressieve of angststoornis. De meeste patiënten 
worden in de eerste lijn behandeld, door de huisarts of door een eerstelijnspsycholoog. 
Als de klachten ernstiger zijn of niet reageren op eenvoudige interventies, vindt vaak 
doorverwijzing plaats naar de tweede lijn: de Geestelijke Gezondheidszorg (GGZ). Bij 
onvoldoende behandelresultaat of complexe problematiek kan de patiënt naar de derde 
lijn verwezen worden; bijvoorbeeld een universitair medisch centrum. Deze manier 
van behandelen, die overigens niet speci!ek is voor de psychiatrie, heet ‘stepped care’. 
De studies in dit proefschrift zijn gebaseerd op behandelgegevens van patiënten in de 
tweede en derde lijn. 
In de dagelijkse behandelpraktijk in de tweede en derde lijn worden patiënten behandeld 
vanwege een breed scala aan klachten. Vaak bestaan er naast de SAS-stoornis waarvoor 
de patiënt hulp zoekt nog andere stoornissen (‘comorbiditeit’). Zo kan er bijvoorbeeld 
ook sprake zijn van middelenmisbruik, of een persoonlijkheidsstoornis. Patiënten met een 
depressie zijn vaak ook angstig, en patiënten met een angststoornis vaak ook somber. 
Daarnaast kan er sprake zijn van gebrekkige therapietrouw waardoor de behandeling 
minder e"ectief wordt. Deze en andere factoren spelen ook een rol bij het kiezen van de 
behandeling, en kunnen maken dat in de dagelijkse behandelpraktijk wordt afgeweken 
van reguliere behandelprotocollen of –richtlijnen. 
Veel kennis over kenmerken van psychiatrische ziekten is afkomstig uit 
bevolkingsonderzoeken. Bij dit type onderzoek worden de klachten van een grote 
steekproef van mensen uit bijvoorbeeld een land in kaart gebracht door middel van 
gestandaardiseerde meetinstrumenten. Een groot deel van deze mensen heeft klachten 
zonder dat een behandeling gezocht wordt. Ook is de laatste decennia veel kennis over 
kenmerken en behandelresultaten van SAS-stoornissen afkomstig van gerandomiseerde 





vaak de primaire vraag of een behandeling ‘x’ beter werkt dan een behandeling ‘y’. Als 
‘bijzaak’ van RCT’s is veel kennis opgedaan over de kenmerken van de ziekte zelf. Bij dit type 
onderzoek worden  vaak strenge selectiecriteria voor inclusie gehanteerd. Behandelingen 
volgens strakke protocollen worden uitgevoerd. Zo worden patiënten met comorbiditeit 
of middelenmisbruik vaak uitgesloten van RCT’s. Het is aangetoond dat het grootste deel 
van de patiënten in de algemene behandelpraktijk om deze redenen niet zouden kunnen 
participeren in een RCT (‘selectiebias’ van RCT’s). Bevindingen van deze RCT’s, maar ook 
die van bevolkingsonderzoeken zijn dus waarschijnlijk slechts beperkt representatief voor 
de patiënten uit de dagelijkse behandelpraktijk. Vanwege het routinematig karakter van 
ROM-metingen bij patiënten die behandeling zoeken, zouden deze  metingen gegevens 
op kunnen leveren over kenmerken van ziektes en behandelresultaten die in grote mate 
representatief zijn voor de klinische praktijk.
In Leiden en omstreken bestaat sinds 2001 een ROM-infrastructuur waarbij 
patiënten die verwezen worden voor behandeling van een SAS-stoornis naar een polikliniek 
van GGZ Rivierduinden (RD) of de afdeling psychiatrie van het Leids Universtitair Medisch 
Centrum (LUMC) tijdens de intake een ROM meting krijgen. Alleen patiënten die te ziek zijn 
om een ROM te ondergaan, of die de Nederlandse taal onvoldoende machtig zijn, worden 
uitgesloten van ROM. Als een behandeling wordt ingesteld, vindt elke 3-4 maanden een 
ROM-vervolgmeting plaats. ROM-metingen worden uitgevoerd door speciaal getrainde 
testverpleegkundigen en zijn primair bedoeld voor de arts en patiënt, voor diagnostiek 
en om voortgang van de behandeling te kunnen evalueren. ROM gegevens zijn echter 
ook geanonimiseerd beschikbaar voor wetenschappelijk onderzoek. Zo kunnen van grote 
groepen patiënten uit de dagelijkse behandelpraktijk (‘real-world patients’) gegevens 
over klachten, symptomen, diagnoses en behandele"ecten gebruikt worden voor het in 
kaart brengen van karakteristieken van ziektebeelden of het identi!ceren van voorspellers 
van behandelresultaten in de dagelijkse behandelpraktijk (‘real-world outcomes’). 
Daarnaast kunnen ROM gegevens gebruikt worden voor ‘benchmarking’: het vergelijken 
van behandelresultaten van instituten, afdelingen of individuele behandelaren voor 
managementdoeleinden.
Doelen van de studies opgenomen in dit proefschrift waren ten eerste het 
beschrijven van correlaten van bepaalde ziektekenmerken bij grote groepen van patiënten 
met SAS stoornissen in de dagelijkse behandelpraktijk, en ten tweede het identi!ceren van 
voorspellers van behandeluitkomsten in de dagelijkse behandelpraktijk. Een secundair 






In hoofdstuk 1 geven wij allereerst een overzicht van de achtergronden 
van ROM, waarbij het belang van objectieve en gestandaardiseerde metingen voor 
psychiatrische diagnostiek duidelijk naar voren komt. Psychiatrische ziekten worden 
geclassi!ceerd met behulp van de DSM-IV: de vierde editie van de ‘Diagnostic and 
Statistical Manual of Mental Disorders’. Dit is een internationaal classi!catiesysteem 
waarin de criteria van alle psychiatrische ziekten beschreven zijn. Omdat ondanks de sterk 
toegenomen kennis van het brein de onderliggende biologische mechanismen van veel 
psychiatrische ziekten tot op heden niet bekend zijn moeten klachten en symptomen 
van de patiënt gebruikt worden voor diagnostische classi!catie. Om dit zorgvuldig te 
kunnen doen, is het van belang om deze klachten en symptomen zo objectief mogelijk 
vast te stellen. Dat is vaak niet eenvoudig omdat veel psychische symptomen een 
grote subjectieve component hebben: bijvoorbeeld verstoorde stemming, angst of 
wanen. Het gebruik van gevalideerde, gestandaardiseerde meetinstrumenten bij de 
psychiatrische diagnostiek verhoogt in belangrijke mate de betrouwbaarheid van deze 
diagnostiek. De ontwikkeling enkele decennia geleden van betrouwbare diagnostische 
meetinstrumenten die gebruik maken van DSM-criteria heeft de mogelijkheden voor 
(epidemiologisch) wetenschappelijk onderzoek enorm vergroot. Dit heeft geresulteerd 
in bevolkingsonderzoeken waarin de prevalentie (het vóórkomen) van psychiatrische 
ziekten kon worden onderzocht. Ook zijn vele meetinstrumenten ontwikkeld, die de 
ernst van bepaalde ziekten (bijvoorbeeld depressie) meten op symptoomniveau, of 
door het sociaal functioneren in kaart te brengen. Voorbeelden van deze lijsten zijn de 
Montgomery Asberg Depression Rating Scale (MADRS; een observatielijst die de ernst 
van depressie meet) en de Short-Form-36 (SF-36; een zelfrapportagelijst die de algemene 
gezondheidstoestand en sociaal functioneren meet). Deze en andere lijsten kunnen bij 
ROM worden gebruik om het verloop van klachten over de tijd te meten. 
Vervolgens geven wij in dit hoofdstuk een overzicht van ROM in het algemeen, 
en ROM in RD en LUMC, en een beschrijving van de ROM-patiëntenpopulatie. Daarnaast 
zetten wij de doelen van het proefschrift uiteen.
In de eerste studie beschreven in dit proefschrift (hoofdstuk 2) bestudeerden 
wij geslachtsverschillen bij patiënten met een ‘Major’ depressieve stoornis (MDD). 
Hoewel geslachtsverschillen in het beloop en symptoompro!el van MDD al vaak zijn 
bestudeerd, blijkt dat bijna alle studies zijn verricht in de algemene bevolking, dus bij 
mensen die niet noodzakelijkerwijs in behandeling zijn, of in RCT-populaties. Gegevens 





studies waren niet altijd consistent. Dit is mogelijk te verklaren door de selectieve 
populaties die waren gebruikt voor deze studies. Toch wordt algemeen aangenomen dat 
er belangrijke verschillen bestaan tussen mannen en vrouwen met MDD, in termen van 
voorkomen, beloop en symptoompatronen. Doel van deze studie was het onderzoeken 
van geslachtsverschillen in klinische karakteristieken bij ‘real-world’ patiënten met 
MDD. Wij gebruikten de eerste ROM meting (‘baseline’) van 1131 patiënten met MDD. 
De belangrijkste bevindingen van deze studie waren dat vrouwen meer en ernstiger 
klachten rapporteerden op ‘subjectieve’ zelfrapportagelijsten, en een lagere algemene 
gezondheidsbeleving hadden dan mannen. Op meer objectieve observatielijsten 
vonden wij geen verschillen in ernst van symptomen tussen mannen en vrouwen. 
Deze bevindingen suggereren dat de subjectieve ziektelast hoger is bij vrouwen met 
MDD dan bij mannen met MDD. Ook vonden wij dat het symptoompatroon tussen 
mannen en vrouwen verschilde, waarbij vrouwen met MDD meer verlies van energie, 
slaperigheid, gevoelens van waardeloosheid, verlies van eetlust, moeheid en libidoverlies 
rapporteerden dan mannen. Deze bevindingen kwamen redelijk overeen met eerder 
gerapporteerde bevindingen van RCT’s of populatiestudies. Een belangrijke conclusie van 
deze eerste studie was dat voor een evenwichtig en betrouwbaar beeld de ROM dient te 
bestaan uit zowel zelfrapportage- als observatielijsten. 
In hoofdstuk 3 gebruikten wij ook eerste ROM metingen van patiënten met 
MDD. In deze studie onderzochten wij verschillen in klinische karakteristieken tussen 
patiënten met een MDD ontstaan voor het 18e jaar en patiënten met een MDD ontstaan 
na het 18e jaar. Eerdere studies vonden aanwijzingen dat de op vroege leeftijd ontstane 
MDD mogelijk een ernstigere vorm is van dezelfde ziekte. Ook deze studies waren 
echter weer voornamelijk in RCT-populaties en in de algemene bevolking verricht. Wij 
gebruikten een bestand van 1105 patiënten met een MDD en een eerste ROM meting, 
om te onderzoeken of deze verschillen ook aangetoond konden worden bij ‘real-world’ 
patiënten. De belangrijkste bevinding van deze studie was dat patiënten met een vroeg 
ontstane depressie vaker een suïcidepoging in het verleden hadden gedaan, en ook 
vaker suïcidale gedachten hadden op het moment van de ROM meting dan patiënten 
met een depressie ontstaan na het 18e jaar. In onze analyses vonden wij geen verschillen 
op andere gebieden van klachten, of in ernst van de symptomen, verschillen die in veel 
eerdere studies wel gevonden werden. De leeftijd van ontstaan kan niet altijd betrouwbaar 
worden vastgesteld omdat de patiënt dit misschien niet meer kan reproduceren, toch kan 
het de clinicus op een relatief eenvoudige wijze helpen bij het inschatten van suïcidaliteit 




Na deze twee studies bij patiënten met MDD gebruikten wij in de volgende 
studie (hoofdstuk 4) de gehele groep van patiënten met SAS stoornissen voor analyses. 
In deze studie bestudeerden wij met behulp van de eerste ROM meting de prevalentie 
en factoren die samenhangen met opzettelijke zelfbeschadiging en suïcidale ideaties 
(DSHI) in een groep van 2844 patiënten die verwezen waren naar RD of LUMC voor 
behandeling van een SAS-stoornis. Uit eerder onderzoek bleek dat DSHI een belangrijke 
voorspeller is voor een geslaagde suïcide. In deze studie vonden wij dat opzettelijke 
zelfbeschadiging bij 55% van de patiënten voorkwam. Getrouwd zijn, hogere opleiding 
en hogere angstscores waren onafhankelijk geassocieerd met een lagere kans op 
DSHI. Tegelijkertijd voorkomende SAS-diagnoses, het hebben van meer depressieve 
symptomen en emotieregulatiestoornissen hingen duidelijk samen met een hogere kans 
op DSHI. Deze resultaten in een grote groep ‘real-world’ patiënten met SAS-stoornissen 
laten zien dat DSHI vaak voorkomt bij patiënten met SAS-stoornissen, en dat er duidelijke 
en gemakkelijk vast te stellen factoren zijn die ermee samenhangen. De bevindingen uit 
deze studie kunnen clinici helpen bij het identi!ceren van patiënten met een verhoogd 
risico op DSHI en suïcide, en hier in hun behandeling speciaal aandacht aan besteden.
In het volgende gedeelte van dit proefschrift gebruikten wij naast eerste 
ROM-metingen ook de vervolgmetingen. Hierdoor was het mogelijk om voorspellers 
van behandeluitkomsten te onderzoeken. In hoofdstuk 5 gebruikten wij van 1489 
patiënten met een MDD de eerste ROM-meting en vervolgmetingen tot 24 maanden 
na de eerste meting. Het doel van deze studie was te onderzoeken of de individuele 
depressieve symptomen gemeten op een zelfrapportagelijst (Beck Depression Inventory-
Revised Version; BDI-II) de behandeluitkomst konden voorspellen. De BDI-II bestaat uit 
21 vragen die gaan over afzonderlijke depressieve symptomen, waarbij de patiënt moet 
aangeven in hoeverre hij de afgelopen twee weken last heeft gehad van het betre"ende 
symptoom. In eerdere studies naar voorspellers van uitkomsten van depressie werd al 
gevonden dat klinische factoren zoals bijvoorbeeld  een vroege leeftijd van ontstaan, 
ernstiger klachten en bepaalde persoonlijkheidstrekken geassocieerd waren met een 
slechtere behandeluitkomst. Het is belangrijk om al in een vroeg stadium patiënten 
met een hoog risico op een slechte behandeluitkomst te kunnen identi!ceren omdat 
deze patiënten mogelijk baat zouden kunnen hebben bij andere behandelingen dan 
de algemene voorgeschreven behandelingen. Zo valt bijvoorbeeld te denken aan extra 
psychotherapeutische interventies bij deze groep. Het systematisch onderzoeken of 
bepaalde depressieve symptomen bij aanvang van de behandeling ook een voorspellende 
waarde zouden hebben, was nog niet eerder gedaan. Wij vonden dat 2 van de 21 





patiënten die hoog scoorden op de symptomen ‘pessimisme’ en ‘verlies van energie’ 
hadden meer kans op een slechte behandeluitkomst. Deze uitkomsten waren gecorrigeerd 
voor eerder gevonden correlaten van slechte behandeluitkomst, en kwamen overeen met 
de bevindingen van een recente studie waarbij de voorspellende waarde van clusters van 
symptomen (in plaats van afzonderlijke symptomen, zoals in onze studie) bij depressie 
was onderzocht. Wij achten deze bevindingen voor de clinicus erg relevant, omdat deze 
voorspellende symptomen gemakkelijk en goedkoop zijn vast te stellen (bijvoorbeeld 
door het afnemen van een zelfrapportagelijst) voor aanvang van de behandeling. 
De laatste studie beschreven in dit proefschrift (hoofdstuk 6) behandelt 
eveneens een onderzoek naar voorspellers van behandeluitkomst in de dagelijkse 
behandelpraktijk, maar nu in de gehele groep van patiënten met SAS-stoonissen. SAS-
stoonissen vertonen een grote mate van overlap in diagnostische criteria, en vaak zijn 
er meerdere comorbide SAS-stoornissen aanwezig zonder dat duidelijk is welke van 
deze stoornissen op de voorgrond staat. Toch worden in de meeste RCT’s patiënten met 
comorbiditeit uitgesloten van deelname aan deze studies, hetgeen de generaliseerbaarheid 
van de resultaten beperkt. Wij gebruikten eerste ROM metingen en vervolgmetingen 
tot 24 maanden na de eerste meting van twee cohorten met in totaal 2284 patiënten 
met één of meer SAS-stoornissen, en onderzochten welke karakteristieken een slechte 
behandeluitkomst voorspelden. Wij vonden dat een hogere leeftijd, het hebben van 
meerdere SAS-stoornissen of het hebben van een somatoforme stoornis, en bepaalde 
persoonlijkheidstrekken (problemen met intimiteit, a"ectlabiliteit, en de neiging tot 
zelfbeschadiging), onafhankelijke voorspellers waren voor een slechte behandeluitkomst. 
In toekomstige studies zou onderzocht moeten worden of deze patiënten baat kunnen 
hebben bij extra of andere interventies.
Algemene discussie
De studies in dit proefschrift hebben inzicht gegeven in een aantal klinische 
aspecten van ‘real-world’ patiënten met SAS-stoornissen. Daarnaast zijn een aantal 
voorspellers voor een slechte behandeluitkomst vastgesteld. Deze voorspellers zijn 
eenvoudig te meten en direct klinisch toepasbaar. De studies in dit proefschrift illustreren 
eveneens de mogelijkheden van wetenschappelijk onderzoek met ROM data. Ook maken 
deze studies ons bewust van de mogelijke beperkingen van ROM. 
Toekomstige mogelijkheden van wetenschappelijk onderzoek met ROM 




behandeluitkomsten bij bepaalde groepen van patiënten. Dit kan resulteren in tabellen 
met risicoschattingen, zoals bijvoorbeeld ook al veelvuldig gebruikt worden bij hart- 
en vaatziekten (zie Hoofdstuk 7; !guur 7.1) In vervolgonderzoek zou als volgende stap 
gekeken kunnen worden naar het e"ect van extra of andere interventies bij subgroepen 
van patiënten met een verhoogd risico op een slechte behandelrespons. Dit is een 
voorbeeld van ‘Comparative E"ectiveness Research’ (CER), en dit soort studies zou kunnen 
leiden tot meer geïndividualiseerde behandelingen. Om dit te realiseren is nationale 
en internationale samenwerking nodig. Dat dit complex maar niet onmogelijk is, blijkt 
bijvoorbeeld uit de oncologie: door internationale samenwerking waarbij decennia lang 
stuctureel en systematisch is gewerkt aan stagering, toepassen van behandelprotocollen 
en monitoring van behandeluitkomsten is de vij+aarsoverleving van kinderen met 
acute lymfatische leukemie spectaculair toegenomen van rond de 50% in 1980 tot 
meer dan 85% in 2012. Om vergelijkbare resultaten te bereiken in de psychiatrie zou op 
grote schaal consensus moeten worden verkregen met betrekking tot relevante ROM-
metingen. Welke pakket aan meetinstrumenten optimaal is bij SAS-patiënten zou moeten 
worden onderzocht. Dat niet kan worden volstaan met enkele zelfrapportagelijsten is 
waarschijnlijk, omdat voor een gebalanceerde ROM-meting zowel zelfrapportage- als 
observatielijsten nodig zijn (Hoofdstuk 2). Gedetailleerde informatie over symptomen, 
comorbiditeit, psychosociaal functioneren, kwaliteit van leven verkregen met ROM zou 
een belangrijke basis kunnen vormen van stagering van SAS-patiënten en het evalueren 
van behandeluitkomsten. 
Mogelijke beperkingen van ROM onderzoek zijn aan het licht gekomen door 
het verrichten van de studies in dit proefschrift. Allereerst zijn er de beperkingen van de 
huidige ROM-infrastructuur van RD en LUMC. De belangrijkste beperking is het ontbreken 
van een koppeling tussen het elektronische patiëntendossier (EPD) en de ROM. Hierdoor 
zijn geen gedetailleerde behandelgegevens beschikbaar, maar ook geen gegevens over 
bijvoorbeeld  psychiatrische voorgeschiedenis en familieanamnese. Hierdoor hebben wij 
in de prospectieve studies niet kunnen corrigeren voor het type behandeling of de mate 
waarin richtlijnen gevolgd zijn. 
Een belangrijke mogelijke beperking van ROM in het algemeen is dat het meten van 
klachten en symptomen door middel van meetinstrumenten altijd onnauwkeurigheiden 
met zich mee brengt. Om een zo betrouwbaar mogelijk beeld van de klachten van de 
patiënt te krijgen, is het noodzakelijk om een brede testbatterij te gebruiken, die bestaat 
uit zowel zelfrapportagelijsten als observatieschalen, en die verschillende domeinen 
bestrijkt. In tijden van bezuiniging en kostenbeheersing van de zorg is het erg belangrijk om 





is ROM verplicht gesteld en het zal niet lang meer duren voordat GGZ-instellingen worden 
afgerekend op behandelresultaten gemeten met ROM. Tegelijkertijd bestaat de neiging 
om dure observatielijsten weg te laten en een zo beknopt mogelijke ROM te realiseren. 
Dat hier een potentiële verarming op de loer ligt moge duidelijk zijn. Bovendien neemt 
het risico op misinterpretatie van ROM gegevens en daaruit voorkomende ongefundeerde 
oordelen toe naarmate de ROM metingen beknopter worden. Bijvoorbeeld: in hoofdstuk 
zes vonden wij dat bepaalde dysfunctionele persoonlijkheidstrekken voorspellend waren 
voor een slechtere behandeluitkomst. Het meten van deze persoonlijkheisdtrekken kost 
behoorlijk wat tijd. Bij het weglaten van het betre"ende instrument zou deze informatie 
verloren gaan, en zouden afdelingen met meer ‘moeilijke’ patiënten onterecht kunnen 
worden afgerekend op tegenvallende behandelresultaten. 
Perspectieven voor toekomstig onderzoek
De studies in dit proefschrift kunnen worden beschouwd als exploratieve studies om 
het potentieel van epidemiologisch onderzoek met ROM-data te illustreren. Een aantal 
aanpassingen, zoals de koppeling van het EPD aan de ROM, zal de mogelijkheden van 
onderzoek met ROM-data in RD en LUMC aanzienlijk vergroten. Naast het dienen als 
basis voor epidemiologisch onderzoek, wordt de RD en LUMC ROM database inmiddels 
als basis gebruikt voor onderzoek in andere domeinen. Voorbeelden van deze domeinen 
zijn biologisch en psychometrisch onderzoek (zie tabel 7.1) en het gebruik van de ROM 
infrastructuur voor het verrichten van metingen in RCTs.
 De grootste uitdaging voor de toekomst is het vaststellen van een 
optimale testbatterij en ROM-infrastructuur voor verschillende behandelsettings en 
patiëntencategorieën, waarbij het bereiken van (inter)nationale consensus (ten aanzien 
van de gebruikte zelfrapportage- en observatielijsten en de bijbehorende norm-waardes) 





ADHD   Attention De!cit Hyperactivity Disorder
AN(C)OVA  Analysis of (co)variance
APA   American Psychiatric Association
BAS   Brief Anxiety Scale
BDI-II   Beck Depression Inventory, Revised Edition
BSI   Brief Symptom Inventory
CER   Comparative E"ectiveness Research
CGI-S   Clinical Global Impression-Severity
CI   Con!dence Interval
CIDI   Composite International Diagnostic Interview
COROM   ROM Research Center Leiden
CPRS   Comprehensive Psychopathological Rating Scale
CVD   Cardiovascular Disease
DAPP-SF  Dimensional Assessment of Personality Pathology-Short Form
DIS   Diagnostic Interview Schedule 
DSHI   Deliberate Self Harm and Suicidal Ideation
DSM(-IV TR)   Diagnostic and Statistical Manual of Mental Disorders (Fourth 
Edition, Text Revision)
ECA   Epidemiological Catchment Area
GAF   Global Assessment of Functioning
HDL   High-Density Lipoprotein
HDRS   Hamilton Depression Rating Scale
HPA-axis  Hypothalamus Pituitary Adrenal-axis
HR   Hazard Ratio
IQR   Interquartile Range
LUMC   Leiden University Medical Center
MADRS   Montgomery-Åsberg Depression Rating Scale
MAS   Mood, Anxiety and Somatoform
MASHBANK  Mood, Anxiety, Somatoform disorders and HPA-axis Biobank
MASQ  Mood and Anxiety Symptom Questionnaire
MDD   Major Depressive Disorder
MDE   Major Depressive Episode





MINI-Plus  Mini International Neuropsychiatric Interview-Plus
NCS(-R)   National Comorbidity Survey(-Replication)
NEMESIS  Netherlands Mental Health Survey and Incidence Study
NIMH   National Institute of Mental Health
OR   Odds Ratio
PAREL   Psychiatrische Academische Registratie Leiden
PCORI   Patient-Centered Outcomes Research Institute
PD   Panic Disorder
PRF   Patient Record Form
QoL   Quality of Life
RCT   Randomised Controlled Trial
RD   Rivierduinen
RMHP   Regional Mental Health Provider
ROM   Routine Outcome Monitoring
SBP   Systolic Blood Pressure
SCL-90   Symptom Checklist-90
SCORE   Systematic Cardiovascular Risk Evaluation
SD   Standard Deviation
SF-36   Short Form-36
SMI   Severe Mental Illness
SPSS   Statistical Package for the Social Sciences
SQ-48   Symptom Questionnaire-48
STAR*D   Sequenced Treatment Alternatives to Relieve Depression
US   United States
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